Cardiac stress and stress adaptation: roles of peroxynitrite and changes in gene expression by HASH(0x7fe9441b1728)
I 
B i o c h e m i c a l  a n d  B i o p h y s i c a l  R e s e a r c h  C o m m u n i c a t i o n s  285 ,  1 2 1 7 - 1 2 1 9  (2001)  
d o i : 1 0 . 1 0 0 6 / b b r c . 2 0 0 l . 5 3 0 8 ,  a v a i l a b l e  on l ine  a t  h t t p : / / w w w . i d e a l i b r a r y . c o m  on  I D E M  
Preconditioning  Decreases  Ischemia/Reperfusion-lnduced  
Peroxynitrite  Formation  
Csaba  Csonka,* Tamás  Csont,! Annamária  Ónody,*  and  Péter  Ferdinandy*'1  
"  Cardiovascular  Research Group, Department  of Biochemistry,  University  of Szeged,  Szeged,  Hungary;  and 1 Department 
of Pharmacology,  Cardiovascular  Research  Group,  University  of Alberta,  Edmonton, Alberta,  Canada  
R e c e i v e d  J u n e  25,  2001  
The  role  for  peroxynitrite  (ONOO")  in  the  mecha-
nism  of  preconditioning  is  not  known.  Therefore,  we  
s tudied  effects  of  preconditioning  and  subsequent  
ischemia/reperfusion  on  myocardial  ONOO"  forma-
tion  in  isolated  rat  hearts.  Hearts  were  subjected  to  a  
precondit ioning  protocol  (three  intermittent  periods  
of global  ischemia/reperfusion  of 5 min duration  each)  
fo l lowed  by  a test  ischemia/reperfusion  (30 min  global  
i schemia  and  15 min  reperfusion).  When  compared  to  
nonprecondit ioned  controls,  preceding  precondition-
ing  improved  postischemic  cardiac  performance  and  
significantly  decreased  test  ischemia/reperfusion-in-
duced  formation of free nitrotyrosine  measured  in  the  
perfusate as  a marker  for cardiac endogenous  ONOO"  
formation.  During  preconditioning,  however,  the  first  
period  of  ischemia/reperfusion  increased  nitroty-
rosine formation, which was attenuated after the third 
period  of ischemia/reperfusion.  We conclude  that  clas-
sic  precondit ioning  inhibits  ischemia/reperfusion-in-
duced  cardiac  formation  of  ONOO"  and  that  subse-
quent  periods  of ischemia/reperfusion  result in  a  gradual  
at tenuat ion  of  ischemia/reperfusion-induced  ONOO"  
generation.  This mechanism  might be involved in isch-
emic  adaptation  of the  heart.  ©  2001 Academic  Press  
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Although  ni t r ic  oxide  (NO)  h a s  been  shown  to  con-
t r i b u t e to t he deve lopment  of cardiac s t ress  adapta t ion ,  
t h e  exac t  role  of  N O  in  myocardial  ischemia/reper-
fus ion  and  ischemic  precondit ioning  is  not  completely  
k n o w n  (see 1 - 3 for reviews).  Myocardial ischemia  leads  
to  an  accumula t ion  of  NO  which  might  contr ibute  to  
i schemia / reper fus ion  in ju ry  (4-7).  We  have  previously  
s h o w n  t h a t  classic  precondit ioning  decreases  t he  
1 To w h o m  c o r r e s p o n d e n c e  s h o u l d  b e a d d r e s s e d  a t  C a r d i o v a s c u l a r  
R e s e a r c h  Group ,  D e p a r t m e n t  of B i o c h e m i s t r y ,  U n i v e r s i t y  of  Szeged ,  
F a c u l t y  of  Medic ine ,  D ó m  t é r  9,  Szeged ,  H u n g a r y ,  H - 6 7 2 0 .  F a x :  
( + 3 6 )  6 2  545  097.  E - m a i l :  P e t e r @ b i o c h . s z o t e . u - s z e g e d . h u .  
harmfu l  accumulation  of  N O  dur ing  ischemia/reper-
fusion in r a t hea r t s  (5). Recent s tudies  suggest t h a t  t h e  
ha rmfu l  effects  of  NO  in  the  hea r t  and  in  the  vascu-
la tu re  are  due  to  t he  format ion  of  peroxyni t r i te  
(ONOO "),  a  toxic reaction  product  of NO and  superox-
ide  (7-9),  r a the r  t h a n  the  possible  toxic  effect  of  N O  
itself. I t is known t h a t  cardiac production  of  superoxide 
radical,  is  accelerated  upon  reperfusion,  therefore,  si-
mul taneous  production  of  N O  and  superoxide  m a y  
favour  the  formation  of  O N O O "  during  ischemia/  
reperfusion  (7-9).  
The  possible  role  for  ONOO"  in  preconditioning  is  
not  known.  Altug  et  al.  have  found  tha t  exposure  of  
isolated r a t  hea r t s  to  1 p M  final  concentration  of  exog-
enous  ONOO" was  capable  of mimicking the  beneficial  
effects  of  ischemic  precondit ioning  in  ra t  hea r t s  (10,  
11). As exogenous  ONOO"  does  not  reflect t he  effect of 
endogenous  ONOO"  format ion  (14), here we  measured  
endogenous  ONOO"  format ion  dur ing  preconditioning  
and  subsequent  ischemia/reperfusion  in isolated  work-
ing  ra t  hear t s  to  clarify  t h e  possible  contribution  of  
endogenous  ONOO"  to  ischemic  preconditioning.  
METHODS 
T h e  inves t iga t ion  c o n f o r m s  t h e  G u i d e  fo r  t h e  ca r e  a n d  u s e  of  
l abo ra to ry  a n i m a l s  p u b l i s h e d  by  t h e  U S  N a t i o n a l  I n s t i t u t e s  of  
H e a l t h  (NIH  pub l i ca t ion  No.  85-23,  r e v i s e d  1985)  a n d w a s  a p p r o v e d  
by  local  e th ics  c o m m i t t e e s .  
Isolated  rat  heart  preparation.  M a l e  W i s t a r  r a t s  ( 3 0 0 - 3 5 0  g)  
w e r e  a n e s t h e t i z e d  w i t h  d i e t h y l e t h e r  a n d  g iven  500  U / k g  h e p a r i n .  
H e a r t s  w e r e  t h e n  i so la t ed  a n d  p e r f u s e d  in  L a n g e n d o r f f  or  w o r k i n g  
m o d e  w i t h  a n  o x y g e n a t e d ,  n o r m o t h e r m i c  K r e b s - H e n s e l e i t  b u f f e r  
s u p p l e m e n t e d  w i t h  0 .3  m M  L- ty ros ine  (13).  Myocard ia l  f u n c t i o n a l  
p a r a m e t e r s  and  l a c t a t e  d e h y d r o g e n a s e  (LDH)  r e l e a s e  w e r e  m e a -
s u r e d  as  descr ibed  (5).  
Experimental  protocol.  A nonpreconditioning  and  a  precondition-
ing  protocol  w e r e  a p p l i e d  be fo re  i n d u c t i o n  of  t e s t  i s c h e m i a /  
r e p e r f u s i o n  a s  desc r ibed  in  de t a i l  (5).  A f t e r  10  m i n  e q u i l i b r a t i o n ,  
p recondi t ion ing w a s  i n d u c e d  by t h r e e  i n t e r m i t t e n t  cycles  of 4.75  m i n  
no-flow  ischemia ,  s e p a r a t e d  by  0.5  m i n  Langendor f f  p e r f u s i o n  fol-
lowed  by  4.75  m i n  ae rob ic  w o r k i n g  p e r f u s i o n .  T h e  0.5  m i n  L a n g e n -
dorf f  pe r fus ion  a l lowed  for  t h e  s p o n t a n e o u s  r e s t o r a t i o n  of  s i n u s  
r h y t h m  before  s w i t c h i n g  to  w o r k i n g  m o d e  b e t w e e n  no-f low  pe r iods .  
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TABLE  1  
Aort ic  Flow,  Left  Ventr icular  End-Diastolic  Pressure ,  and  
L a c t a t e  Dehydrogenase  Release  in  Nonprecondit ioned  and  
Precondi t ioned  Hea r t s  before  and  af ter  Test  Ischemia  and  
Repe r fus ion 
A F  L V E D P  
(mL/min)  (kPa)  
L D H 
(mU/min/g) 
Before t e s t  i schemia / reper fus ion  
N o n p r e c o n d i t i o n e d  45.9  ±  1.2  0.54  ±  0.05  
P r e c o n d i t i o n e d  43.6  ±  2.1  0.52  ±  0.05  
n.d. 
n .d . 
Af te r  i schemia / reper fus ion  
N o n p r e c o n d i t i o n e d  16.4  ±  1.1  1.76  ±  0.05  
P r e c o n d i t i o n e d  25.1  ±  1.6*  1.34  ±  0.08*  
163.0  ±  11.6  
63.9  ±  12.3*  
Note,  n .d . ,  nonde tec tab le ; * P <  0 . 0 5  vs co r respond ing  nonprecon-
d i t i o n e d  group ,  n  =  7  in  each  group.  
N o n p r e c o n d i t i o n e d  control  a n d  precondi t ioned  h e a r t s  w e r e  t h e n  
s u b j e c t e d  to  30  m i n  global  no-flow  ischemia  followed  by  15  m i n  
r e p e r f u s i o n . 
Measurement  of nitrotyrosine,  a marker  for  ONOO'  in  the  perfus-
ate.  O N O O "  p romotes  n i t r a t i o n  of  phenolic  c o m p o u n d s  s u c h  a s  
t y r o s i n e ,  t h e  n i t r a t i o n  of  which  l eads  to  t h e  f o r m a t i o n  of  a  s t a b l e  
p r o d u c t ,  3 -n i t ro ty ros ine  (12).  Therefore ,  to m e a s u r e  c a r d i a c  O N O O "  
g e n e r a t i o n ,  Krebs -Hense le i t  buf fer w a s  s u p p l e m e n t e d  w i t h  0 .3  m M  
L - t y r o s i n e  a n d  f ree n i t ro ty ros ine  fo rmat ion w a s  de tec ted  in  t h e  per -
f u s a t e  a s  a  m a r k e r  of  myocard ia l  O N O O "  g e n e r a t i o n  (7,  13).  Ty-
r o s i n e a t  0 .3 m M does not a f fec t card iac mechan ica l  f unc t i on  (7).  F r e e  
n i t r o t y r o s i n e  concen t ra t ion  w a s  m e a s u r e d  before  p recond i t ion ing ,  
a f t e r t h e  f i r s t a n d  t h i r d  no-flow period  of precondi t ioning ,  as  wel l  a s  
f o l l owing t e s t  i schemia . S a m p l e s  of coronary e f f luen t d u r i n g  Langen -
dorff  perfus ion  per iods  were  collected  for  30  s  and  s tored  in  - 8 0 ° C  
unt i l  assayed  for n i t ro tyros ine .  F ree  n i t ro tyros ine  was  m e a s u r e d  by  
EL1SA  (Cayman  Chemicals ,  Ann  Arbor,  Ml)  a s  descr ibed  (13).  
Briefly,  p e r f u s a t e  s amples  were  incubated  overn ight  wi th  an t i -
n i t ro tyros ine  rabbi t  IgG  and  n i t ro tyros ine  ace ty lcho l ines te rase  
t r a c e r  in  precoated  (mouse  an t i - rabb i t  IgG)  microp la tes  followed  by  
development  with  E l lman ' s  reagent .  Ni t ro tyros ine  fo rma t ion  w a s  
normalized  to  coronary  flow  and  wet  weight  of  the  h e a r t s  a n d  ex-
pressed  as  pmol/min/g.  
Statistics.  Da ta  were  expressed  a s  m e a n s  ±  SEM  a n d  ana lyzed  
wi th  ANOVA.  P  <  0 .05  w a s  accepted  as  a  s ta t i s t ica l ly  s ign i f i can t  
difference. 
RESULTS 
In  nonpreconditioned  control  hearts,  test  ischemia/  
reperfusion  resulted  in  a  marked  decrease  in  aortic  
flow  (AF)  and  a  considerable  increase  in  left  ventricu-
lar  end-diastolic  pressure  (LVEDP)  and  LDH  release  
(Table  1).  When  preconditioning  was  applied  before  
test  ischemia,  postischemic  AF  increased  and  LVEDP  
and  LDH  release  decreased  showing the  protective  ef-
fect  of classic  preconditioning  against  acute  ischemia/  
reperfusion injury  (Table  1).  
In  the  nonpreconditioned  control  group,  test  isch-
emia/reperfusion  markedly  increased  cardiac  nitroty-
rosine formation. Preceding preconditioning with  three  
brief  periods  of  no-flow  ischemia  significantly  de-
creased  test  ischemia/reperfusion-induced  nitrotyro-
sine  formation  (Fig.  1).  In  the  preconditioned  group,  
however,  the  first  cycle  of  4.75  min  no-flow  ischemia  
followed  by  reperfusion  markedly  increased  nitroty-
Nonpreconditioned Preconditioned 
Before l/R  After  l/R  Before PRE  1S| P R E  3rd PRE  After l/R 
F I G .  1.  Effect  of  precondi t ion ing  a n d  t e s t  i s chemia / r epe r fu s ion  on  cardiac  fo rmat ion  of  f ree  ni t rotyrosine ,  a  m a r k e r  for  endogenous  
p e r o x y n i t r i t e  fo rmat ion . Ni t ro ty ros ine w a s m e a s u r e d  in  t h e p e r f u s a t e by ELISA. P R E ,  precondi t ioning;  ÏÏR,  i schemia / reper fus ion .  *P<  0 . 0 5  
v s  c o r r e s p o n d i n g  "before  I/R"  or  "before PRE"  va lues .  
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ros ine  formation, which  was  a t tenuated  a f te r the  third  
cycle  of  no-flow ischemia  (Fig.  1).  
DISCUSSION 
This  is  the  first  demonstrat ion  t ha t  preceding  isch-
emic  preconditioning  inhibits  endogenous  cardiac  
ONOO"  production  induced  by  tes t  ischemia/reper-
fusion, and tha t subsequent  cycles  of ischemia/reperfu-
sion  resul t  in  a gradual  decrease  in ONOO"  formation.  
I t  is  well  established  tha t  myocardial  ischemia  leads  
to  an  accumulation  of  NO  in  the  hear t  which  is  asso-
ciated  with  a  deterioration  of  myocardial  mechanical  
funct ion during reperfusion. We have  previously  found  
t h a t  ischemic  preconditioning  markedly  decreases  NO  
accumulation  during  test  ischemia  and  reperfusion,  
improves  postischemic  cardiac  function, and  decreases  
t h e  release  of  LDH  (5).  As  many  studies  suggest  
t h a t  NO-dependent  myocardial  injury  is  mediated  by  
O N O O "  (4,  6,  7),  and  tha t  ONOO"  formation  deterio-
r a t e s  myocardial  mechanical  function  (13),  we  hypoth-
esized  that  ischemic preconditioning  at tenuates  ONOO"  
formation,  thereby  protecting  the  hear t  against  func-
t ional  damage.  Accordingly,  we  have  found  here  that  
ischemic  preconditioning  markedly  decreased  ONOO"  
format ion  upon  ischemia/reperfusion.  
Although  preconditioning  a t tenuated  ONOO"  for-
ma t ion  upon  test  ischemia/reperfusion  in  our  present  
s tudy,  the  first  brief  cycle  of preconditioning  ischemia/  
reperfusion  significantly enhanced  ONOO"  formation,  
however,  after  the  th i rd  cycle  of  ischemia/reperfusion  
O N O O "  formation  was  reduced.  This  may  show  that  
O N O O "  formed during  ischemia/reperfusion might  act  
a s  a  trigger  for preconditioning,  but  preconditioning  in  
t u r n  decreases  formation  of  ONOO"  upon  subsequent  
cycles  of ischemia/reperfusion. ONOO"  as  a  trigger  for  
preconditioning  is supported  Altug  et al.  (10),  who  de-
scribed  that  infusion  of  exogenous  ONOO"  at  1  pM  
final  concentration  into  the  perfusion  buffer is  able  to  
mimic  the  effects  of  ischemic  preconditioning  in  iso-
la ted  crystalloid  perfused r a t  hearts ,  which  was  abol-
ished  by  the  adminis t ra t ion  of  the  antioxidant  7V-2-
mercaptopropionylgly cine. 
In  conclusion,  our  present  study  is  the  first  demon-
s t ra t ion  tha t  ischemic  preconditioning  decreases  
ischemia/reperfusion-induced  endogenous  formation  of  
ONOO".  This mechanism  might  be involved  in  precon-
ditioning-induced  cardioprotection.  
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Abstract  To  profile  gene  expression  patterns  involved  in  ische-
mic  preconditioning,  we  monitored  global  gene  expression  
changes  by DNA  microarray  analysis  of  3200  rat-specific  genes  
and  by  real-time  quantitative  polymerase  chain  reaction  in  rat  
hearts.  Forty-nine  genes  with  altered  expression  were  found  
after  ischemia/reperfusion  as  compared  to  control  non-ischemic  
hearts  and  31  genes  were  characteristic  for  classic  precondition-
ing  followed  by  ischemia/reperfusion  as  compared  to  ischemia/  
reperfusion  without  preconditioning.  Genes  with  altered  expres-
sion  due  to  ischemia  and/or  preconditioning  included  those  con-
trolling  protein  degradation,  stress  responses,  apoptosis,  meta-
bolic  enzymes,  regulatory  proteins,  and  several  unknown  cellular  
functions.  Metallothionein,  natriuretic  peptides,  coagulation  fac-
tor  VII,  cysteine  proteinase  inhibitor,  peroxisome  proliferator  
activator  receptor  y  and  myosin  light  chain  kinase  genes  were  
previously  suspected  to  be  related  to  several  cardiovascular  dis-
eases,  however,  most  of  these  genes  have  not  previously  been  
shown  to  be  related  to  myocardial  ischemia/reperfusion.  Some  
genes  were  observed  to  change  specifically  in  response  to  pre-
conditioning:  oligoadenylate  synthase,  chaperonin  subunit  E,  a  
c G M P  phosphodiesterase  (PDE9A1),  a  secretory  carrier  mem-
brane  protein,  an  amino  acid  transporter,  and  protease  28  sub-
unit.  None  of  these  genes  has  previously  been  shown  to  be  in-
volved  in  the  mechanism  of  preconditioning.  
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1.  Introduction  
Ischemic  heart  disease  is  a  ma jo r  cause  of  mortal i ty  in  the  
western  world.  Effective  therapeutic  strategies  for  protecting  
the  ischemic  myocardium  are  much  sought  af ter .  Ischemic  
precondi t ioning  is  a  well-described  adaptive  response  in  which  
brief  exposure  to  ischemia  markedly  enhances  the  ability  of  
t he  heart  to  withstand  a  subsequent  ischemic injury  (see  [1] for 
review).  Preconditioning  confers  a  remarkable  cardioprotec-
* Corresponding  author.  Fax:  (36)-62-432  576.  
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tion  in  a  variety  of  species  including  humans  (see  [1,2]  for  
reviews),  although  the  cardioprotective  effectiveness  of  ische-
mic  preconditioning  might  be  attenuated  in  the  heart  during  
aging  and  some  disease  states  such  as  hyperlipidemia  and  
diabetes  (see  [3]  for  review).  Preconditioning  can  be  elicited  
by  different  sublethal  stress  signals,  such  as  brief  periods  of  
ischemia,  hypoxia,  rapid  electrical  pacing,  heat  stress,  admin-
istration  of  bacterial  endotoxin,  etc.  The  cardioprotective  ef-
fect  of  preconditioning  shows  two  distinct  phases.  The  early  
phase  (classic  preconditioning)  is  manifested  within  minutes  
after  the  preconditioning  stimulus  and  has  a  durat ion  of  less  
than  2-3  h.  The  late  phase  is  characterized  by  a  slower  onset  
(20  h)  and  a  durat ion  of  up  to  72  h.  
The  underlying  molecular  mechanisms  of  ischemic  precon-
ditioning  have  been  extensively  investigated  in  the  hope  of  
identifying  new  rational  approaches  to  therapeutic  protection  
of  the  ischemic  myocardium.  In  spite  of  the  intensive  research  
in  the  past  nearly  2  decades,  the  exact  biochemical  mechanism  
of  preconditioning  is  still  a  question  of  debate  due  to  the  
complexity  of  the  cellular  mechanisms  involved  in  this  phe-
nomenon.  A  variety  of  substances  and  ion  channels,  i.e.  ad-
enosine,  bradykinin,  nitric  oxide,  superoxide,  peroxynitrite,  
calcitonin  gene-related  peptide,  cGMP,  protein  kinases,  nor-
epinephrine,  ATP-sensitive  K +  channels,  etc.,  have  been  
shown  so far to  play  a  role  both  in  ischemia/reperfusion  injury  
and  in  the  development  of  the  cardioprotective  effect  of  pre-
conditioning  [2,4,5],  However,  the  traditional  biochemical  and  
pharmacological  approaches  have  been  insufficient  so  far  to  
explore  the  key  cellular  events  in  ischemia/reperfusion  injury  
and  preconditioning.  Recent  studies  therefore  attempted  to  
identify  gene  activity  changes  during  coronary  occlusion  in  
the  mouse  heart  using  a  mouse  c D N A  array  of  588  genes  
[6]  and  in  a  rat  infarction  model  using  c D N A  array  of  about  
7000 rat  genes  [7], However,  still  very  little  is known  about  the  
gene  expression  pat tern  of  the  heart  in  response  to  ischemia/  
reperfusion  and  preconditioning.  
Therefore,  to  profile  gene  expression  patterns  associated  
with  ischemia/reperfusion  and  classic  preconditioning,  we  
used  c D N A  microarrays  of  3200  rat  genes  to  monitor  tran-
script  levels  in  rat  hearts  in  the  hope  of  identifying  new  cel-
lular  pathways  involved  in  cardiac  ischemia  and  ischemic  
adaptat ion. 
2.  Materials  and  methods  
The  investigation  confomis  to  the  Guide  for  the  Care  and  Use  of  
Laboratory  Animals  published  by  the  US  National  Institutes  of  
0014-5793/03/S22.00  ©  2003  Federation  of  European  Biochemical  Societies.  Published  by  Elsevier  Science  B.V.  All  rights  reserved,  
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Table  1  
Primers  used  in  Q-PCR  analysis  
Gene  product  
(3-Actin 
Chaperonin  e  
Natriuretic  peptide  type  B  
Anion  exchange  protein  2  
Metallothionein-ll 
PPARy 
Betaine-homocysteine  methyltransferase  
Cysteine  proteinase  inhibitor  
Forward  primer  
TTCAACACCCCAGCCATGT 
TACAGCTCTGCAGATGAAGGATGCTT 
GGACCAAGGCCCTACAAAAGAACTTC 
CCATGGGTGGCATCTGTGCCCTC 
TCGCCATGGACCCCAACTGCTCCTGTG 
CGGAAGCCCTTTGGTGACTTTATGG 
GGAACCCAGAGTTGCCACCAGATGG 
GCCACTGCTTGAAAAGAAAACCAATGGG 
Reverse  primer  
GCATACAGGGACAACACAGCC 
TGACATCCGTAAGCCTGGAGAATCTG 
GCCGGAGTCTGCAGCCAGGAGGTC 
GCAGTAGGTCCCCAATGACCATGGAG 
GAAGCCTCTTTGCAGATGCAGCCCTG 
GATGGGCTTCACGTTCAGCAAGCC 
AAATCCCCTTTCTGGGGCGAGCTCC 
GGTCAGCTCATCATTTTTGGATTTGTTAG 
Health  (N1H  publication  No.  85-23,  revised  1996)  and  was  approved  
by  local  ethics  committees.  
2.1.  Perfusion  protocol  of  isolated  rat  hearts  
Male  Wistar  rats  (300-350  g)  were  anesthetized  with  diethylether  
and  given  500  U/kg  heparin.  Hearts  were  then  isolated  and  perfused  
in  Langendorff mode  with  an  oxygenated,  normothermic  Krebs-Hen-
seleit  buffer as  described  [8]. Three  different perfusion  protocols  were  
applied  (n = 5-8  in  each  group).  Hearts  were  subjected  to  either  a  
preconditioning  or  a  non-preconditioning  protocol  followed  by  test  
ischemia/reperfusion  as  described  in  detail  [8,91.  After  10  min  equili-
bration,  preconditioning  was  induced  by  three  intermittent  cycles  of  
5  min  no-flow ischemia,  separated  by  5 min  aerobic  perfusion.  Time-
matched  non-preconditioned  and  preconditioned  hearts  were  then  
subjected  to  30  min  global  no-flow  ischemia  followed  by  120  min  
reperfusion.  A  time-matched  control  group  was  aerobically  perfused  
for  190  min.  Heart  rate  and  coronary  flow  were  monitored  through-
out  the  perfusion  protocol  in  all  groups  [8].  Lactate  dehydrogenase  
release was measured  from coronary  effluent collected  for  5 min  at  the  
beginning  of  the  perfusion  and  at  0-5  min  and  115-120  min  of  re-
perfusion  after  30  min  global  ischemia  and  at  corresponding  periods  
in  controls  as  described  [8].  At  the  end  of  the  perfusion  protocols,  
hearts  from  all  groups  were  frozen  and  powdered  with  a  pestle  and  
mortar  in  liquid  nitrogen.  
2.2.  RNA  preparation  
Total  RNA  was  purified  from  each  group  (25-25  mg  tissue  from  
each  heart)  with  NucleoSpin  RNA  purification  kit  (Macherey-Nagel,  
Duren,  Germany)  according  to  the manufacturer's  instructions.  RNA  
preparations  from  each  group  (n = 3,  randomly  selected  from  each  
group)  were  pooled,  and  their  quantities  and  qualities  were  assessed  
by  gel  electrophoresis  and  spectrophotometry.  Total  RNA  was  used  
for  microarray  analysis  as  well  as  for  reverse  transcription  quantita-
tive  polymerase  chain  reaction  (QRT-PCR).  
2.3.  Microarrays,  probe  preparations  and  hybridizations  
Construction  and  use of  microarrays  were as  described  [10]. Briefly, 
3200  amplified  cDNA  inserts  from  rat  heart,  kidney,  liver  and  brain  
libraries  were  purified  with  MultiScreen-PCR  plate  (Millipore),  resus-
pended  in  50% dimethyl  sulfoxide/water,  and  arrayed  on  amino-silan-
ized  slides  (Sigma-Aldrich,  St.  Louis,  MO,  USA)  using  a  MicroGrid  
Total  Array  System  (BioRobotics,  Cambridge,  UK)  spotter  with  16  
pins  with  a 4X4  formal.  All  clones  were  spotted  in  duplicate.  After  
printing,  DNA  was  UV  crosslinked  to  the  slides  (Stratagene,  Strata-
linker,  700  mJ)  and  stored  at  room  temperature.  Prior  to  hybridiza-
tion,  the  slides  were  blocked  in  1  X saline  sodium  citrate  (SSC),  0.2%  
sodium  dodecyl  sulfate  (SDS),  1%  bovine  serum  albumin  for  30  min  
at  42°C,  washed  with  water  and  dried  with  high  pressure  air.  15  pg  
total  RNA  from each sample  was  amplified  by a linear antisense  RNA 
amplification  method,  and  labeled  with  Cy3  or  Cy5  fluorescent  dye  
during  reverse  transcription  as  described  previously  [1 lj.  Briefly, 2  pg 
of  amplified  RNA  was  labeled  with  0.4  pM  random  nonamers,  0.1  
mM  d(G/T/A)TPs,  0.05  mM  dCTP  (Amersham  Pharmacia  Biotech,  
UK),  20  U  RNasin  (Fermentas,  Vilnius,  Lithuania),  1  X first strand 
buffer,  200  U  RNase  H  (—) point  mutant  M-MLV  reverse  transcrip-
tase  (Fermentas),  and  0.05  mM  Cy3-dCTP  or  Cy5-dCTP  (NEN  Life  
Science  Products,  Boston,  MA,  USA)  in  20  pi  total  volume.  The  
RNA,  primer  and  RNasin  were  denatured  at  75°C  for  5  min  and  
cooled  on  ice before adding  the  remaining  reaction  components. After 
2  h incubation  at  37°C,  the  heteroduplexes  were  purified  as  described  
for recovery  [12], denatured  and  the mRNA  was alkali  hydrolyzed  for  
15  min  at  37°C  and  neutralized  with  3  M  NaOAc  (pH  5.0).  The  
labeled  cDNA  was  purified  with  a  PCR  purification  kit  (Macherey-
Nagel)  according to the manufacturer's  instructions.  Probes  generated  
from  the  control  and  ischemic  or  preconditioned  heart  samples  were  
mixed,  reconstituted  in  12  pi  hybridization  buffer  (50%  formamide,  
5 X SSC,  0.1% SDS,  100 pg/ml  salmon  sperm  DNA)  and  applied  onto  
the  array  after denaturation  by  heating  for  1 min  at  90°C.  The  slide  
was  covered  with  a  22  mm X 22 mm  coverslip,  and  sealed  with  DPX  
Mountant  (Fluka,  Buchs,  Switzerland)  in  order  to  prevent  evapora-
tion.  Slides  were incubated  at  42°C for  20  h  in  a  humid  hybridization  
chamber.  After  hybridization  the  mountant  was  removed  and  the  
arrays  were  washed  by  submersion  and  agitation  for  10  min  in  
1 XSSC  with  0.1%  SDS,  for  10  min  in  0.1%xSSC  with  0.1%  SDS  
and  for  10 min  in  0.1 XSSC  at  room  temperature,  then  rinsed  briefly  
in  deionized  water  and  dried.  
2.4.  Scanning  and data  analysis  
Each  array  was  scanned  under  a  green  laser  (532  nm)  (for  Cy3  
labeling)  and  under  a  red  laser  (660  nm)  (for  Cy5  labeling)  using  a  
ScanArray  Lite  (GSI  Lumonics,  Billerica,  MA,  USA)  scanning  con-
focal  fluorescent  scanner  with  10 pm  resolution.  Image  analysis  was  
performed  by  ScanAlyze2  software  (http://www.microarrays.org/soft-
ware.html).  Each  spot  was defined by manual  positioning  of  a grid  of  
circles over  the image. The  average  pixel  intensity  and  the  local  back-
ground  of  each  spot  were  determined.  A  measure,  i.e.  'expression  
ratio'  (MRAT,  denotes the median  of the  set  of  background-corrected  
single  pixel  intensity  ratios  of  the  two  channels  within  the  spot),  was  
determined  [13],  This  average  expression  ratio  for  all  genes  on  the  
array  was  normalized  to  1.0.  For  background  corrections  those  data  
were  calculated  as  negatives  where  the  average  intensity  of  the  spot  
was  smaller  than  two  times the  average  background  of  the same  area.  
Significant  spots  have  more  than  0.55  CHGTB2  values  in  both  Cy3  
and  Cy5  channels.  Each  experiment  was  performed  twice  using  both  
fluorescent  dyes for labeling  control  and  sample  to  reduce the  number  
of  false positive  or  false negative ratios  deriving from possible  uneven  
incorporation  of  fluorescent  dyes  during  labeling,  or  from  other  ex-
perimental  variables  introduced  by  hybridization,  washing  conditions  
or  array  features.  Therefore,  from  each  RNA  pool  two  probes  were  
generated:  a  Cy5-labeled  and  a  Cy3-labeled  one  in  order  to  perform  
replicate  'color-flip'  experiments  suggested  by  other  authors  [14.15].  
Replica  spots  (on  the same array)  and  replica  experiments  (two differ-
ent  arrays)  resulted  in  four  data  points  for  every  gene.  Those  spots  
were  excluded  from  further  analysis  when  ratios  of  the  replica  spots  
had  a more than  two-fold  difference. The  same restriction  was  applied  
for  the  average  ratios  of  the  replica  experiments.  
2.5.  Real-lime  quantitative  PCR  
Relative  QRT-PCR  was  performed  on  a  RotorGene  2000  instru-
ment  (Corbett  Research,  Sydney, Australia)  with  gene-specific primers 
and  SybrGreen  protocol  to  confirm  the  gene  expression  changes  
observed  by  using  microarrays.  20 pg  of  total  RNA  from  each  pool  
was  reverse  transcribed  in  the  presence  of  poly(dT)  sequences  in  a  
total  volume  of  20 pi.  After  dilution  of  the  mix  with  80  pi  of  water,  
2  pi  of  this  mix  was  used  as  template  in  the  QRT-PCR.  Relative  
expression  ratios  were  normalized  to  P actin.  The  PCR  primers  used  
in  this  study  are  listed  in  Table  1.  All  the  PCRs  were  performed  in  
triplicate. 
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Table  2  
Genes  with  altered  expression  in  response  to  ischemia/reperfusion  when  compared  to  non-ischemic  hearts  
Functional  cluster  Gene  product  Accession  number  Ratio S.D. 
Bioactive  peptides  Atrial  natriuretic  factor  M27498 2.68 0.45 
Cytoskeleton,  extracellular  matrix  proteins  Procollagen,  type  1)1,  a l  W89883 2.64 0.38 
a-Tubulin NM_022298 2.66 0.98 
Energy  metabolism  Mus  domesticas  strain  MilP  mitochondrion  genome  AW545415 0.52 0.1 
NADH-ubiquinone  oxidoreductase  B15  NM  012985  2.28 0.02 
Heal  shock  proteins  Chaperonin  subunit  e  AA956164 1.87 0.11 
Wagneri  gene  for  105-kDa  heal  shock  protein  AW544862 2.47 0.24 
Heal  shock  protein,  86 kDa  1  AJ428213 3.5 0.5 
Metabolic  enzymes  Glycine-A-acyllransferase AA237628 0.57 0.03 
Jsocitrate  dehydrogenase  3 (NAD+)  a  NM  053638  1.87 0.38 
Formiminotransferase  cyclodeaminase  NM  053567  0.5 0.05 
Aconitase  1  AA875134 0.58 0.1 
Others Putative  sialoglycoprotease  type  2  AA273893 0.56 0.06 
Mouse  mRNA  for  AFlq  AB083464 0.6 0.01 
Elongation  factor  Tu  AA8I9168 0.6 0.05 
14-3-3  protein  y subtype D17447 1.94 0.06 
Homo  sapiens  SPG  protein  AA067045 2.12 0.07 
Mus  musculus  antigen  4F2  AW545809 2.31 0.07 
Mouse  histocompatibility  2,  class  11 antigen  A  a  NM  010378  0.58 0.02 
GS4 AF492385 1.91 0.03 
Homo  sapiens  CHMP1.5  protein  (CHMP1.5)  AA066250 2.46 0.16 
Signal  peptidase  NM_031723 2.8 0.34 
Homo  sapiens  HSPC245  AA260293 2.01 0.15 
Glutaminyl-tRNA  synthetase  BE329136 1.99 0.26 
Receptors,  ion  channels,  membrane  proteins  Cytokine  receptor-like  molecule  AA899612 0.59 0.06 
Low-density  lipoprotein  receptor-related  protein  NM  053541  0.6 0.01 
Homo  sapiens  solute  carrier  family  39  (zinc  transporter)  NM  130849  0.45 0.04 
Regulatory  proteins,  kinases,  phosphatases  Homo  sapiens  zinc  finger  protein  28  AW536277 2.03 0.18 
Fas-activated  serine/threonine  FAST  kinase  AA956496 1.93 0.19 
Mus  musculus  forkhead  protein  FK.HR  AA221124 2.11 0.21 
Signal  transduction  Ras  oncogene  neuroblastoma,  Nras  NMJ380766 0.59 0.12 
Synaptic  proteins  Synaptic  vesicle  protein  2B  AF372834 0.44 0.16 
Ubiquitin  system  Non-canonical  ubiquitin  conjugating  enzyme  1  AA250689 0.6 0.01 
Raltus  norvegicus  ubiquitin-like  protein  AW545652 2.45 0.39 
Unknown EST AA276424 0.55 0.11 
Human  DNA  sequence  from clone  1178H5  AW541466 0.58 0.04 
Homo  sapiens  12ql5  BAC  RPCI11-444B24  AW545696 0.58 0.14 
EST AA261708 0.59 0.04 
EST AA268104 0.59 0.01 
Clone:  4933424L15:  p-defensin-containing  protein  NM  031810  0.6 0.06 
EST AA388512 1.99 0.14 
Mus  musculus  clone:  2510040L10  AA244814 2.04 0.21 
EST AA242702 2.07 0.17 
Homo  sapiens  unknown  protein  IT12  AW536219 2.18 
EST AA412944 2.32 0.14 
EST AA073606 2.37 0.24 
EST AA266972 2.49 0.49 
Drosophila  melanogaster  genomic  sequence  AA407331 2.91 0.98 
All  experiments  were  done  in  duplicate  and  data  were  calculated  from  four  intensity  ratios.  'EST'  denotes  expressed  sequence  tag.  
3.  Results  and  discussion  
3.1.  Gene expression alteration  after  ischemialreperfusion  
Relative  gene  expression  changes  in  response  to  ischemia  
and  reperfusion  were  determined  using  the  expression  profiles  
of  t ime-matched  control  hearts  as  baseline.  Changes  of  3200  
genes  were  followed  by  rat-specific  c D N A  microarrays.  In  
response  to  ischemia  and  reperfusion,  out  of  3200  genes  
1468  showed  significant  intensity  (see  Section  2  for  statistical  
calculations)  and  1.6%  showed  altered  expression:  28  genes  
exhibited  significant  up-regulat ion  and  21  were  down-regu-
lated  (Table  2).  Little  is  known  about  the  possible  role  of  
m o s t  of  these  genes  in  ischemia/reperfusion.  
In  a  recent  report ,  global  expression  analysis  in  response  to  
renal  ischemia  was  per formed  by  Yoshida  et  al.  [16],  They  
f o u n d  that  most  of  the  genes  showing  altered  expression  are  
involved  in  cell  structure,  extracellular  matrix,  tissue  repair,  
and  cell  division/differentiation.  By  using  an  Affymetrix  oligo-
nucleotide  microarray  containing  10000  gene-specific  samples  
they  found  122 genes,  the  expression  of  which  changed  due  to  
ischemia-induced  acute  renal  failure.  In  our  present  study,  
several  genes  with  similar  characteristics  were  altered  due  to  
myocardial  ischemia,  i.e.  tubulin,  procollagen,  glycine-A-acyl-
transferase,  several  metabolic  enzymes  and  proteins  involved  
in  programmed  cell  death.  We  detected  extensive  changes  in  
heat  shock  proteins  in  our  present  study.  A  chaperonin  and  
two  heat  shock  proteins  (86  and  105  kDa)  were  induced  by  
ischemia.  The  induction  of  heat  stress  proteins  is  well  known  
in  response  to  myocardial ,  renal,  and  cerebral  ischemia  [17-
20],  however,  this  is  the  first  demonstrat ion  that  chaperonin  
subunit  e  is  significantly  up-regulated  due  to  cardiac  ischemia/  
reperfusion. 
Ischemia/reperfusion  repressed  several  genes  including  some  
mitochondrial  genes  and  aconitase,  a  major  enzyme  of  the  
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Table  3  
Genes  with  altered  expression  due  to  preconditioning  followed  by  ischemia/reperfusion  when  compared  to  either  ischemic/reperfused  hearts  
without  preconditioning  or  non-ischemic  controls  
Functional  cluster  Gene  product  Accession Ratio  1  S.D. Ratio  2  S.D. 
number (Isc/Norm) (1) (Prec/Isc) (2) 
Bioaclive  peptides  Natriuretic  peptide  precursor  type  B  NM  031545  0.73 0.06 1.76 0.21 
Calcium-dependent  binding  Pentaxin-relaled  gene  W42321 0.97 0.09 1.80 0.24 
proteins 
Cyloskeleton,  extracellular  Class  1 |3-tubulin ABOI 1679 0.65 0.18 0.66 0.01 
matrix  proteins  
Heat  shock  proteins  Chaperonin  subunit  5,  e  AA955792 1.87 0.11 2.18 0.21 
Metabolic  enzymes  (2',5')01igoadeny!ale  synthase  1  ZI 8877 1.17 0.15 1.75 0.14 
cGMP  phosphodiesterase  (PDE9A1)  AA273765 1.51 0.26 3.29 0.89 
Peroxisome  proliferalor  activator  receptor  y  NM  013124  0.95 0.23 0.50 0.14 
Protease  (macropain)  28  subunit,  a  NM  017278  1.1 0.31 0.56 0.13 
Betaine-homocysleine  methyltransferase  NM  030850  1.36 0.21 0.57 0.05 
AAAcylsplnngosine  amidohydrolase  1  NM  053407  1.21 0.19 1.70 0.22 
Metal  binding  proteins  Melallothionein  11  H32024 1.08 0.16 1.69 0.08 
Others 18S,  5.8S,  and  28S  ribosomal  RNAs  V01270 2.8 0.29 1.85 0.14 
Coagulation  factor  VII  AA271041 1.29 0.2 1.99 0.21 
Nucleolar  phosphoprolein  of  140  kDa  AA408077 1.07 0.19 2.03 0.31 
Heparin  cofactor  II  AF096869 1.08 0.09 2.08 0.42 
P-Globin X05080 1.08 0.34 0.66 0.01 
Kell  blood  group  glycoprotein  AA900226 0.86 0.11 0.51 0.18 
Cysteine  proteinase  inhibitor  M924I8 0.98 0.09 0.63 0.11 
Receptors,  ion  channels,  Secretory  carrier  membrane  protein  (SCAMP3)  AF005036 1.78 0.27 1.59 0.05 
membrane  proteins  
Neutral  and  basic  amino  acid  transporter  U10110 1.78 0.38 1.64 0.14 
Anion  exchanger  2  NM  017048  1.76 0.29 1.84 0.28 
Lymphatic  endothelium-specific  hyaluronan  AA269330 1.88 0.11 0.58 0.01 
receptor  Lyve-1  
Regulatory  proteins,  kinases,  Myosin  light  chain  kinase  AW142U4 1.02 0.24 0.59 0.14 
phosphatases 
Signal  transduction  Frizzled  homolog  4  AW140615 1.2 0.09 0.55 0.19 
Unknown Unknown  protein  AA259369 1.09 0.08 3.11 0.64 
Unknown  protein  W34106 1.42 0.18 0.47 0.02 
Unknown  protein  AA260880 0.92 0.25 0.54 0.21 
Unknown  protein  AW539764 1.03 0.06 0.55 0.08 
Unknown  protein  AA259659 1.42 0.25 0.57 0.04 
Unknown  protein  AA277040 0.78 0.13 0.59 0.14 
Unknown  protein  1.27 0.11 0.62 0.09 
All  experiments  were  done  in  duplicate  and  data  were  calculated  from  four  intensity  ratios.  'Isc'  denotes  ischemia/reperfusion,  'Norm'  nonis-
chemic  controls,  and  'Prec'  preconditioning.  
ci trate  cycle.  It  is  well  known  tha t  ischemia/reperfusion  results  
in  mitochondrial  damage  leading  to  cell  apoptosis  or  necrosis  
[21-23],  however,  little  is  known  about  the  cellular  mecha-
nisms  of  these  phenomena .  
Lynn  et  al.  studied  the  gene  expression  profile  of  ischemic  
in jury  produced  by  left  coronary  artery  occlusion  without  
reperfusion  in  mouse  hearts.  They  used  an  array  with  only  
588  gene-specific  probes  and  found  only  a  small  number  of  
genes  affected  by  ischemia.  Genes  with  altered  expression  were  
those  encoding  proteins  implicated  in  oxidative  stress,  apopto-
sis  and  cardiac  muscle  development  [6],  In  a  rat  infarction  
model ,  a  detailed  gene  expression  analysis  was  performed  us-
ing  a  microarray  containing  7000 c D N A s  [7] and  several  genes  
encoding  proteins  involved  in  cytoskeletal  architecture,  con-
tractility,  and  metabolism  were  identified.  In  accordance  with  
their  findings,  we  found  several  genes  in  the  present  study  
which  exhibited  changes  in  expression  in  response  to  ische-
mia/reperfusion,  i.e.  heat  shock  proteins,  ubiquinone  oxidore-
ductase,  ubiquinone  binding  protein,  collagen,  tubulin,  and  
atr ial  natriuretic  factor .  
In  our  present  study,  several  clones  encoding  hypothetical  
proteins  or  ESTs  having  no  homology  to  known  proteins  
exhibited  significant  up-  or  down-regulation.  The  cellular  
funct ion  of  these  genes  and  their  relationship  to  myocardial  
ischemia/reperfusion  needs  to  be  elucidated.  
3.2.  Gene expression alteration due to preconditioning 
T o  study  the  effects  of  preceding  preconditioning  on  ische-
mia/reperfusion-induced  gene  expression  patterns,  we  used  
c D N A  microarrays  to  monitor  alterations  in  gene  expression  
of  ischemic  rat  hearts  with  and  without  preconditioning.  
Genes  exhibiting  characteristic  changes  in  expression  due  to  
preconditioning  are  shown  in  Table  3.  Out  of  3200  rat  genes  
1450  had  significant  intensity  values  but  only  1%  of  them  
showed  altered  expression:  14  clones  were  overexpressed  
and  17  repressed  (see  Section  2  for  statistical  calculations).  
In  order  to  confirm  the  differential  expression  of  genes  re-
vealed  by  microarray  analysis  of  rat  hearts  after  ischemia  with  
and  without  preconditioning,  several  genes  were  analyzed  by  
real-time  fluorescent  QRT-PCR.  We  selected  seven  genes  of  
which  the  expression  was  significantly  altered  in  precondi-
tioned  hearts  for  real-time  R T - P C R  analysis  (Fig.  1).  The  
differential  expression  of  these  genes  revealed  an  almost  per-
fect  concordance  with  the  microarray  data.  Genes  encoding  
chaperonin  subunit  e,  anion  exchange  protein  2  and  metal-
lothionein  II  had  a  very  significant  rise  in  transcription  rate,  
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Fig.  1.  Quantitative  determination  of  transcript  levels  by  real-time  
PCR.  Changes  in  transcript  levels  in  rat  hearts  during  ischemia  
(light  box)  and  ischemia  with  preconditioning  (dark  box)  were  con-
firmed  by  triplicate  real-time  PCR.  (3-Actin  was  used  as  a  control.  
The  expression  of  the  following  genes  was  determined:  chaperonin  
subunit  e:  cite;  natriuretic  peptide  precursor  type  B:  npp-,  anion  ex-
change  protein  2:  aex;  melallothionein  II:  mth;  peroxisome  prolifer-
ator  activator  receptor  y:  pparg;  betaine-homocysteine  methyltrans-
ferase:  bmh;  cysteine  proteinase  inhibitor:  cpi.  Dashed  lines  indicate  
the  interval  —1.8-  to  1.8-fold  regulation  (corresponding  to  
logio = 0.255)  in  which  changes  in  expression  were  considered  not  
significant. 
while  the  na t r iu re t ic  pep t ide  p recu r so r  type  B  gene  showed  a  
less  p ronounced  induc t ion .  G e n e s  encod ing  peroxisome  p r o -
l i fera tor  ac t iva tor  recep tor  y  ( P P A R y )  a n d  beta ine-homocys-
teine  methy l t rans fe rase  showed  repress ion,  a l though  the  cys-
te ine  pro te inase  inh ib i to r  gene  exhibi ted  m o d e r a t e  repression  
a t  t he m R N A  level.  
Changes  in  the  express ion  of  s o m e  genes  by  precondi t ioning  
fo l lowed  by  i schemia / reper fus ion  were  similar  to  those  
changed  by  i schemia / reper fus ion  a lone  (overexpressed:  a  se-
c re tory  m e m b r a n e  p ro te in ,  an  a m i n o  acid  t r anspor te r ,  an  
an ion  exchanger ,  a  r i bosoma l  R N A  and  a  chaperon in  gene;  
repressed:  |3-tubulin).  Because  in  the  case  of  precondi t ion ing  
t h e  cont ro l  sample  was  i schemia / reper fus ion  alone,  the  expres-
sion  of  these  genes  changed  m o r e  dramat ica l ly  when  com-
pa red  to  non- ischemic  cont ro ls .  Th is  suggests  t h a t  these  genes  
m i g h t  have  significant  roles  in  ischemic  a d a p t a t i o n  of  the  
h e a r t  dur ing  single  i schemia  w i t h o u t  p recondi t ion ing  as  well.  
T h e  rest  of  the  genes  listed  in  T a b l e  3  a r e  those  which  were  
specifically  and  differentially  expressed  in  response  to  precon-
di t ioning  and  were  nol  altered  af ler  single  ischcmia/reperfu-
sion.  A m o n g  these  genes  mela l lo th ionein ,  coagulat ion  fac tor  
VII ,  cysteine  prote inase  inhibi tor ,  P P A R y  and  myosin  light  
chain  kinase  genes  were  previously  shown  to  have  connections  
with  ischemia  or  o ther  hear t  diseases  [24-33],  Hypoxia  pre-
condi t ion ing  induced  the  expression  of  melal lothionein  in  the  
bra in  [25].  We  f o u n d  here  tha t  the  (2 ' ,5 ' )o l igoadenylate  syn-
thase  gene  showed  overexpression  in  response  to  precondi-
t ioning.  It  has  been  previously  shown  by  o thers  tha t  the  
m R N A  level  of  this  gene  rose  m o r e  than  two-  to  three-fold  
a f t e r  24  h  recovery  f rom  ischemia  in  the  rat  brain  [26],  There-
fore ,  it  is  plausible  to  speculate  tha t  ol igoadenylate  synthase  
might  have  a  protect ive  effect  on  the  hear t  as  well.  Chaper -
onin  subuni t  £  and  natr iuret ic  pept ide  precursor  type  B  also  
exhibited  up-regulat ion  due  to  precondi t ioning.  N o n e  of  these  
genes  has  previously  been  shown  to  be  involved  in  precondi-
t ioning. 
A  m o r e  d rama t i c  induct ion  was  detected  in  the  expression  
of  a  c G M P  phosphodies te rase  (PDE9A1) .  Al tera t ions  in  
c G M P  levels  in  the  hear t  have  previously  been  shown  in  re-
sponse  to  precondi t ioning  [27],  however ,  this  is  the  first  dem-
ons t ra t ion  tha t  the  expression  of  a  phosphodies terase  gene  is  
al tered  d u e  to  precondi t ioning.  
P P A R y  exhibited  one  of  the  mos t  p ronounced  repressions  
due  to  precondi t ioning.  P P A R y  has  been  shown  to  be  in-
volved  in  several  cardiovascular  pathologies  including  a thero-
sclerosis  and  ischemic  hear t  disease,  however ,  this  is  the  first  
demons t r a t i on  t ha t  P P A R y  plays  a  role  in  ischemic  precondi-
t ioning.  Interestingly,  mos t  of  the  previous  studies  show  tha t  
pharmacologica l  act ivat ion  of  P P A R y  protects  the  ischemic  
hea r t  [28-30],  In  cont ras t ,  o u r  present  s tudy  shows  tha t  pre-
condi t ioning  leads  t o  a marked  repression  of  the  P P A R y  gene.  
This  suggests  tha t  t he  role  of  P P A R y  in  ischemic  injury  and  
ischemic  a d a p t a t i o n  is  still  unclear .  
Degrada t ion  of  myocardia l  s t ructura l  prote ins  in  myocar -
dial  infarct ion  has  been  shown  to  be  reduced  by  a  cysteine  
prote inase  inhibi tor  [31].  In  ou r  present  s tudy  a  1.59-fold  re-
pression  was  detected  by  mic roar ray  analysis  and  a  1.75-fold  
repression  by  real- t ime  quant i ta t ive  P C R .  It  seems  tha t  the  
activity  of  cysteine  proteases  is  favored  in  precondi t ioning.  
A n o t h e r  gene  related  to  prote in  degrada t ion  was  also  re-
pressed:  p ro tease  28  subuni t  had  a  1.79-fold  repression;  this  
gene  has  a  regula tory  func t ion  in p r o t e a s o m e f o r  small  prote in  
Table  4  
Heart  rale,  coronary  flow,  and  lactate  dehydrogenase  (LDH)  release  in  non-ischemic  time-matched  control,  ischemia/reperfusion,  and  precondi-
tioning+ischemia/reperfusion  groups  al  the  beginning  of  perfusion,  upon  early  reperfusion  (rep.)  and  at  the  end  of  the  reperfusion  in  isolated  
rat  hearts  
Group  Basal  5 min  rep.  120 min  rep.  
Heart  rate  (beats/min)  
Non-ischemic  control  244 ± 4 2 4 3 1 5 244 1  5 
Ischemia/reperfusion 240 ± 4 246112 249 1  9  
Preconditioning+ischemia/reperfusion 248 ± 6 248112 24617 
Coronary  flow  (ml/min/g)  
Non-ischemic  control  14.7 ±1.0 17.011.0 17.010.9 
Ischemia/reperfusion 15.811.1 15.712.9 12.211.2* 
Preconditioning+ischemia/reperfusion 15.611.2 16.311.6 15.610.9 
LDH  release  (mU/min/g)  
Non-ischemic  control  nd nd nd 
Ischemia/reperfusion nd 671198* 422172* 
Precondilioning+ischemia/reperfusion nd 148156** 223157* 
Data  are  means±S.E.M.;  nd,  non-detectable,  below  the  detection  limit  (77 =  5—8 in  each  group).  
* P < 0 . 0 5  vs.  corresponding  control,  * P < 0 . 0 5  vs.  ischemia/reperfusion.  
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substrate  degradation  [32]  and  has  implications  for  oxidative  
stress  [33].  
3.3.  Limitations  of  the  study  
The  stability  of  the  preparat ion  upon  long-term  perfusion  is  
a  general  concern  in  isolated  heart  preparat ions.  Here  we  used  
a  Langendorff  preparat ion  with  no  left  ventricular  balloon  to  
unload  the  heart  f rom  'af ter load  pressure '  and  to  maintain  a  
good  coronary  perfusion  th roughout  the  perfusion  protocol.  
As  shown  in  Table  4,  in  the  non-ischemic  time-matched  con-
trol  group,  heart  rate  and  coronary  flow  were  stable  and  no  
L D H  release  was  detected  which  show  the  stable  aerobic  con-
dition  of  the  heart .  Precondit ioning  significantly  decreased  
postischemic  L D H  release  showing  the  well-known  cardiopro-
tective  effect  of  precondit ioning  in  this  model  (Table  4).  As  
the  present  study  was  per formed  in  crystalloid-perfused  iso-
lated  rat  hearts  and  the  analysis  of  gene  expression  was  done  
using  cardiac  tissue tha t  did  not  contain  components  of  blood,  
the  mechanisms  of  ischemia/reperfusion  injury  and  precondi-
t ioning  might  be  somewhat  different  in  the  present  ex  vivo  
experimental  model  as  compared  to  in  vivo  situations.  A  fur -
ther  limitation  of  the  present  study  is  tha t  analysis  of  cardiac  
tissue  for  gene  expression  pat tern  was  done  at  the  end  of  the  
2-h  reperfusion  to  allow  time  for m R N A  accumulat ion  and/or  
degradation.  Therefore,  the  present  study  cannot  distinguish  
between  the  ' trigger'  and  'media tor '  genes  of  precondit ioning  
(see  [2-4]  for  reviews);  however,  addressing  this  issue  raises  
many  technical  problems  in  study  design  and  needs  fur ther  
studies  in  the  future.  
In  summary,  here  we  present  a  number  of  genes  of  which  
the  expression  is  significantly  altered  due  to  ischemia/reperfu-
sion  and  precondit ioning  in  the  heart .  Al though  some  of  the  
genes  have  previously  been  shown  to  play  a  role  in  ischemia/  
reperfusion  injury,  this  is  the  first  demonstra t ion  that  most  of  
the  genes  presented  here  are  involved  in  classic  precondit ion-
ing  and  ischemia/reperfusion.  The  newly  identified  genes  in  
ou r  present  study  migh t  lead  to  a  better  understanding  of  
the  cellular  mechanisms  of  the  remarkable  cardioprotect ion  
elicited  by  ischemic  precondit ioning.  
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Abstract 
Objective:  We  investigated  the  influence  of  experimental  hyperlipidemia  on  the  formation  of  cardiac  NO,  superoxide,  and  peroxynitrite  
( O N O O ~ )  in  rat  hearts.  Methods:  Wistar  rats  were  fed  2%  cholesterol-enriched  diet  or  normal  diet  for  8  weeks.  Separate  groups  of  
normal  and  hyperlipidemic  rats  were  injected  twice  intraperitoneally  with  2 X 2 0  p.mol/kg  FeTPPS  (5,10,15,20-tetrakis-[4-sul-
fonatophenyl]-porphyrinato-iron[III]),  a  O N O O "  decomposition  catalyst,  24  h  and  1  h  before  isolation  of  the  hearts.  Results:  A  
cholesterol  diet  significantly  decreased  myocardial  N O  content,  however,  myocardial  Ca~  -dependent  and C a :  -independent  NO  synthase  
activity  and  NO  synthase  protein  level  did  not  change.  Myocardial  superoxide  formation  and  xanthine  oxidase  activity  were  significantly  
increased;  however,  cardiac  superoxide  dismutase  activity  did  not  change  in  the  cholesterol-fed  group.  Dityrosine  in  the  perfusate,  a  
marker  of  cardiac  O N O O  formation,  and  plasma  nitrotyrosine,  a  marker  for  systemic  O N O O "  formation,  were  both  elevated  in  
hyperlipidemic  rats.  In  cholesterol-fed  rats,  left  ventricular  end-diastolic  pressure  (LVEDP)  was  significantly  elevated  as  compared  to  
controls.  Administration  of  FeTPPS  normalized  LVEDP  in  the  cholesterol-fed  group.  Conclusion:  We  conclude  that  cholesterol-enriched  
diet-induced  hyperlipidemia  leads  to  an  increase  in  cardiac  O N O O "  formation  and  a  decrease  in  the  bioavailability  of  N O  which  
contributes  to  the  deterioration  of  cardiac  performance  and  may  lead  to  further  cardiac  pathologies.  
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1.  Introduction  
High-cholesterol  diet  is  regarded  as  an  important  factor  
in  the  development  of  cardiac  diseases  since  it  leads  to  
development  of  hyperlipidemia,  atherosclerosis,  and  is-
chemic  heart  disease.  The  heart  of  hyperlipidemic/atheros-
clerotic  patients  adapts  poorly  to  oxidative  or  other  kinds  
of  stress,  suggesting  that  the  endogenous  adaptive  mecha-
nisms  against  myocardial  stress  are  impaired  [1].  The  
focus  of  research  so  far  has  been  mainly  on  the  coronary  
effects  of  cholesterol,  i.e.  coronary  sclerosis,  and  the  
possible  direct  effect  of  hypercholesterolemia  on  the  heart  
was  neglected.  Very  few  studies  looked  at  the  cellular  
effects  of  cholesterol-enriched  diet  on  the  myocardium;  
however,  intracellular  lipid  accumulation  in  car-
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diomyocytes  and  several  alterations  in  the  structural  and  
functional  properties  of  the  myocardium  have  been  ob-
served  [2,3].  Furthermore,  we  have  previously  shown  that  
cholesterol-enriched  diet-induced  hyperlipidemia  at-
tenuates  the  cardioprotective  effect  of  ischemic  precondi-
tioning  via  a  mechanism  independent  from  the  vascular  
effects  of  hyperlipidemia  ([4,5],  see  Ref.  [6]  for  review).  
Increasing  evidence  accumulated  in  recent  years  show-
ing  that  high-cholesterol  diet  impairs  NO-cGMP  signaling  
in  both  endothelial  and  nonendotheliai  cells  [4,7-9].  In  the  
normal  heart,  nitric  oxide  (NO)  is  synthesized  by  Ca2 + -
dependent  NO  synthases  in  cardiac  myocytes,  vascular  and  
endocardial  endothelium  (NO  synthase  III)  as  well  as  in  
specific  cardiac  neurons  (NO  synthase  I)  and  plays  an  
important  role  in  the  regulation  of  coronary  circulation  and  
cardiac  contractile  function  [10].  Atherosclerosis  is  a  well  
known  'NO  deficient  state'  in  the  vasculature  which  leads  
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to sustained  arterial  hypertension  (see  Ref.  [11]  for review) 
and reduced  cardiovascular  tolerance  to stress  (see Ref.  [6]  
for  review).  Lefer  and  Ma  [7]  observed  reduced  NO  
release  from  rabbit  aorta  in  hypercholesterolemia,  and  
Deliconstantinos  et  al.  [9]  showed  that  incorporation  of  
high  concentrations  of  cholesterol  into  endothelial  cell  
membranes  caused  downregulation  of  NO  synthase.  Re-
duced  vascular NO  release  in hyperlipidemia  has  been  also  
shown  as  a  consequence  of  increased  formation  of  
superoxide,  which  then  reacts  with  NO  to  form  perox-
ynitrite  (ONOO")  [12,13].  However,  the  effect  of  hy-
perlipidemia  on  the  formation  of  NO,  superoxide,  and  
ONOO"  in  the  heart  is  not  known.  
We  have  previously  shown  that  cardiac  NO  level  is  
significantly  decreased  in  hearts  of  cholesterol-fed  rats  [4],  
However,  the  mechanism  of  reduced NO  level  in  the  heart  
is  not  known.  Here  we  hypothesized,  that  the  decrease  in  
cardiac  NO  level  is  secondary  to  increased  production  of  
superoxide  and  formation  of  ONOO - .  Therefore,  in  the  
present  study we  systematically  analyzed  if  hyperlipidemia  
influences  formation  of  cardiac  NO,  superoxide,  and  
ONOO - .  Here  we  measured  myocardial  levels  of  NO,  
superoxide,  and  their  reaction  product  ONOO - .  We  also  
determined  activities  of  major  enzymatic  sources  for  NO  
and  superoxide,  i.e.  NO  synthases  and  xanthine  oxido-
reductase,  the  major  antioxidant  enzyme  superoxide  dis-
mutase (SOD)  as well  as several  parameters of  myocardial  
contractile  function.  
2.  Methods  
The  investigation  conforms  with  the  Guide for  the  Care  
and  Use  of  Laboratory  Animals  published  by  the  US  
National  Institutes  of  Health  (NIH  Publication  No.  85-23,  
revised  1996)  and were  approved  by  the  ethics  committee  
of  the  University  of  Szeged.  
2.1.  Experimental  groups,  induction  of  hyperlipidemia  
Male  Wistar  rats  (18-weeks-old),  housed  in  a  room  
maintained  at  12  h  light-dark  cycles  and  a  constant  
temperature  of  22±2°C,  were  fed  laboratory  chow  en-
riched  with  2% cholesterol  or  standard  chow  for  8  weeks.  
At  the  end  of  the  diet  period,  hearts  were  isolated  for  
measurement  of  cardiac  function  and  biochemical  parame-
ters.  Separate  groups  of  normal  and  hyperlipidemic  rats  
were  injected  twice  intraperitoneally  with  2X20  jxmol/kg  
FcTPPS  (5,10,15,20-tetrakis-[4-sulfonatophenyl |-por-
phyrinato-iron[III]),  a ONOO -  decomposition  catalyst,  24  
h  and  1  h  before  the  isolation  of  the  hearts  to  allow  
sufficient  time  for  repair  mechanisms  and  de  novo  protein  
synthesis  to  recover  ONOO--induced  cellular  injury.  At  
the  end  of  the  8-week  diet  period,  body  weights  of  the  
animals  were  350-400  g,  and  there  were  no  significant  
difference  between  groups;  plasma  cholesterol  and  tri-
glyceride  level  increased  by  20%  and  300%,  respectively,  
which  was  consistent  with  our  previous  findings  [14],  
2.2.  Measurement  of  cardiac  function  in  isolated  rat  
hearts 
At  the  end  of  the  diet  and  FeTPPS  treatment,  rats  were  
anesthetized  with  diethyl  ether  and  injected  intravenously  
with  500  U/kg  heparin.  After  30  s,  hearts  were  excised  
and  placed  in  perfusion  fluid  of  4°C  until  contractions  
ceased.  Each  heart  was  then  cannulated  through  the  aorta  
and the left atrium and prepared for working  heart perfused 
at  37 °C  with  Krebs-Henseleit  bicarbonate  buffer  con-
taining  (in  mM) NaCl  118.4,  KC1 4.1,  CaCl,  2.5,  NaHC03  
25,  KH2P04  1.17,  MgCl2  1.46  and  glucose  11.1;  gassed  
with  95%  0 2  and  5%  C 0 2  and  supplemented  with  0.3  
mmol/1  L-tyrosine  [15].  Preload  (1.7  kPa)  and  afterload  
(9.8  kPa)  were  kept  constant  throughout  the  experiments.  
After a  10  min normoxic,  normothermic  perfusion,  cardiac  
mechanical  functional  and  hemodynamic  parameters  in-
cluding  heart  rate  (HR),  coronary  flow  (CF),  aortic  flow  
(AF),  left  ventricular  developed  pressure  (LVDP)  and  its  
first  derivatives  (+d/7drmaJ1,  -dP/drmax),  and  left  ven-
tricular end-diastolic  pressure  (LVEDP)  were  monitored  as  
described  [15,16].  Coronary  effluent  and  myocardial  tissue  
were  sampled  and  frozen  in  liquid  nitrogen  for  further  
biochemical  measurements.  
2.3.  Measurement  of  cardiac  NO  and  superoxide  
In  separate  experiments,  NO  content  of  ventricular  
tissue  was  measured  using  electron  spin  resonance  spec-
troscopy  after  loading  the  heart  with  the  NO-specific  spin  
trap  Fe2+-A/-methyl-D-glucosamine-dithiocarbamate  
(MGD)  as  described  [15,16].  The  spin-trap  for  NO  was  
prepared  freshly  before  each  experiment.  MGD  (175  mg)  
and FeS04  (50  mg)  dissolved  in  distilled  water  (pH  7.4,  
volume  6  ml)  was  infused  into  the  aortic  cannula  under  
Langendorff  perfusion  (constant  pressure  at 9.8  kPa)  for 5  
min  at  a  rate  of  1  ml/min  in  order  to  measure  basal  
myocardial  NO  content.  Tissue  samples  from  the  apex  of  
the  heart (approximately  150  mg)  were collected  at the end 
of  the  infusion  of  Fe2+(MGD)2  and  placed  into  quartz  
ESR  tubes  and  frozen  in  liquid  nitrogen.  Electron  spin  
resonance  spectra  of  NO-Fe2 +(MGD)2  adducts  were  
recorded  with  a  Bruker  ECS 106  spectrometer  (Rhein-
stetten,  Germany;  ESR  parameters:  X  band,  100  kHz  
modulation  frequency,  160  K  temperature,  10  mW  micro-
wave  power,  2.85  G  modulation  amplitude, 3356  G central  
field)  and  analyzed  for  NO  signal  intensity  as  described  
[161. 
Superoxide  production  in  freshly  minced  vcntricles  was  
assessed  by  lucigenin-enhanced  chemiluminescence  [I5|.  
Approximately  100  mg of  the  apex  of  the  heart was  placcd  
in  1  ml  air-equilibrated  Krebs-Henseleit  solution  con-
taining  10 mmol/l  HEPES-NaOH  (pH 7.4)  and 5  p.mol/1  
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lucigcnin.  Chcmilumincsccnce  was  measured  at  room  
temperature  in  a  liquid  scintillation  counter  using  a  single  
active  phoiomulliplicr  positioned  in  out-of-coincidence  
mode  in  the  presence  or  absence  of  the  superoxide  
scavenger  nitroblue  letrazolium  (NBT,  200  p.mol/1).  NBT-
inhibilablc  chcmiluminescencc  was  considered  an  index  of  
myocardial  superoxide  generation.  It  should  be  noted  that  
NBT,  like  other  superoxide  scavengers,  is  not  entirely  
specific  for  superoxide.  
2.4.  Measurement  of  cardiac  NO  synthase,  xanthine  
oxidoreductase,  and  SOD  activities  
To  estimate  endogenous  enzymatic  NO  production,  
Ca2+-dependent  and  Ca2+-independent  NO  synthase  ac-
tivities  in  ventricular  homogenates  were  measured  by  the  
conversion  of  L-[MC]arginine  to  l-[l4C]citrulline  as  we  
previously  described  [15].  Powdered  frozen  ventricular  
tissue  was placed  in  four volumes  of  ice-cold  homogeniza-
tion  buffer (composition  given  in Ref.  [17])  and  homogen-
ized  with  an  Ultra-Turrex  disperser.  The  homogenate  was  
centrifuged  (lOOOXg  for  10  min)  at 4°C  and  the  superna-
tant  was  kept  on  ice  for  immediate  assay  of  enzyme  
activities.  The  protein  concentration  was  measured  from  
the  supernatant  using  a  Lowry-Folin  method.  Samples  
were  incubated  for  25  min  at  37 °C  in  the  presence  or  
absence  of  either  EGTA  (1  mM)  or  EGTA  plus  Na-
monomethyl-L-arginine  (1  mM)  to  determine  the  level  of  
Ca2+-dependent  and  Ca2+-independent  NO  synthase  ac-
tivities,  respectively.  
Activity  of  xanthine  oxidoreductase  (xanthine  oxidase  
and  xanthine  dehydrogenase),  one  of  the dominant  sources  
of  superoxide  in  rat hearts,  was  determined  from  ventricu-
lar  homogenates  by  a fluorometric kinetic  assay  based  on  
the  conversion  of  pterine  to  isoxanthopterine  in  the  pres-
ence  (total  xanthine  oxidoreductase  activity)  and  absence  
(xanthine oxidase activity) of  the electron acceptor  methyl-
ene  blue  as  described  [15,18].  Ventricular  homogenates  
were  prepared  as  for  the  measurement  of  NO  synthase  
activity. 
Total  activity  of  SOD  was  measured  by  a  spectro-
photometric  assay  using  a  kit  (Randox  Laboratories  Ltd,  
UK).  Approximately  100  mg  ventricular  tissue  was  
homogenized  in  10  volumes  of  ice-cold  phosphate  buffer  
(0.01  M,  pH 7.0).  Total  SOD  activity  in homogenates  was  
determined  by  the  inhibition  of  formazan  dye  formation  
due  to  superoxide  generated  by  xanthine  and  xanthine  
oxidase. 
2.5.  Measurement  of  cardiac  NO  synthase  III  (Western  
blot) 
Ventricular  homogenates  used  for  NO  synthase  activity  
assays  were further diluted  in the homogenization  buffer to 
allow  loading  of  25  |xg of  total  protein  in  each  lane  of  8%  
polyacrylamide  gel.  Electrophoresis  was  conducted  at  200  
V,  8  mA  for  1.5  h,  and  proteins  were  transferred  on  to  
nitrocellulose  membrane  (25  V,  200  mA,  4°C,  1.5  h)  by  
Western  blotting.  Membranes  were  then  incubated  at room 
temperature  for  1 h  with  monoclonal  anli-NO  synthase  III  
antibody  (Transduction  Laboratories  Lexington,  KY,  USA)  
at  1:200  dilution,  and  then  with  horseradish  peroxidase-
conjugated  polyclonal  goal  anti-mouse  IgG  (Transduction  
Laboratories)  at  1:500  dilution  for  2  h.  The  membranes  
were  then  developed  with  an enhanced  chemiluminescence  
kit  (NEN  Boston,  MA,  USA).  NO  synthase  III  level  was  
assessed  by  densitometry.  
2.6.  Measurement  of  markers  of  ONOO  
We measured  both dityrosine  by  spectrofluorometry  and  
free  nitrotyrosine  by  enyme-linked  immunosorbent  assay  
(ELISA;  Cayman  Chemical,  Ann  Arbor,  MI,  USA)  in  the  
perfusate  as  markers  of  cardiac  ONOO"  formation  [15].  
ONOO"  promotes  nitration  of  phenolic  compounds  such  
as tyrosine,  the nitration of  which  leads to the formation  of  
stable  products,  dityrosine  and  3-nitrotyrosine.  Therefore,  
to  measure  cardiac  ONOO"  generation,  Krebs-Henseleit  
buffer  was  supplemented  with  L-tyrosine  and  dityrosine  
and  nitrotyrosine  formation  was  detected  in  the  coronary  
effluent  as  described  [15].  Dityrosine  and  nitrotyrosine  
formation was normalized to coronary flow  and wet weight 
of  the  hearts  and  expressed  as pmoles/min/mg  protein.  
We  also  measured  plasma  nitrotyrosine  as  a  marker  of  
systemic  ONOO"  generation  as  described  [13].  Plasma  
ONOO-  concentration  was  expressed  as  nmoles/1.  
2.7.  Measurement  of plasma  malondialdehyde  (MDA)  
MDA  is  a  marker of  lipid  peroxidation  that reacts  with  
thiobarbituric  acid  (TBA).  As  the  reaction  is  not  entirely  
specific  for  MDA,  the  assay  is  called  the  thiobarbituric  
acid-reactive  substance  (TBARS)  assay  [19].  Plasma  sam-
ples  were  mixed  thoroughly  with  1.2  volumes  of  a  stock  
solution  of  15%  w/v  trichloroacetic  acid,  0.375%  w/v  
TBA  and 0.25 N  HC1 and heated for 30 min  at 95 °C. After 
cooling  and  centrifugation  at  1000Xg  for  10  min,  the  
supernatant  containing  TBARS  were  extracted  in  butanol  
and  assayed  spectrophotometrically  at  535  nm.  Freshly  
diluted  tetramethoxypropane  which  yields  MDA  was  used  
as  the  externa]  standard.  
2.8.  Statistical  analysis  
Data  were  expressed  as  means±S.E.M.  and  analyzed  
with  unpaired  f-test  or  ANOVA  followed  by  Tukey's  test  
as  appropriate.  PC0.05  was  accepted  as  a  statistically  
significant  difference.  
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3.  Results  
3.1.  Cardiac  NO  content  and  NO  synthase  
Myocardial  NO  content  was  significantly  decreased  in  
the  hyperlipidemic  group  as  measured  by  electron  spin  
resonance  spectroscopy  after  ex  vivo  spin  trapping  of  NO  
in  isolated  hearts  (Fig.  I A). 
To  test  whether  a  decrease  in  cardiac  NO  in  hyper-
lipidemia  is  a  consequence  of  diminished  enzymatic  
synthesis,  we  measured  cardiac  activities  of  NO  synthases.  
Endogenous  enzymatic  sources  of  NO,  Ca2 +-dependent 
and  Ca2+-independent  NO  synthase  activities  (Fig.  IB)  
were  not  changed  in  the  myocardium  due  to  cholesterol  
diet.  As  Ca2+-independent  NO  synthase  activity  was  
negligible  in  both  groups,  we  have  measured  only  NO  
synthase  III  protein  content.  NO  synthase  III  did  not  
change  in  hyperlipidemic  hearts  when  compared  to  con-
trols  (Fig.  1C).  
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3.2.  Cardiac  superoxide,  xanthine  oxidase  and  
superoxide  dismutase  
To  test  if  cholesterol-enriched  diet  increases  cardiac  
superoxide  generation,  we  performed  a  lucigenin-enhanced  
chemiluminescence  assay  in  freshly  minced  cardiac  tissue.  
Cardiac  superoxide  generation  was  significantly  increased  
due  to  the  high-cholesterol  diet  as  compared  to  controls  
(Fig.  2A).  To  test  possible  changes  in  the  enzymatic  
synthesis  of  superoxide,  we  measured  the  activity  of  
xanthine  oxidoreductase  enzyme  complex,  one  of  the  
major  enzymatic  sources  of  superoxide  in  rat  hearts.  
Xanthine  oxidase  activity  was  significantly  increased  in  the  
hyperlipidemic  group  (Fig.  2B).  We  also  assayed  total  
activity  of  SOD  in  the  myocardium,  the  major  enzyme  
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Fig.  I.  Myocardial  NO  contcnt  (A),  myocardial  Ca"'-dependent  and  
Ca  ' -independent  NO synthase  activity  (13),  and  NO  synthase  III  protein  
content  (C)  in  the  control  (Cont)  and  cholesterol-led  (Choi)  groups.  
Results  are  mcans±S.E.M.  (n=7  in  both  groups).  *P<0.05  vs.  control.  
Fig.  2.  Cardiac  superoxide  production  (A),  myocardial  xanthine  oxide  
activity  (B).  and  myocardial  SOD  activity  (C)  in  the  control  (Cont)  and  
cholesterol-fed  (Choi)  groups.  Results  are  meansiS.E.M.  (n=7  in  both  
groups).  *P<0.()5  vs.  control.  
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Fig.  3.  Dityrosine  (A)  formation  in  the  perfusate,  a  marker  for  cardiac  
peroxynitrile  generation;  plasma  nitrotyrosine  (B) concentration,  a  marker  
for  systemic  peroxynitrile  generation;  and  plasma  malondialdehyde  (C)  
concentration,  a  marker  for  systemic  lipid  peroxidation  in  the  control  
(Cont)  and  cholesterol-fed  (Choi)  groups.  Results  are  means±S.E.M.  
(n=7  in  both  groups).  *P<0.05  vs.  control.  
responsible  for  detoxification  of  superoxide.  SOD  activity  
was  not  changed  in  hyperlipidemic  hearts  when  compared  
to  controls  (Fig.  2C).  
3.3.  Cardiac  ONOO  
To  test  formation  of  ONOO  in  the  heart,  isolated  
hearts  obtained  from  cholesterol-fed  and  control  groups  
were  perfused  with  a buffer supplemented  with  0.3  mmol/l  
L-tyrosine.  Markers  of  cardiac  ONOO  generation,  
dityrosine  (Fig.  3A)  in  (he  coronary  effluent,  were  in-
creased  in  the  cholesterol-fed  group  as  compared  to  
controls.  The  formation  of  the  other  cardiac  peroxynitrile  
marker,  nitrotyrosine,  in  the  coronary  effluent,  was  not  
statistically  significantly  increased  in  the  cholesterol-fed  
group  (control  10.48±2.27;  cholesterol-fed  14.19±4.56).  
3.4.  Systemic  ONOO  "  
We  also  studied  if  high-cholesterol  diet  increased  sys-
temic  formation  of  ONOO  . Therefore,  plasma  free  nitro-
tyrosine  concentration  was  measured  in  control  and  choles-
terol-fed  groups  as  a  marker  for  systemic  ONOO"  forma-
tion.  Plasma  free  nitrotyrosine  was  increased  approximate-
ly  two-fold  in  cholesterol-fed  rats  as  compared  to  controls  
(Fig.  3B).  
3.5.  Plasma  malondialdehyde  
We  also  studied  if  high-cholesterol  diet  increased  sys-
temic  lipid  peroxidation  due  to  oxidative  stress.  Therefore,  
plasma  malondialdehyde  concentration  was  measured  in  
control  and  cholesterol-fed  groups  as  a marker  for  systemic  
lipid  peroxidation.  Plasma  malondialdehyde  was  signifi-
cantly  increased  in  cholesterol-fed  rats  as  compared  to  
controls  (Fig.  3C).  
3.6.  Cardiac  function  
To  test  if  an  increase  in  cardiac ONOO"  formation  leads  
to  alterations  in  cardiac  performance,  cardiac  contractile  
parameters  were  measured  in  isolated  working  hearts.  
LVEDP  was  significantly  increased  in  the  hyperlipidemic  
group  as compared  to controls.  Other  parameters  of  cardiac  
performance  such  as  heart  rate,  aortic  flow,  coronary  flow,  
left  ventricular  developed  pressure,  +dP/d / m a x ,  —dP/drmax  
were  not  affected  significantly  by  cholesterol-diet  when  
compared  to  the  control  group  (Table  1).  To  further test  if  
hyperlipidemia-induced  elevation  of  LVEDP  was  due  to  
enhanced  ONOO"  formation,  hyperlipidemic  and  normal  
Table  1  
Cardiac  functional  parameters  in  the  control  and  cholcsterol-fed  groups  
HR CF AF CO LVDP +dP/d/„ lox -dP/d/„„„ LVEDP 
Control 
Cholesterol-fed 
271.0+7.5 
270.3 ±9.4 
22.9±0.5 
22.1 ±0.5 
43.4±2.0 
45.3 ±1.2 
66.3±2.5 
67.4±  1.6  
18.2+0.4 
18.9±0.4 
839.5 ±45.2 
945.0±40.2 
460.0±34.2 
483.8±41.6 
0.52±0.05 
0.85±0.05* 
Heart  rate  (HR,  beats/min);  coronary  flow (CF,  ml/min);  aortic  flow (AF, ml); cardiac  output  (CO, ml/min);  left ventricular  developed  pressure  (LVDP,  
kPa);  left  ventricular  end-diastolic  pressure  (LVEDP,  kPa);  +dP/dl„,:lx  (kPa/s);  -dP/d/ m a x  (kPa/s).  Values  are  means±S.E.M.  («=8  in  each  group).  
*P<0.05  shows  significant  difference  compared  to  control.  
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Fig. 4.  Left ventricular end-diastolic  pressure  (LVEDP)  in control  (Cont),  
cholesterol-fed  (Choi),  and  cholesterol-fed+FeTPPS-treated  (Chol + 
FeTPPS)  groups.  Results  are  means±S.E.M.  (n=8  in  each  group).  *P<  
0.05  vs.  control, # P<0.05  vs.  cholesterol-fed.  
rats  were  treated  with  FeTPPS,  a  ONOO"  decomposition  
catalyst.  In  the  hyperlipidemic  group,  LVEDP  was  re-
covered  to  control  values  after  FeTPPS  treatment,  how-
ever,  FeTPPS  did  not  change  LVEDP  in  the  normal  group  
(Fig.  4).  
4.  Discussion  
The  present  results  show  that  cholesterol-enriched  diet  
for  8  weeks  markedly  reduces  cardiac  NO  level,  enhances  
cardiac  formation  of  superoxide  and  their  reaction  product  
ONOO",  thereby  leading  to  an  increase  in  LVEDP,  which  
can  be  prevented  by  pretreatment  with  a  ONOO"  de-
composition  catalyst,  FeTPPS.  This  is  the  first  demonstra-
tion  that  high-cholesterol  diet  leads  to  enhanced  ONOO"  
formation  in  the  heart  which  results  in  a  deterioration  of  
cardiac  function.  
In  accordance  with  our  previous  studies  [4]  we  have  
found  in  the  present  study  that  high-cholesterol  diet  leads  
to  a  decrease  in cardiac  NO  level.  Here  we  further tested  if  
a  decrease  in  cardiac  NO  is  due  to  diminished  NO  
biosynthesis.  Therefore,  we  measured  the  activity  and  the  
protein  content  of  endogenous  enzymatic  sources  of  NO,  
Ca2  h-dependent  and  Ca2  ^-independent  NO  synthases.  We  
have  shown  here  that  high-cholesterol  diet  does  not  affect  
the  activity  of  NO  synthases  and  NO  synthase  III  protein  
content  in  the  myocardium.  This  finding  shows  that  high-
cholesterol  diet-induced  decrease  in  cardiac  NO  is  not  a  
consequence  of  diminished  enzymatic  synthesis.  It  was  
therefore  plausible  to  speculate  that  cholesterol  diet  leads  
to  an  enhanced  elimination  of  NO.  
It  is  well  known  that  NO  rapidly  reacts  with  superoxide  
to  form  the  cytotoxic  species  ONOO  [20].  Hyper-
lipidemia  has  been  shown  to  increase  production  of  
reactive  oxygen  species  including  ONOO  in  the  vascula-
ture  113,20—22).  Although  it  is  not  known  if  hyper-
lipidemia  leads  to  increased  formation  of  reactive  oxygen  
species  in  the  heart,  it  is  plausible  to  speculate  that  this  
mechanism  is  involved  in  the  enhanced  breakdown  of  NO  
in  the  myocardium  in  hyperlipidemia.  Therefore,  we  
measured  cardiac  superoxide  and  ONOO"  production.  
Myocardial  superoxide  level  was  significantly  increased  
due  to  cholesterol  diet  in  this  study.  One  of  the  major  
sources  of  superoxide  in  the  rat  heart  is  the  xanthine  
oxidoreductase  (XOR)  enzyme  [23],  which  comprises  both  
xanthine  dehydrogenase  (XDH)  and  xanthine  oxidase  
(XO).  Our  results  show  that  hyperlipidemia  increased  
myocardial  activity  of  XO.  We  also  assessed  if  a  di-
minished  elimination  of  superoxide  also  plays  a  role  in  
cholesterol-rich  diet-induced  enhanced  superoxide  level,  
however,  SOD  activity  in  the  myocardium  was  not  
changed  in  the  cholesterol-fed  group.  These  results  show  
that  the  increase  in  cardiac  superoxide  in  the  hyper-
lipidemic  group  is  a  consequence  of  increased  superoxide  
synthesis  at  least  in  part  by  enhanced  XO  activity.  
NAD(P)H  oxidase  activity,  another  important  source  of  
cardiac  superoxide  has  not  been  measured  in  this  study.  
In  addition  to  increased  myocardial  superoxide  forma-
tion,  we  have  found  here  that  high-cholesterol  diet  in-
creases  formation  of  a  potential  marker  of  cardiac  
ONOO",  dityrosine  in  the  perfusate.  This  is  the  first  
demonstration  that  hyperlipidemia  increases  ONOO"  for-
mation  in  the  heart.  In  contrast  to  dityrosine,  perfusate  
nitrotyrosine  was  not  statistically  significantly  increased  in  
our  present  study.  This  can  be  explained  by  recent  results  
showing  that  at  relatively  low  level  of  ONOO",  nitro-
tyrosine  formation  is  suppressed  in  favor  of  dityrosine  
[24],  The  source  of  ONOO"  release  in  the  heart  was  not  
determined  in  the  present  study.  Coronary  and  endocardial  
endothelial  cells,  specific  cardiac  nerves,  and  cardiac  
myocytes  may  all  potentially  contribute  to ONOO"  forma-
tion  in  the  heart,  since  all  of  these  cells  are  able  to  
synthesize  NO  and  superoxide.  We  have  also  found  that  
hyperlipidemia  increases  the  plasma  nitrotyrosine  level,  a  
marker  for systemic  ONOO "  generation.  This  is  in  accord-
ance  with  our  previous  study  showing  an  increase  in  serum  
nitrotyrosine  in  rabbits  with  high-cholesterol  diet  [13].  The  
reason  why  nitrotyrosine  level  was  increased  in  the  plasma  
but  not  in  the  coronary  effluent  is  not  clear.  However,  an  
increased  systemic  ONOO "  formation  has  a greater  chance  
to  increase  nitrotyrosine  level  in  the  circulating  plasma  in  
vivo,  whereas  cardiac  ONOO"  formation  has  less  chance  
to  increase  nitrotyrosine  significantly  in  the  perfusate  as  
the  perfusion  buffer  passes  through  the  coronary  circula-
tion  only  once  in  the  Langendorff  preparation.  It  should  be  
noted  that  dityrosine  and  nitrotyrosine  have  been  criticised  
as  being  specific  for ONOO  , e.g.  myeloperoxidase  activi-
ty  in  the  presence  of  nitrite  may  also  lead  to  nitrotyrosine  
formation  [24,25],  However,  both  myeloperoxidase  activi-
ty  and  nitrite  concentration  arc  very  low  in  granulocyte-
free,  Krebs-perfused  hearts.  This  suggests  that  the  
myeloperoxidase  pathway  does  not  substantially  contribute  
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to  nitrotyrosinc  formation  in  our  present  study.  Further-
more,  biochcmical  data  suggesting  (hat  ONOO"  does  not  
cause  tyrosine  nitration  |26]  have  been  recently  refuted  
|271.  Nevertheless,  NO,  radical  may  also  contribute  to  
nitrotyrosinc  formation  [24].  
The cytotoxic effccts of  ONOO"  include  lipid  peroxida-
tion,  nitration  of  tyrosine  residues,  oxidation  of  sulfhydryl  
groups,  DN A-strand  breakage  [28],  and  inhibition  of  
mitochondrial  respiration  [20],  leading  to  tissue  injury,  
which  manifests  itself,  e.g.,  as  a  depression  in  myocardial  
contractile  function |29j.  Many studies show  that enhanced 
formation  of  ONOO"  in  the  myocardium  is  cytotoxic  to  
the  heart  and  contributes  to  ischemia/reperfusion  injury  
both  in  vitro  and  in  vivo,  the  spontaneous  loss  of  cardiac  
function,  as  well  as  cytokine-induced  myocardial  contrac-
tile  failure  in  isolated  rat  hearts  and  in  dogs  in  vivo  
[30-32].  Many  studies  show  a  correlation  between  
ONOO"  formation  and  deterioration  of  cardiac  function  
[31].  Therefore,  here  we  tested  if  increased  ONOO"  in  
hearts  of  cholesterol-fed  rats  leads  to  a  deterioration  of  
cardiac  function.  We  have  found  a  significant  increase  in  
LVEDP  in  the  cholesterol-fed  group.  LVEDP  elevation  is  
the  most  sensitive  parameter of  cardiac  dysfunction  show-
ing  that  the  capability  of  the  heart  to  relax  is  deteriorated.  
This finding is  in  accordance  with  a study  by  Schwemmer  
et  al.  who  reported  a  substantial  decline  in  myocardial  
contractile  and  relaxation  parameters  in  hypercholes-
terolemia  guinea-pig  hearts  [33].  
To  further  test  if  an  increase  in  LVEDP  was  due  to  
ONOO"  formation,  we  examined  the effect of  FeTPPS,  a  
ONOO"  decomposition  catalyst,  on  cardiac  performance  
in  cholesterol-fed  and  control  groups.  FeTPPS  catalyzes  
the  isomerization  of  ONOO"  to  nitrate  anion  and  thereby  
decreases  its  decomposition  to  highly  reactive  inter-
mediates  such  as  nitrogen  dioxide  and  hydroxyl  radical  
[34],  Our  results  show  that  pretreatment  with  FeTPPS  
normalizes  LVEDP in the cholesterol-fed  group, but it does 
not  change  LVEDP  in  the  control  group.  This  finding  
further  suggests  that  hyperlipidemia  induces  ONOO"  
formation  in  the  rat  heart  which  leads  to  an  increase  in  
LVEDP.  As  the  biochemical  measurements  were  not  
repeated  in  the FeTPPS  groups,  some  unspecific effects of 
FeTPPS  on cardiac NO  and superoxide  formation  may also 
account  for  the effect of  FeTPPS,  which  is  a limitation  of  
this  study.  
Our  present  results  do  not  clarify  the  exact  cellular  
mechanisms  by  which  cholesterol  diet  leads  to  an  in-
creased  formation  of  superoxide  and  therefore  ONOO".  
We  used  an  isolated,  crystalloid-perfused  rat  heart  model  
in  our  present  study.  In  this  model,  the  direct  effect  of  
plasma  lipids  and  the  effect  of  atherosclerosis  can  be  
excluded,  since  Wislar  rats  show  moderate  increase  in  
serum  cholesterol  level  and  no  substantial  functional  
atherosclerosis  develops  due  to  cholesterol  diet  [4,35,36].  
Therefore,  enhancement  of  ONOO"  is  most  likely  due  to  
the accumulation of tissue/membrane  cholesterol  [2] rather 
than  the  dircct  acute  effccts  of  high  serum  lipids  itself.  
However,  we  have  also  found  that  plasma  MDA  level,  a  
marker  for  lipid  peroxidation,  was  significantly  increased  
in  the  cholcslerol-fcd  group.  Although  the  source  of  
plasma  MDA  was  not  determined,  one  may  speculate  the  
role  of  oxidized  lipoproteins.  Recent  evidence  shows  that  
oxidized  low  density  lipoprotein  (oxLDL)  is  deposited  in  
the  myocardium  which  leads  to  expression  of  oxLDL  
receptor  (LOX-1)  and  thereby  induces  apoptosis  and  
cardiac  dysfunction  [37,38].  
In  summary,  hyperlipidemia  stimulates  ONOO"  gene-
ration  in  the  heart  which  leads  to  myocardial  dysfunction.  
Targeting  ONOO"  with  pharmacological  tools  may  be  an  
exciting  new  strategy  to protect  the  heart  and  the  vascula-
ture  in  hyperlipidemia.  
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L  Abstract  Cardiac stress adaptation is deteriorated in hyperlipidemia pos-
sibly due to deterioration of nitric oxide (NO) metabolism. However, inhibi-
tion of HMG-CoA reductase,  a key enzyme in the mevalonate pathway, was 
shown to increase the level of endothelial NO-synthase (eNOS) mRNA. Here 
we studied the effect of dietary and pharmacologic modulation of the mevalo-
nate pathway on cardiac NO synthesis. Rats were fed 2 % cholesterol-enriched 
or normal diet for 8 weeks. Normal and cholesterol-fed animals were treated 
with farnesol, a major metabolite of the mevalonate pathway (2.2 mg/kg  i.p.)  
or with the HMG-CoA reductase inhibitor lovastatin ( 3 X 5  mg/kg per  os for 
3  days,  n  =  5 - 6  in  each  group).  Cardiac  NO  content  was  significantly  
decreased in cholesterol-fed rats as assessed by electron spin resonance spec-
troscopy,  however,  other treatments did not influence  cardiac NO  content.  
Cardiac activity of Ca2+-dependent  NOS was unaffected by  cholesterol-diet  
and by treatment with either farnesol or lovastatin, as assessed by 14C-citrullin 
assay.  Ca2+-independent  NOS activity was negligible  in  all groups.  Cardiac  
eNOS protein content measured by Western blotting was also unchanged in 
all groups. We conclude that cholesterol-diet decreases cardiac NO content, 
however, cholesterol diet-induced inhibition of the mevalonate pathway does 
not account for the decreased NO level in the heart, and that the mevalonate 
pathway does not influence cardiac NO biosynthesis. 
L:  Key words  Hyperlipidemia -  heart -  nitric oxide -  mevalonate pathway  -
superoxide 
Introduction 
High cholesterol level is regarded as an important factor 
in the development of ischemic heart diseases. The heart 
of hyperlipidemic/atherosderotic patients adapts poorly 
to  oxidative  or  other  kinds  of  stress,  showing  that  
endogenous  adaptive  mechanisms  against  myocardial  
stress  are  impaired  (30).  In  hypercholesterolemia,  the  
mevalonate  pathway  might  be  downregulated  due  to  
cholesterol-induced  inhibition  of  3-hydroxy-3-methyl-
glutaryl-CoA  (HMG-CoA)  reductase,  the  rate-limiting  
enzyme  of  this  pathway  (30).  Therefore,  excess  exoge-
nous  cholesterol  inhibits  formation  of  polyprenyl  
derivates (2,16). Farnesol and geranylgeraniol, the most 
important polyprenyl products of the mevalonate path-
way, are utilized for protein prenylation and synthesis of 
other polyprenyl derivatives such as ubiquinone. Preny-
lation of several proteins including nuclear protein lamin 
B and a number of GTP-binding regulatory proteins  (G  
proteins) is a prerequisite for their physiological function 
(15).  The highly lipophyl  15-carbon  farnesyl,  or the  20-
carbon  geranylgeranyl  side  chains  of  G proteins  can  
anchor  them  into  lipid  membranes,  which  is  essential  
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for  their  function  in  signal  transduction  pathways.  
Ubiquinone plays a major role in the mitochondrial  elec-
tron-transport  system  and  serves  as  an  endogenous  
antioxidant,  therefore,  it  protects  the  ischemic-reper-
fused myocardium in rats (17). Consequently,  inhibition 
of polyprenyl  biosynthesis may impair  signal-transduc-
tion  processes and the endogenous antioxidant  defence  
system  in the myocardium.  Indeed, we  have  previously  
shown that ischemic adaptation of the myocardium was 
impaired  in  hypercholeslerolemic  rat  hearts  (12,  33),  
however,  it was  recaptured  by  treatment  with  farnesol  
showing that hyperlipidemia led to the inhibition, of the 
mevalonate pathway (8). 
In normal hearts, nitric oxide (NO) is synthesized  by  
Ca2+-dependent  NO  synthases  (NOS)  in  cardiac  myo-
cytes,  vascular,  and  endocardial  endothelium  and  spe-
cific cardiac neurons.  NO plays an important role in the 
regulation of coronary circulation, contractile function, 
and  ischemic  adaptation  of  the  heart  (22).  Increasing  
number  of evidence accumulated  in recent years  show-
ing that high-cholesterol diet impairs NO -  cyclic guano-
sine  3':5'-monophosphate  (cGMP)  signalling  in  both  
endothelial and nonendothelial cells (6,12,26). We have 
previously  shown  that  cardiac  NO level  is  significantly  
decreased in rats with experimental hyperlipidemia (12).  
In contrast to the aforementioned findings, inhibition of 
HMG-CoA  reductase  by  statins  has  been  shown  to  
increase  mRNA  level  of  endothelial  type  NO-synthase  
(eNOS)  in  human  endothelial  cells  (24,  25).  It  is  not  
known,  however,  if  inhibition  of  HMG-CoA  reductase  
affects NO synthesis significantly in the heart tissue, and 
if the mevalonate pathway plays a role in the regulation 
of cardiac NO level. 
Therefore, the aim of the present study was to inves-
tigate  the  effect of  the  modulation  of  the  mevalonate  
pathway  by  dietary  cholesterol  and  by  the  HMG-CoA  
reductase  inhibitor  lovastatin  on  cardiac  NO level  and  
NOS activities in rat hearts. 
Here we show that although cholesterol  diet-induced  
hyperlipidemia decreases cardiac NO level, it is not medi-
ated by the mevalonate pathway, and that the mevalonate 
pathway  does not  play a significant role in  cardiac NO 
synthesis. 
Experimental protocol 
Eighteen weeks old male Wistar rats were fed 2 % choles-
terol-enriched  or  normal  diet  for  8  weeks.  The  body  
weights  of the animals  after the  diet  period  were 420  -
500 g,  and there were no significant  difference between 
normal and cholesterol-fed groups. Wistar rats were cho-
sen  for  the  study,  since  this  species  shows  moderate  
increase  in  serum  cholesterol  level  due to  high  choles-
terol  diet,  and  no  substantia]  atherosclerosis  develops,  
however,  accumulation  of  tissue  cholesterol  leads  to  
strong biochemical  effects (19,29).  Therefore, any non-
specific effect of coronary atherosclerosis resulting from 
decreased  coronary  perfusion  can  be  excluded  in  this  
model  (12). The 8-week cholesterol-enriched  diet  mod-
erately increased serum  cholesterol  from  1.53 ±  0.08 to 
1.96  ±  0.07  (n  =  6,  p  <  0.05)  and  markedly  increased  
serum triglyceride from 0.47 ± 0.04 mmol/L to 1.62 ± 0.07 
(n =  6, p <  0.05)  mmol/L,  respectively,  similarly to  our  
previous studies (4,8,12).  
Animals  on  normal  or  cholesterol-rich  diet  were  
treated  either  with  the  HMG-CoA  reductase  inhibitor  
lovastatin ( 3 X 5  mg/kg per  os for 3 days at the end  of  
diet), or farnesol, a major metabolite of the mevalonate 
pathway (2 X 2.2 mg/kg ¿p., 6 and 1 hours before isola-
tion of hearts, n = 5 - 6 in each group). 
Rats  were  then  anesthetized  with  diethyl  ether,  
heparin  (500 U/kg ¿v.) was given, and the heart was iso-
lated  and  perfused  for  1 min  at  37  °C in  Langendorff  
mode with Krebs-Henseleit buffer as described (3,11) to 
wash out blood. Ventricular tissue was frozen for further 
measurements of NOS activities, and NOS protein. 
In  separate  experiments,  hearts  were  perfused  in  a  
"working" mode (3) to measure cardiac haemodynamic 
parameters such as heart rate (HR), coronary flow (CF), 
aortic flow (AF), and left ventricular end-diastolic pres-
sure  (LVEDP). HR was derived from the left ventricular 
pressure curve,  CF was measured by collecting effluents 
from the right atrium in a measuring cylinder for a time 
period, and AF was measured by a calibrated rotameter 
(KDG Mobrey, Sussex, UK).  LVEDP was measured by a 
pressure  transducer  (B.  Braun,  Melsungen,  Germany)  
connected  to  a  small  polyethylene  catheter  which  was  
inserted into the left ventricle. 
Materials and  methods 
This investigation  conforms the  Guide for the  care and 
use of laboratory animals published by the US National 
Institutes of Health (NIH publication No. 85-23,  revised 
1996) and it was approved by local ethics committee. 
i.  Measurement of cardiac  NO by electron spin resonance 
spectroscopy 
To measure  NO level  in  cardiac tissue  directly,  in  vivo  
spin-trapping of NO was applied, followed by ESR analy-
sis of left ventricular tissue samples as described  (3,5,9,  
39).  The spin trap diethyl-dithio-carbamate  (DETC, 200 
mg/kg),  50 mg/kg  FeSO, and 200 mg/kg sodium  citrate  
were slowly administered intravenously into the femoral 
vein under ether anaesthesia. DETC dissolved in distilled 
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wate r  "was injected separately from FeS04  and sodium  cit-
r a t e  in  0.5  mL  total  vo lume  to  avoid  prec ip i ta t ion  of  
Fe2 + (DETC)2. FeS04  and sodium  citrate were dissolved  in  
distilled water, the p H  was set to  7.4 with  1 mol /L  NaOH,  
and  brought  to  1 mL volume  before injection.  Five  min-
u t e s  after  DETC,  FeS0 4 ,  and  citrate  t rea tment ,  hear t s  
were  isolated  and per fused  in  the Langendorff m o d e  for  
1 m i n u t e  to  eliminate blood,  and  approximately  150  m g  
t i s sue  samples  of  the  left  ventricles  were  placed  in to  
qua r t zESR  tubes, f rozen in liquid nitrogen  unti l  assayed  
f o r  ESR  spectra  of  the  NO-Fe2 +(DETC)2  complex.  
Fe2 +(DETC)2 has high  affinity for NO while fo rming  NO-
Fe2 +(DETC)2 .  The  specific  triplet  signal  of  the  NO-
Fe2 +(DETC)2  is  s u p e r i m p o s e d  on  the  d o m i n a n t  back-
g r o u n d  spectra  of  Cu2 +(DETC)2 .  The  detection  l imit  of  
N O  b y  this  ESR me thod  is  0.05 nmol  (27).  ESR  spectra  
w a s  recorded  with  a  Bruker  ECS 106 (Rheinstetten,  Ger-
m a n y )  spectrometer  operat ing  at  X band  with  100  k H z  
modu la t ion f requency at a temperature  of 160 K, using  10  
m W  microwave  power  to  avoid  saturation.  Scans  were  
t r aced  with  2.85  G modula t ion  amplitude,  340  G  sweep  
wid th ,  and  3356  G central  field  as  described  (27).  After  
subt rac t ion  of  the  backg round  signal  of  Cu2 +(DETC)2 ,  
analysis  of NO content  was per fo rmed  with double  inte-
gra t ion .  The values were expressed in arbi t rary  units.  
Z  Measurement  of  NOS activities 
NOS  activities  in cardiac homogenate  of f rozen  ventric-
u l a r  tissue were de te rmined  f r o m the rate  of  conversion  
of L-[1 4C]arginine to L-[14C]citrulline as described  (9,10).  
Samples  were incubated  for 25 min  at  37  °C in  the  pres-
ence or absence of either EGTA (1 mmol/L) or EGTA plus 
N G -monomethyl-L-arginine  (1 mmol/L)  to de termine  the  
level of Ca 2 +-dependent and - independent NOS activities,  
respectively. NOS activities were expressed in  p m o l / m i n /  
m g  prote in .  Pro te in  concentra t ions  of  vent r icu lar  
homogena t e s  were  de te rmined  by  a bic inchoninic  acid  
p r o t e i n  assay kit  (Sigma  St. Louis,  MO).  
Z  Measurement  of eNOS protein  content  
(Western  immunoblotting)  
Approximate ly  200  m g  frozen  left  ventricular  samples  
w e r e  homogenized  in  a  buf fe r  containing  10  m m o l / L  
HEPES,  0.32  m m o l / L  sucrose,  0.1  mmol /L  EDTA,  1.0  
m m o l / L  DTT,  10 pg/mL trypsin  inhibitor,  10 pg/mL  leu-
pep t in ,  2.1  pg/mL  aprot inin,  and  10  pL PMSF  (pH  7.2),  
a n d  centr i fuged  at  1.000  g  for  10  min  at  4  °C.  
Homogena t e s  were fu r the r diluted in this buffer to  allow  
load ing  of 25 pg of total prote in  in each lane  of  8 %  poly-
acrylamide  gel. Electrophoresis  was conducted  at  200  V,  
8 m A  for  1.5 h, and prote ins were transferred on to  ni t ro-
cellulose m e m b r a n e  (25 V, 200 mA,  4 °C,  1.5 h)  by  West-
ern  blotting.  Nitrocellulose  sheets  were  then  washed  
overnight  in  TBS-Tween-20  (0.2%,  v/v)  containing  5%  
dried  skimmed  milk  powder  to block  nonspecific  b ind-
ing  sites.  After washing,  membranes  were  incubated  at  
room  temperature  for  1 h  with  monoclonal  anti-eNOS  
antibody  (Transduction  Laboratories  Lexington,  KYj  at  
1:200 dilution. After repeated  washing in  TBS with  0.2%  
Tween-20, membranes  were incubated  with  horseradish  
peroxidase-conjugated  polyclonal  goat  ant i -mouse  JgG  
(Transduction Laboratories Lexington,  KY) at  1:500 dilu-
tion  at room temperature  for 2 h. Membranes  were  then  
washed  and  developed  to  per form  chemiluminescence  
detection  with  enhanced  chemiluminescence  kit  (NEN  
Boston,  MA)  and  exposed  to X-ray  film.  Cardiac  eNOS  
protein  level  was  measured  by  scanning  the  imrnuno-
blots  by  sheet  scanner.  Band  density  was  calculated  by  
integrating  tire  area  (in  pixels)  and  expressed  in  arbi-
t rary  units.  
L  Measurement  of superoxide  production  
To  assess  if  hyperlipidemia  leads  to  increased  cardiac  
superoxide  formation,  in  separate  experiments,  super-
oxide  p roduc t ion  in  freshly  minced  ventricles  was  
assessed  by Iucigenin-enhanced  chemiluminescence  in  
no rma l  and  hyper l ipidemic  cont ro l  groups  (9,  37).  
Approximately  100 mg of the apex of the heart was placed 
in  1 mL air-equilibrated  Krebs-Henseleit  solution  con-
taining  10 mmol/L HEPES-NaOH  (pH  7.4) and  5 pmol /L 
Iucigenin  (9).  Chemiluminescence  was  measu red  at  
r oom temperature  in  a liquid  scintillation  counter  us ing  
a single active photomult ipl ier posit ioned in out-of-coin-
cidence mode  in  the  presence  or  absence  of the  super -
oxide  scavenger  n i t ro  blue  te t razol ium  (NBT,  200  
pmol/L).  NBT-inhibitable  chemiluminescence  was  con-
sidered an index of myocardial superoxide  generation.  
Z  Statistics  
Data were expressed  as means  ±  SEM and analysed  with  
one-way  ANOVA  followed by Bonferroni  test.  P  <  0.05  
was accepted  as statistically  significant difference. 
Results 
L  Cardiac function 
Cholesterol-rich  diet  increased  LVEDP,  however,  o ther  
cardiac  functional  parameters  were  not  affected  signi-
ficantly  when compared  to controls.  Additional  farnesol  
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Table  1  Cardiac functional parameters in isolated rat hearts 
Groups HR CF AF LVEDP 
Control 269 + 8 22.4 ±0.5 44.3 ±2.2 0.48 ±0.05 
Cholesterol-fed 265 +tO 21.3 ±0.6 45.7 ±2.5 0.87 ±0.06* 
Farnesol 271 ±8 22.9 ±0.7 43.6 + 2.3 0.50 ±0.04 
Chol+Far 265 ± 9 21.4 ±0.4 44.9 ±1.5 0.83 + 0.06* 
Lova 272 + 7 22.0 ±0.5 41.9 ± 2.1 0.51 ±0.06 
Chol+Lova 267 + 9 21.7 ±0.8 47.1  ±  1.9  0.90 + 0.07« 
Normal or cholesterol-fed animals were treated with farnesol (Farnesol; Chol+Far), 
or with lovastatin (Lova; Chol+Lova). Heart rate (HR, beats/min); Coronary flow (CF, 
mL/min); Aortic flow {AF, mL/min);  Left ventricular end-diastolic  pressure (LVEDP, 
kPa). Values are means ± SEM ( n = 6  in each group). *P <  0.05 significant difference 
vs. control. 
or  lovasta t in  t r e a tmen t s  either  in  the  normal  o r  in  the  
choles terol- fed g r o u p s  were wi thout  effect (Table  1).  
with  lovastatin.  Lovastatin  failed  fo  change  cardiac  NO  
when  compared  to nontreated  normal  or  cholesterol-fed  
groups,  respectively  (Fig.  1).  
Cardiac  NOS activities and  eNOS protein  levels  
To test  if changes  in  cardiac  NO  level  is due  to  different  
rate  of  NO  synthesis,  NOS  activities  and  NOS  protein  
contents  were  assayed  in  all  groups .  Cardiac  Ca2+-
dependent  NOS  activity  was  not  influenced  by  choles-
terol-enriched  diet when  compared  to  normal  controls.  
Neither  farnesol, nor  lovastatin  influenced  cardiac  NOS  
activities  (Fig.  2A.).  Similarly  to  NOS  activities,  cardiac  
eNOS protein content was not influenced by the different 
t reatments  (Fig.  2B.).  As  cardiac  calcium-independent  
A 
L  Cardiac  NO conten t 
Af ter  an  8-week  choles terol -enr iched  diet,  myocardial  
N O  level  was  s ignif icantly  decreased  in  cholesterol-fed  
a n i m a l s  when  c o m p a r e d  to  no rma l  rats  as  assessed  by  
e lec t ron spin spec t roscopy af ter  in  vivo  spin trapping.  To  
test if t he decreased NO level in cholesterol-fed rats is due 
to inh ib i t ion  of the meva lona te  pathway,  cholesterol-fed  
ra ts w e r e t reated with farnesol ,  a major metabolite of the 
m e v a l o n a t e  pa thway.  Farnesol  t rea tment  did  not  influ-
ence t h e a t t enua ted N O level in the cholesterol-fed  group  
or the basa l NO level in the no rma l group. To fur ther test 
if a d i rec t  inhibi t ion  of HMG-CoA reductase changes  NO  
c o n t e n t ,  n o r m a l  a n d  cholesterol-fed  rats  were  t reated  
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Fig.  1  Cardiac  NO level measured by electron spin resonance spectroscopy in rat 
hearts.  Rats  were fed  2%  cholesterol-enriched  (Choi)  or normal  diet  (Cont)  for 8 
weeks.  Normal  and  cholesterol-fed  animals  were  treated  with  farnesol  (Far;  
Chol+Far), a major metabolite of the mevalonate pathway (2.2 mg/kg i.p.),  or with 
the HMG-CoA reductase inhibitor lovastatin (Lov; Chol+Lov, 3 X 5  mg/kg perosfor 
3 days, n =  5 -  6 in each group). Data are mean ± SEM.  *p <  0.05 vs. controls. 
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Fig. 2  Cardiac eNOS activity assessed by a "C-cltrulline assay  (A) and  cardiac eNOS 
protein content measured by western blotting  (B). Rats were fed 2%  cholesterol-
enriched (Choi)  or normal diet (Cont) for 8 weeks. Normal and cholesterol-fed ani-
mals were treated with farnesol  (Far; Chol+Far), a major metabolite of the meval-
onate pathway (2.2 mg/kg i.p.),  or with the HMG-CoA reductase inhibitor lovastatin 
(Lov; Col+Lov, 3 X 5  mg/kg per  osfor 3 days,  n = 5 - 6  in each group). Data are 
mean ± SEM. 
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(iNOS)  activity  was  below  the  detection  limit  in  all  
groups, cardiac iNOS protein content was not measured. 
Cardiac superoxide  production  
To investigate if cardiac NO level is decreased in choles-
terol-fed  animals  due  to  increased  free  radical  forma-
tion,  we  measured  superoxide-anion  production  in  
hearts  of  normal  and  cholesterol-fed  animals  by  luci-
genin-enhanced  chemiluminescence  assay.  Cholesterol-
enriched diet significantly increased superoxide produc-
tion  (control:  146.9  ±  9.4,  hyperlipidemic:  366.4  ±  35.0  
cpm X mg"1 wet weight, p < 0.05, n = 6 and 7). 
Discussion 
We  have  found  that  high  cholesterol  diet-induced  
decrease  in  cardiac  NO  level  was  not  associated  with  
changes in cardiac NOS activities and NOS protein con-
tent.  The  HMG-CoA  reductase  inhibitor  lovastatin,  or  
farnesol, a major metabolite of the mevalonate pathway, 
did not restore cardiac NO level in  cholesterol-fed rats.  
Neither  farnesol,  nor  lovastatin  changed  cardiac  NO  
level,  NOS  activities,  and  NOS  protein  in  normal  rats.  
This is the first demonstration that cardiac NO synthesis 
is not affected significantly by pharmacologic or dietary 
modulation of the mevalonate pathway in rats. We have 
also  found  here  that  cardiac  superoxide  generation  is  
enhanced in cholesterol-fed rats, which may explain the 
decreased cardiac NO level in hyperlipidemia. 
A number of evidences suggest that HMG-CoA reduc-
tase inhibitors (statins) affect vascular NO production in 
different experimental models.  Inhibition of HMG-CoA 
reductase by statins blocks hypoxia-mediated  downreg-
ulation of eNOS and increases  eNOS mRNA level in the 
mouse aorta (1,24) and in hypercholesterolemic  rabbits  
(21).  Endres et al.  (7)  found that  simvastatin  increased  
the  activity  of  calcium-dependent  NOS  in  the  mouse  
aorta  by  2-  to  3-fold.  Increased  NO  level  has  been  
reported in cultured bovine aortic endothelial  cells after 
simvastatin treatment (20). Although these findings sug-
gest the role of the mevalonate pathway in the regulation 
of  vascular  NO  production,  the  exact  mechanisms  
remained unknown. 
In contrast to the aforementioned  findings  in vascu-
lar tissue, we have found here that in the heart tissue, nei-
ther hyperlipidemia nor inhibition of HMG-CoA reduc-
tase by lovastatin affected NOS activities  and  NOS pro-
tein content. This may show that the regulation of NOS 
activities  and  NOS protein  synthesis  is not affected sig-
nificantly by the mevalonate pathway in the heart tissue. 
It is well known that high cholesterol level influences 
NO-cGMP signalling pathway.  Lefer and  Ma observed a 
reduced  NO  release  from  rabbit  aorta  in  hypercholes-
terolemia  (26).  Deliconstantinos  et  al.  showed  that  in-
corporation  of  high  concentration  of  cholesterol  into  
endothelial  cell membranes caused  a downregulation  of  
NO synthesis in cultured bovine  aortic endothelial  cells  
(6).  Feron  et  al.  found  that  in  cultured  bovine  aortic  
endothelial  cells,  experimental  hypercholesterolemia  
decreased NO production but did not  affect eNOS pro-
tein content  (14).  Further studies  in this model  showed  
that hypercholesterolemia-induced  deterioration of NO 
production,  measured  in  a single  cell  by  NO  selective  
electrode, was due to increased production of caveolin-1 
(13).  In contrast to these  findings,  increased eNOS level 
and  NO production  were  found  in  cholesterol  treated  
cultured bovine  aortic  endothelial  cells  (28).  We  have  
found in the present study that cholesterol  diet-induced  
hyperlipidemia although decreases NO level, but it does 
not change NOS activity and NOS protein content in the 
rat heart. This shows that the decreased cardiac NO level 
is not due to impaired NO synthesis, however, it suggests 
that  the breakdown  of  cardiac  NO  is  increased  due  to  
hyperlipidemia.  The  mechanism  of  decreased  cardiac  
NO level in hyperlipidemia remains unknown. However, 
it is well known  that hyperlipidemia  leads to  increased  
production of reactive oxygen species  (ROS) in the vas-
culature which leads  to formation of peroxynitrite  (18,  
23,  31,  32,  34,  36).  We  have  found  here  an  increased  
superoxide production in hyperlipidemic hearts, so it is 
plausible  to  speculate  that  elevated  ROS production  is  
responsible  for  decreased  NO  level  in  hyperlipidemic  
myocardium.  The  source  of  increased  superoxide  for-
mation  in  hyperlipidemic  hearts  has  not  been  deter-
mined in the present study. It has been previously shown 
that hypercholesterolemia leads to increased angiotensin 
II levels and angiotensin receptor subtype  1 expression, 
which  upregulates  NADPH  oxidase  activity,  a  major  
source of superoxide in the vasculature  (35,38).  There-
fore,  it is  plausible to  speculate  that increased  NADPH  
oxidase activity due to hyperlipidemia is a major source 
of  increased  superoxide  production  in  hyperlipidemic  
hearts. 
The major limitation  of the present  study is that  no  
direct evidences were provided showing the  magnitude  
of the blockade of the mevalonate  pathway in the myo-
cardium  either  by  cholesterol  diet  or  lovastatin  treat-
ment.  However, the dose of lovastatin  used in the pres-
ent study is well above the human therapeutic range and 
it is comparable to other studies using lovastatin to inves-
tigate the role of the mevalonate pathway in NOS expres-
sion  (1, 21, 24, 25).  Nevertheless,  it cannot be  excluded 
that  cholesterol  diet  and  lovastatin  treatment  ineffec-
tively blocked the mevalonate  pathway.  
Taken  together,  this  is  the  first  demonstration  that  
modulation of the mevalonate pathway does not change 
the bioavailability of NO in heart.  Furthermore,  choles-
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lerol-enriched  diel-induced  decrease  in  NO  bioavaila-
bility  in  the  heart  is  not  dependent  on  the  mevalonale  
pathway.  Therefore,  to  restore  NO level  in  the  heart  in  
hyperlipidemia,  pharmacological  manipulation  of  the  
mevalonale pathway does not seem to be a valid  option.  
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ORIGINAL  ARTICLE  
Defibrillator)/ Action  of Glibenclamide  Is Independent from 
ATP-Sensitive  l<+ Channels  and  Free Radicals 
Csaba Csonka,  MD,  PhD,  Annamária  Ônody,  MSC,  Tamás  Csont, MD,  PhD,  and  
Péter  Ferdinandy,  MD,  PhD 
Abstract::  This study investigated  whether glibenclamide  exerts a 
defibrillator)' action  and if this action  is  mediated  by a blockade of 
ATP-sensitive  JC channels (KATI>) or by an anti-free radical mecha-
nism.  Aerobically  perfused  isolated  rat  hearts were  subjected  to  10  
min of  pacing-induced  ventricular  fibrillation  (VF)  followed  by  10  
min of perfusion without pacing (post-VF period), in the presence of 
solvent  (controls),  I \iM KATP  blocker glibenclamide,  10 \iM KATP 
opener cromakalim, and their combination, respectively.  In controls, 
pacing-induced VF caused a significant deterioration in cardiac func-
tion in the post-VF period. Spontaneous defibrillation was 42%. Glib-
enclamide improved post-VF cardiac function and resulted  in  100% 
(P <  0.05)  spontaneous defibrillation.  Cromakalim  did  not signifi-
cantly affect post-VF cardiac function and the incidence of spontane-
ous defibrillation as compared with controls. The combination of the 
compounds improved cardiac function and resulted in 83% (P < 0.05) 
spontaneous  defibrillation.  In  separate  experiments,  2,5-
dihydroxybenzoic acid formation in the perfusate as a marker of hy-
droxy] radical  formation was measured  by high-performance liquid 
chromatography  and cardiac superoxide production was assessed by 
lucigenin-enhanced  chemiluminescence  during pacing-induced  VF.  
Glibenclamide did not affect hydroxy] radical generation or myocar-
dial  superoxide  content  during VF.  The  conclusion  is  that gliben-
clamide exerts a  defibrillator)' action  and improves post-VF cardiac 
function in rat hearts and these effects are independent from KATP and 
free radicals. 
Key  Words:  cromakalim, free radicals,  glibenclamide, KATP,  rat  
heart, ventricular fibrillation 
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Ventricular  fibrillation (VF)  is  the  most  common  cause  of  sudden  cardiac  death, which  represents  the single  largest  
cause of "natural" dcatL :n the developed world.',2  Moreover,  
VF occurs commonly in patients after myocardial infarction as 
well  as after cardiac  surgery.  The  dominant  therapeutic  tools  
for patients with life-threatening ventricular arrhythmias have 
become the different defibrillators. Although defibrillators re-
duce cardiac mortality and anti-arrhythmic drugs alone gener-
ally are not thought to improve survival, concomitant therap) 
with  anti-arrhythmic  drugs  in defibrillator recipients  remains  
common. The use  of anti-arrhythmic  drug therapy  in combi-
nation with implantable cardioverter defibrillator is synergistic 
in terms of beneficial effects but also has the potential  for ad-
verse interactions. Therefore, to examine the evidence for "hy-
brid" therapy, using combinations of drugs and nonphaimaco-
logic treatments to reduce the incidence of VF and to increase 
spontaneous  defibrillation  are of  great  clinical  importance.  
Two conditions appear to be important for the initiation of VF: 
abnormal  myocardium,  coronary  arteries,  or cell  membrane  
ion  channels;  and transient modulating events,  such as  ische-
mia. Unfortunately, the exact mechanism of VF is still  poorly 
understood.3 
Glibenclamide  is  an  oral,  second-generation  sulfonyl-
urea drug, commonly used for treatment of non-insulin depen-
dent  diabetes  mellitus.  Glibenclamide  blocks  ATP-sensitive  
potassium channels (KAXP)  in the membrane of pancreatic  13-
cells and leads to insulin secretion. K A T P  was first described by 
Noma4  in  cardiomyocytes.  Two  forms  of  KATP  have  been  
identified: a sarcolemmal  form and  another form in the mito-
chondrial  inner membrane.5,6  Glibenclamide has been widely 
used  and well  established  as  an effective,  nonselective  K A T P  
blocker. Although opening of K A T P  has been shown to produce 
myocardial  anti-ischenric  effect7  and  to  play  a major role  in  
ischemic preconditioning,8,9  it  is believed  to favor the  devel-
opment  of reentry  arrhythmias  including  VF.  K A T P  blockers  
protect  ischemic  myocardial  cells  against  action  potential  
shortening,10  thereby  exerting  81111-31711)411111)0 effects and  at-
tenuating proarrbythmic  effects of  KATP  openers.  Therefore.  
Ka T P  blockers,  such  as glibenclamide,  show  anti-arrhythmic  
including some anti-fibrillatory effects in several  animal mod-
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els  of  ischemia/reperfusion-induced  arrhythmias11-10  as  well  
as  in humans.17  In  an isolated  rat  heart model,  glibenclamide  
has  been  found  to  exert  a defibrillatory  action  after  regional  
ischemia.18  VF  suppression  produced  by  the  combination  of  
glibenclamide  and the KATP  opener RP 49356  raised  the  pos-
sibility  that  glibenclamide-induced  defibrillation  is  mediated  
by  a pharmacologic  mechanism  distinct  from the modulation 
of K a t p .  18 We have previously shown that pacing-induced  VF  
results  in deterioration of cardiac function after termination  of  
VF and that this is mediated  at least  in part by VF-induced  free  
radical  formation.  
Therefore,  the  objectives  of  this  study  were  to  investi-
gate  whether glibenclamide  exerts a deiibrillatory  action  and  
whether  this  action  is  mediated  by  a blockade  of KA T P  in  a  
pacing-induced  VF  model  without  ischemia/reperfusion  in  
isolated  rat  hearts.  We  also  tested  whether  glibenclamide-
induced defibrillation is mediated by an inhibition of free radi-
cal  formation,  and whether glibenclamide is  able to  attenuate  
deterioration of cardiac mechanical  function after VF. 
Here we show that glibenclamide exerts a deiibrillatory 
action  in  a pacing-induced  VF model  and improves  post-VF  
cardiac function. These effects are not dependent on the block-
ade of K a t p  or inhibition of free radical  formation.  
METHODS 
The investigation conforms to the Guide for  the care  and  
use  of laboratory  animals  published by the US National  Insti-
tutes of Health (publication no. 85-23, revised  1996)  and was 
approved by local ethics  committees.  
Chemicals 
Cromakalim  (SmithKline  Beecham,  Essex,  U.K.)  and  
glibenclamide (Sigma, St. Louis, MO, U.S.A.) were dissolved 
in  dimethylsulfoxide  and the  perfusion buffer contained  the  
different  compounds  throughout  the  experimental  protocols.  
The  final  concentration of  dimethylsulfoxide was  5  *  10 -3%  
(vol/vol)  in each group, which does not influence cardiac func-
tion.19,20  AH other chemicals were purchased from Sigma  (St.  
Louis,  MO,  U.S.A.).  
isolated  Rat  Heart  Preparation  
Male Wistar rats (300-350 g) were anesthetized with di-
ethyl  ether.  After  IV  administration  of  heparin  (500  U/kg),  
hearts were isolated  and perfused in Langendorff mode or in a 
working  mode.21  Perfusion was  carried  out  with  an  oxygen-
ated Krebs-Henseleit buffer with the following components (in 
mM):  118.4  NaCl,  4.1  KC1,  2.5  CaC]2,  25  NaHCOs,  1.17  
KH,P0 4 ,1 .46  MgCl2,  and 11.1 glucose.  Preload (1.7 kPa) and 
fterload  (9.8  kPa)  were kept constant  throughout  the  experi-
ments.  The  perfusion  buffer  was  continuously  equilibrated  
with 95% O,  and 5% CO, (pH 7.4; 37°C).  Heart rate, left ven-
tricular  developed  pressure  (LVDP),  maximum  value  of  the  
first derivative of LVDP (+dP/dtn,0X)!  and left ventricular end-
diaslolic pressure were measured from the left  intraventricular  
pressure  curve.  Left  ventricular  pressure  was  measured  by  
means  of  a  pressure  transducer  (B.  Braun,  Melsungen,  Ger-
many) connected to a small polyethylene catheter inserted into 
the left ventricle through the left atrial  cannula.21-22  Ventricu-
lar pressure was on-line digitized and recorded. Coronary flow 
was measured by collecting effluent from the right atrium  in a 
measuring  cylinder  for a timed period.  Aortic  flow was  mea-
sured  by  a  calibrated  rotameter  (KDG  Flowmeters,  Sussex,  
U.K.).21 
Epicardial electrocardiogram was monitored throughout 
the experimental  period  by two  silver electrodes  attached  di-
rectly to the surface of the heart to determine VF. 
Induction  of Ventricular  Fibrillation  by  
Electrical  Pacing  
VF was induced by rapid electrical pacing (20 Hz,  1,200  
beats/min)  for  10 min using  (double-threshold)  square  wave  
impulses  of  1-ms duration by  an electric  stimulator  (Experi-
metria,  Budapest,  Hungary)  through  silver  electrodes.23  The  
active lead was attached directly to the surface of the apex  of  
the heart and the ground lead was attached to the metal  aortic  
cannula.  These conditions  suppressed the sinus node  activity  
and resulted in VF. VF started immediately after commence-
ment  of  rapid  pacing.  During  the  pacing-induced  VF,  the  
hearts  were  switched  to  Langendorff  perfusion  to  maintain  
coronary perfusion. 
Experimental  Protocol  
The experimental protocol is shown in Figure  1.  
First Series of Experiments 
In the first series of experiments we investigated the ef-
fect of glibenclamide  on spontaneous  defibrillation and post-
VF cardiac function.  The perfusion fluid contained solvent, 1 
pMKA T P  blocker  glibenclamide,  10  pM nonselective  KATP  
opener cromakalim,  and their combination throughout the ex-
perimental  protocol,  respectively.  The  concentration  of  glib-
enclamide and cromakalim was selected according to our pre-
vious studies showing that glibenclamide at 1 \iMwas the most 
effective concentration to antagonize the maximal  anti-ische-
mic  effect of  the  KATP  opener  cromakalim  at  10  ¡sM in  rat  
hearts19  and to block the protective effect of ischemic precon-
ditioning.24  Glibenclamide  at  higher  doses  was  found  to  
worsen  basal  and postishemic  myocardial  function,  and  the  
most effective anti-ischemic concentration of cromakalim was  
10 pM in  isolated  working  rat hearts.19  Rat  hearts were  per-
fused  for  10  min  in  "working" perfusion  to  record  baseline  
parameters  for  cardiac  performance.  Hearts  (n  =  12  in  each  
group) were then subjected to  10 min VF induced by pacing at 
20 Hz under Langendorff perfusion as described 23  After ter-
mination of pacing.  5 min Langendorff perfusion was applied 
to allow  spontaneous  defibrillation before switching  to  work-
s'  2003  Lippincoti  Williams  &  Willtins  917 
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Experimental  protocol  in  isolated  rat  hearts  
First  series  of  experiments:  VF  p0E'-vr  pelloci  
(pacing at 2 0  Hz)  Langendorfl  ,woi king"  mode-
Control  I  '  V/7ZV/////A  I  I  
Glib d  mm) i  v/zmz?////,  i  i  
Croma  (10  MM) I  I  I  
Glib  ( 1  ,jM)+  Croma  ( 1 0  m m )  I  1 ^ / / / / / / / / ¿ 7 A  I  I  
Second  series  of  experiments:  
Solvent  I  
Glib  (1  pM)  I  ^  
i  i  i  i  i  i  
0  10  13  20  25  35 min 
FIGURE  1.  Isolated  rat  hearts  (n  =  12  in  each  group)  were  perfused  for  10  min  in  "working"  perfusion  to  record  baseline  
parameters  for  cardiac  performance,  then  subjected  to  10  min  ventricular  fibrillation  (VF)  induced  by  pacing  at  20  Hz  under  
Langendorff  perfusion.  After termination  of pacing,  5 min of Langendorff  perfusion was applied to allow spontaneous  defibrillation  
before  switching  to working  perfusion  (post-VF  period,  open  bars).  Incidence  of spontaneous  defibrillation  was  measured  in  the  
post-VF  period.  When  VF  was  spontaneously  terminated  or  after  mechanical  defibrillation  when  sinus  rhythm  was  restored,  the  
perfusion  was  converted  to  working  mode  for  an  additional  10  min  to  measure  post-VF  cardiac  function.  The  perfusion  fluid  
contained  solvent  (control),  1  pM  glibenclamide  (Glib),  10  pM  cromakalim  (Croma),  and  their  combination  (Glib  +  Croma)  
throughout  the  experiment,  respectively.  In  separate  experiments,  hearts  were  subjected  to  3  min  pacing-induced  VF  and  
2,5-dihydroxybenzoic  acid  formation  and  cardiac  superoxide  production  were  measured  (n  =  7  in  each  group).  
ing perfusion.  If VF was  spontaneously  terminated  and  sinus  
rhythm  was restored, the perfusion was  converted  to  working  
mode  for  an  additional  10  min  to  measure  post-VF  cardiac  
function. In hearts not showing spontaneous defibrillation, me-
chanical  defibrillation was  attempted  after the 5-min  Langen-
dorff perfusion period  to measure post-VF cardiac function. In 
case  of  unsuccessful  defibrillation, post-VF  cardiac  function  
was not  measured.  
Second  Series  of  Experiments  
In  the  second  series  of  experiments we investigated  the  
effect  of  glibenclamide  on  oxygen  free  radical  formation  in  
separate  experiments.  The  perfusion  buffer  contained  1  \sM  
glibenclamide  or its solvent throughout the experiments. After 
10 min  working perfusion, hearts  (n  =  7 in  each  group)  were  
subjected  to  3  min  pacing-induced  VF.  Our  previous  study  
demonstrated  a maximal  oxygen  free radical  formation  al the 
3rd  min  of pacing-induced  VF.2 j  Coronary  effluent was  col-
lected  for 30 seconds  at the  3rd min  of pacing-induced  VF and 
2,5-dihydroxybenzoic acid (2,5-DHB A) content as a marker of 
hydroxy!  radical  formation  was  immediately  measured  by  
high-performance  liquid  chromatography  (HPLC).  In  addi-
tion, approximately  150 mg cardiac tissue from the apex  of the 
left ventricle  was collected  and  cardiac  superoxide  production  
was  measured  by  lucigenin-enhanced  chemiluminescence  in  
freshly minced  tissue  as  described.25  
Measurement  of  Hydroxyl  Radical  Formation  
To measure cardiac formation of hydroxyl radicals in the 
second  series  of experiments, the perfusate was  supplemented  
with  1 mM salicylate.  The formation of 2,5-DHBA, the prod-
uct  of  the  reaction  of  salicylate  and  hydroxy]  radical,27  was  
measured  from the coronary  effluent at the 3rd min of pacing-
induced  VF. Coronary  effluent was  filtered  through  a  Millex-
HV  filter  (0.45  gm  pore  size,  Nihon  Millipore,  Ltd.,  Yon-
ezawa, Japan). Each sample (20 pi) was injected onto a  Merck  
50734  LiChrospher  100  RP-18  cartridge  (Merck,  Darmstadt,  
Germany). The HPLC unit consisted  of a Gilson 307 pump,  an 
ESA  (Chelmsford, MA,  U.S.A.)  Model  5011  analytical  cell,  
and  an  ESA  Coulochem  II  electrochemical  detector.  Elution  
buffer contained  50  mM  sodium  acetate,  50 mM  citric  acid,  
25% methanol, and  5%  i-propanol  (pH 2.5). The flow rate was 
0.5 ml/min. The detection potential was maintained  at 750 mV. 
Peaks  were  identified  by  authentic  standard  (2,5-dihy-
droxybenzoic  acid,  Sigma,  St. Louis,  MO, U.S.A.)  as well  as  
by injecting the bydroxylated  products of salicylic acid  from  a  
pure  hydroxyl  radical  generating  system, i.e., Fenton  reaction  
(50 gM FeS04  and  100  pM H 2 0 2  final  concentrations).  
In  separate  experiments,  we  also  tested  whether  glib-
enclamide directly scavenges hydroxyl radical  in vitro.  Fenton 
reaction was used to generate hydroxyl  radicals in the presence 
and  absence  of  1 pAf and  10 pM glibenclamide  or its  solvent  
dimethylsulfoxide  (0.1,  1%  [vol/vol]).  Formation  of  2,5-
DHBA  was measured  as described  previously.  
Measurement  of  Superoxide  Radical,  a  Marker  
for  Reactive  Oxygen  Species  Formation  
In the  second  series  of  experiments,  myocardial  super-
oxide  production  in  freshly  minced  cardiac  tissue  from  the  
apex  of the  left ventricle  was assessed  by  lucigenin-enhanced  
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chemiluminescence  method  using  5  pM  lucigenin  as  de-
scribed.25  Chemiluminescence  was  measured  in  the  presence  
and absence of the superoxide scavenger nitro blue tetrazolium 
(200 pM) using a scintillation  counter (Packard, Meriden,  CT,  
U.S.A.).  Nitro  blue  tetrazolium-inhibitable  chemilumines-
cence  was  considered  an  index  of  myocardial  superoxide  
generation. 
Statistics 
Data were expressed as means ± SEM. Groups were ana-
Ij'zed with one-way analysis  of variance followed by the Bon-
ferroni test. Incidence of VF was compared by the Fisher  Exact  
test  between  groups.  P  <  0.05  was  accepted  as  indicating  a  
statistically  significant difference. 
RESULTS 
Cardiac  Function  and  
Spontaneous  Defibrillation  
In the solvent-treated  control  group, pacing-induced  VF  
markedly  decreased  cardiac  function  in  the  post-VF  period  
when compared with basal values (Fig. 2). After termination  of  
pacing,  the  incidence  of  spontaneous  defibrillation  was  42%  
(Fig-  3).  
The  nonselective  KA X P  blocker  glibenclamide  (1  pM)  
did  not  influence basal  cardiac  hemodynamic  parameters  ex-
cept coronary  flow (Table 3). However, glibenclamide signifi-
cantly  improved  cardiac  function  after  pacing-induced  VF  
(Fig. 2)  and resulted  in  100% (P < 0.05) spontaneous  defibril-
lation  (Fig.  3).  
To  investigate whether KA X P  plays  a role in the  mecha-
nism  of the defibrillatory effect and the improvement  of post-
VF cardiac function by glibenclamide, hearts were perfused in 
the presence of the combination of  1  pM glibenclamide  and  10  
pM cromakalim  (a nonselective KA X P  opener)  and  10 pM cro-
makalim  alone, respectively.  Cromakalim  alone did not affect 
post-VF cardiac function (Fig. 2) and the incidence  of sponta-
neous  defibrillation  (42%  NS,  Fig.  3)  as compared  with  con-
' rols. Cromakalim did not affect the effects of glibenclamide as 
the combination of the compounds  significantly improved  car-
diac  function and  resulted  in  83%  spontaneous  defibrillation  
(Fig. 2),  effects similar to  that  of glibenclamide  alone.  
Cardiac  Hydroxyl  Radical  Generation  
To  investigate  whether  the  possible  effects  of  gliben-
clamide  are  mediated  by  an  inhibition  of  free  radical  forma-
tion,  hearts  were perfused  in the presence  of  1 raM salicylate,  
and  cardiac  2,5-DHBA  formation  was  measured  from  the  
coronary  effluent by HPLC  as  a  marker  of  cardiac  hydroxyl  
radical  production.  Glibenclamide  (1  pAT) did  not  affect  car-
diac  hydroxyl  radical  generation  at  the  3rd  min  of  pacing-
induced VF when compared  with nontreated  controls (Table  1).  
Before VF Post-VF 
t  m 
5  t5  600  
5;  a.  
+  400  
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FIGURE  2.  Effects  of  glibenclamide  (Gl),  cromakalim  (Cr),  
their  combination  (Gl  +  Cr),  and  their  solvent  (control,  C)  on  
aortic  flow  (AF  (A),  left  ventricular  end-diastolic  pressure  
(LVEDP) (B), and maximum value  of the first derivative  of  LVDP 
(+dP/dtmax)  (C)  measured  before  pacing-induced  ventricular  
fibrillation  (VF)  (n =  12  in each group)  and  at the  15th  min  of  
post-VF  period  (after VF,  n = 9-12).  Data  are mean  ±  SEM, *P 
< 0.05  vs  controls.  
Hydroxyl  Radical  Generation  in  Vitro  
We  also  investigated  the effects of different concentra-
tions of glibenclamide  on hydroxyl radical  formation in  vitro.  
Hydroxyl  radicals  were  produced  by  Fenton  reaction  in  the  
presence  of different  concentrations  of glibenclamide  and  its  
solvent.  Glibenclamide  (1 pM and  10 \iM)  did not inhibit  2,5-
DHBA  production.  The  solvent  dimethylsulfoxide  (0.1  and  
1%  [vol/vol])  concentration-dependently  decreased  2,5-
DHBA  formation  in  vitro  (Table  2);  however,  lower  concen-
trations  had  no effect (data  not  shown).  
Cardiac  Superoxide  Anion  Generation  
In addition to cardiac hydroxyl radical formation, we  in-
vestigated  the effect of  1 pM glibenclamide  on cardiac  super-
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FIGURE  3.  Incidence  of  spontaneous  defibrillation  after  10-
min  electrical  pacing-induced  ventricular fibrillation  (VF)  in the 
presence  of  glibenciamide  (Glib),  cromakalim  (Croma),  their  
combination  (Glib  +  Croma),  and  their  solvent  (control),  re-
spectively.  *P <  0.05  vs  controls  (n  =  12  in  each  group).  
oxide  anion  foirnation.  Glibenciamide  did  not  affect  cardiac  
superoxide  generation  as assessed  by lucigenin-enhanced  che-
miluminescence  in  freshly  minced  cardiac  tissue  when  com-
pared  with  solvent-treated  controls  at  the  3rd  min  of  pacing-
induced  VF (Table  1).  
DISCUSSION 
Our results show that the K A T P  blocker glibenciamide  at  
a  1 -\iM concentration  increases  the  incidence  of  spontaneous  
defibrillation and  attenuates  the  deterioration  of cardiac func-
tion after pacing-induced  VF  in  isolated  rat  hearts.  This  is  the  
first demonstration that glibenciamide  exerts  a potent  defibril-
latory effect and improves post-VF cardiac function in an elec-
trical  pacing-induced  V F  model  in  rat  hearts.  We  further  
showed  that the defibrillatory action  of glibenciamide  is inde-
pendent from K a t p  blockade,  as the nonselective K A T P  opener  
cromakalim  did  not  modify  the  effect  of  glibenciamide.  We  
TABLE  1.  Effects  of glibenciamide  (Glib),  cromakalim  
(Croma),  their  combination  (Glib  +  Croma),  and  their  
solvent  (Control)  on  heart  rate  (HR)  and  coronary  flow  (CF)  
Glib 
(1  yM)  +  
Cont ro l G l ib  (1  yM)  
C r o m a 
(10  yM)  
C r o m a 
(10  yM)  
HR  before  297  +  7  260  +  7  277  +  7  2 8 8 + 7 
HR  af ter  277  +  6  2 5 8 +  13  261  ± 7  271  ± 9  
C F  before  24.2  ±  1.1  2 1 . 5 +  1.1*  27.3  +  1.3  2 4 . 7 + 1 . 1 
C F  af ter  26.1  ± 0 . 9  22.2  ±  2 .5  26.3  ±  1.2  23.9  +  0.8  
Dala  arc mean  ± SEM.  *P  <  0.05 vs  comrois.  
Values measured  before pacing-induced  VF (n =  12 in each group) and  al  
the  15lh min  of post-VF period  (after VF,  n  = 9-12  in each  group).  
TABLE  2.  2,5-dihydroxyben2oic  acid  (2,5-DHBA)  formation  
measured  by  HPLC  as  a  marker  for  cardiac  OH  radical  
generation  and  superoxide  production  
Unt rea ted  1 y M  » i ibenc lamiue  
2 , 5 - D H B A  formation  
( 1 0 " 9  mol /min)  37.4  +  9.20  31.8  +  3.16  
Lucigenin  chemiluminescence  
(cpm/mg)  895  +  126.5  896  ± 1 5 1 . 2  
Data  are  means  +• SEM. 
Values  measured  by  lucigenin-enhanced  chemiluminescence  in  untreated  
control  and  glibenciamide  treated  hearts  at  the  3rd  min  of  electrical  pacing-
induced  VF  (n = 7 in each  group).  
also  observed  that  these  effects of  glibenciamide  are  not  de-
pendent  on  any  anti-oxidant  mechanism.  
K a t p  is known to play a dual role in cardiac  arrhythmias.  
Activation  of K A T P  may  exert proarrhythmic  effect via  short-
ening  of  action  potential.  Tosaki  et  al.28  suggested  that  exac-
erbations  of  reperfusion-induced  arrhythmias  by  cromakalim  
are  also  associated  with  K +  efflux and  that  the  K A T P  blocker  
glibenciamide  reduces  the  incidence  of  reperfusion-inducec.  
V F and  ventricular  tachycardia  in isolated  rat  heart.  D'Alonzo  
et  al.29  have  also  found that  glibenciamide  has  potential  anti-
arrhythmic  activity  in  isolated  rat  hearts.  El-Reyani  et  al.30  
have  shown  that  glibenciamide  has  no  anti-arrhythmic  effect  
but it improves survival after coronary artery ligation  in rats by 
increasing  the possibility  of recovery  from  VF.  Accordingly,  
glibenciamide  has been found to induce  spontaneous  termina-
tion  of  VF  after  regional  ischemia/reperfusion.12  Rees  and  
Curtis18  reported  that  glibenciamide  possesses  defibrillator)  
activity  after regional  ischemia  and  raised  the  possibility  that  
this  effect  of glibenciamide  is independent  from  K A X P  block-
ade. Our present results showed that glibenciamide was able  to  
induce  spontaneous  defibrillation  after  pacing-induced  VF  
without  ischemia  and  reperfusion  and  this  action  was  not  in-
hibited  by  the nonselective  K A X P  opener  cromakalim.  There-
fore, this is the  first  demonstration  that  glibenciamide  exerts a 
defibrillatory action  in the heart via a mechanism  independent  
from  K a x p  in  a pacing-induced  VF  model.  
We  have  previously  shown  that  pacing-induced  VF  is  
capable  of  eliciting  free  radical  formation  even  in the  absence  
T A B L E  3.  Relative  inhibition  produced  by  glibenciamide  
(Glib)  and  dimethyl-sulfoxide  (DMSO)  on  
2,5-dihydroxybenzoic  acid  (2,5-DHBA)  formation  as  a  
marker  of  hydroxyl  radical  generation  in  vitro  
2 ,5 -DHBA  formation  Glib  (1  yM)  Glib  (10  yM)  
(%  of  untreated)  88.2  +  20.2  8 2 . 0 +  10.8  
2 .5 -DHBA  formation  0.1%  D M S O  1%  D M S O  
( %  of  untreated)  20.0  ±  7.9*  3 . 9 +  1.2*  
Data  are  mean  ±  SEM.  *P  < 0.05 vs.  untreated.  n = 3  in each  group.  
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of  ischemia  and «perfusion.23  We  have  found  here  thai  Die  
dciibrillaiory action of glibenclamide  was not inhibilcd by the 
KATP  opener  cromakalim,  which  showed  that  this  effect  is  
KATP-independent.  Therefore,  we  hypothesized  that  gliben-
clamide may exert its defibriJlatory effect by scavenging  oxy-
gen  free  radicals.  However,  glibenclamide  had  no  effect  on  
either myocardial  hydroxy] or superoxide radical  formation in 
our present  study. Moreover, glibenclamide  did not influence 
hydroxyl  radical  formation  in  vitro  as  assessed  by  HPLC,  
showing that the deiibrillalory action of glibenclamide may be 
independent from any antioxidant  mechanism. This finding is 
in accordance with that of Noda et al.,31 who found that gliben-
clamide did not scavenge superoxide and hydroxyl  radicals in 
vitro as measured by electron  spin resonance spectroscopy.  
Opening of KATP  leads  to membrane  hyperpolarization  
and  shortening of action  potential,  both effects resulting  in a 
reduction  in  intracellular  calcium  levels.  Therefore,  KATP  
openers are known as cardioprotective agents.32 Moreover, re-
cent findings suggest that opening of cardiac sarcolemmal33 or 
mitochondrial34,35 KATP increases myocardial free radical pro-
duction,  which  could  trigger  cardioprotection.32,34,35  How-
ever,  it is  well  established  that a  pathologic  increase  in  free  
radical  production leads to a diminished cardiac performance 
and arrhythmias. Therefore, we can speculate that KATP block-
ers  may  indirectly  decrease  cardiac  oxygen  free  radical  pro-
duction  influenced  by KATP  activation,  thereby  preventing  
hearts against VF. Here we did not find changes in free radical 
production  due  to  glibenclamide  treatment;  therefore,  our  
present results do not support this hypothesis. 
Unfortunately,  the exact mechanism  of  glibenclamide-
induced, KATP-independent defibrillation remains unknown. It 
has been shown that the effects of glibenclamide are not solely 
related to its action on KAXP.  Tominaga et al.36  reported that 
glibenclamide inhibits chloride conductance in guinea pig ven-
tricular  myocytes,  thereby  exerting  anti-arrhythmic  effect.  
Glibenclamide has been shown to stimulate lactate production 
during  normoxic perfusion37  and to  attenuate the increase  in  
lactate production during hypoxia.38 Rees and Curtis18 showed 
that glibenclamide widened QT interval and caused sinus bra-
dycardia  during  regional  ischemia.  This  effect  of  gliben-
:lamide was not antagonized by the KATP  opener RP 49356. 
Picard et al.39 showed that glibenclamide prevented the reper-
fusion-induced membrane arachidonic acid release. The afore-
mentioned  KATP-independent  actions  of  glibenclamide  may  
contribute to its defibrillatoiy effect. 
It has been  shown that reperfusion-induced VF signifi-
cantly  worsens  cardiac  mechanical  function when  measured  
after termination  of  VF  and  restoration  of  sinus  rhythm  and  
that this effect of VF is independent from the severity of ische-
nia.40,41  We have further shown that electrically  induced  VF 
without ischemia and reperfusion also causes a deterioration in 
post-VF  cardiac  function.23  The  exact  mechanism  of  VF-
induced  cardiac  dysfunction  is  not  completely  known.  Free  
radical  formation,23  Ca2H  overload,42  reduced  levels  of  ATP 
and  creatine  phosphate,4j  and  alterations  in  mitochondrial  
gene  expression41  are  thought  to  be  responsible  for reduced 
posl-VF  cardiac  performance.  We  may  speculate  that  VF-
induced mild  demand ischemia  in the present  pacing-induced 
VF model may account for the post-VF deterioration of cardiac 
function. However, glibenclamide is known to worsen the out-
come of ischemia/reperfusion.19  In our present  study gliben-
clamide  improved  posl-VF  cardiac  function,  which  argues  
against  VF-induced  demand  ischemia  as a cause of the dete-
rioration of post-VF cardiac function. Nevertheless, this is the 
first  demonstration that glibenclamide is able to attenuate VF-
induced cardiac mechanical dysfunction; however, the mecha-
nism of this effect remains unknown. 
Taken together, we have found here that glibenclamide 
exerts  a  defibrillatory  action  and  improves  post-VF  cardiac  
function in isolated rat heart and that these effects are indepen-
dent from KATP  and inhibition of free radical  formation. The 
possible clinical application of these effects of glibenclamide 
in the treatment of sudden cardiac death in defibrillator recipi-
ent patients needs further investigation. 
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D'Souza,  Savio  P.,  Derek  M.  Yellon,  Claus  Martin,  
Rainer Schulz, Gerd Heusch, Annamaria Onody, Peter 
Ferdinandy,  and  Gary  F.  Baxter.  B-type  natriuretic  
peptide  limits  infarct  size  in  rat  isolated  hearts  via  KATP  
channel  opening.  Am  J  Physiol  Heart  Circ  Physiol  284:  
H1592-H1600,  2003.  First  published  January'  9,  2003;  
10.1152/ajpheart-.00902.2002.—B-type  natriuretic  peptide  
(BNP) has been reported to be released from the myocardium 
during  ischemia.  We hypothesized  that  BNP mediates  car-
dioprotection  during  iscliemia-reperfusion  and  examined  
whether exogenous BNP limits myocardial infarction and the 
potential  role  of  ATP-sensitive  potassium  (KATP) channel  
opening. Langendorff-perfused rat hearts  underwent 35 min 
of left coronary artery occlusion  and 120 min of «perfusion. 
The control  infarct-to-risk  ratio was  44.S  ±  4.4% (means  ±  
SE).  BNP  perfused  10  min  before  ischemia  limited  infarct  
size  in  a  concentration-dependent  manner,  with  maximal  
protection  observed  at  10~R  M < infarct-to-risk  ratio: 20.1  ±  
5.2%, P  <  0.01 vs.  control),  associated with a 2.5-fold eleva-
tion of myocardial  cGMP above the  control  value.  To examine 
the  role  of  KATP channel  opening,  glibenclamide  (10~®  M).  
5-hydroxydecanoate  (5-HD;  lO""1  M),  or HMR-1098 Q0"s  M)  
was coperfused with BNP (,10-s  M). Protection afforded by BNP 
was abolished by glibenclamide  or 5-HD but not by HMR-1098, 
suggesting the involvement  of putative  mitochondrial but not 
sarcolemmal  KATP channel  opening.  We conclude that  natri-
uretic peptide/cGMP/KATP channel signaling may constitute an 
important injury-limiting mechanism in myocardium. 
cGMP; iscliemia-reperfusion; infarct size; preconditioning 
NATRIURETIC  PEPTIDES ARE  RELEASED from many tissues  in  
response  to  physiological  and  pathological  stimuli.  A-
type  (atrial)  natriuretic  peptide  (ANP)  and  B-type  
(brain or ventricular) natriuretic peptide (BNP) are the 
predominant  natriuretic peptides  in mammalian  myo-
cardium.  stored  within  secretory  granules  as  propep-
tides (2,  6. 24). Release  of propeptides  and the  cleaved  
products in response to dilatation  of the  cardiac cham-
bers  in  conditions  such  as heart  failure has  been  well  
described.  Under  such  conditions,  the  classical  endo-
ci-ine actions of ANP and BNP include vasodilatation of 
some peripheral vascular beds and natriuresis (38. 39).  
Address  for  reprint  requests  and  other  correspondence:  G.  F.  
Baxter. Dept. of Basic Sciences, The  Royal  Veterinary  College,  Univ.  
of  London,  Royal  College  St..  London  N W l  0TU,  UK  (E-mail:  
gfbaxter  ^rvc.ac.uk). 
These actions are  mediated by elevation  of  intracellu-
lar  cGMP after peptide  binding to  natriuretic  peptide  
receptor type  A (NPR-A),  a membrane-bound  particu-
late  guanylyl  cyclase  (2, 6,15,  29).  
BNP is the  principal  natriuretic  peptide in  ventric-
ular myocardium.  Experimental  and clinical  evidence  
suggests  that  brief  episodes  of  ischemia  or  hypoxia,  
insufficient to  cause  alterations  in  end-diastolic  pres-
sure  or  irreversible  tissue  injury,  can  evoke  a  rapid,  
release of BNP from cardiac tissue.  Hypoxic  perfusion 
of isolated hearts led to a rapid increase of BNP immu-
noreactivity  in  coronary  effluent  (35).  In  patients  un-
dergoing  percutaneous  transluminal  coronary  angio-
plasty.  coronary  sinus  BNP  concentration  increased  
rapidly  after  balloon  deflation  (33),  and  circulating  
plasma concentrations of BNP were elevated 4.5-fold in 
patients after episodes of unstable angina (32). A func-
tional role for the rapid release  of BNP in response  to  
brief periods of myocardial ischemia is not known.  The 
recognition in recent years that several  neurohormonal  
mediators  are released from myocardium  during brief 
periods of ischemia  underpins the current m echanistic 
model  of ischemic preconditioning (1, 8,  28).  Autocrine  
and  paracrine  mediators  acting  on  G  protein-coupled  
receptors,  notably  adenosine,  bradykinin,  opioid  pep-
tides,  and catecholamines,  participate in the  activation  
of a multiple-stage  signal transduction  pathway.  This  
involves  opening  of  ATP-sensitive  potassium  (KATP)  
channels  as  either  a  downstream  or  proximal  event  
essential  for conferring resistance to  a  subsequent  ep-
isode  of ischemia.  NPR-A  does  not  couple  through  G  
proteins but,  through  elevation  of cGMP,  NPR-A  acti-
vation could modulate KATP channel activity (16). Thus 
the  signal pathway activated  by BNP might  represent  
an alternative prosurvival  mechanism.  To test the hy-
pothesis  that  BNP  is  cytoprotective  during  ischemia-
reperfusion through the  opening  of KATP  channels,  we  
examined  the  ability  of  exogenous  BNP  to  limit  irre-
versible myocardial injury, defining the involvement  of  
KATP  channel  opening using  pharmacological  blockers  
of  KATP  channels.  
The casts of publication  of this article were defrayed in part  by the 
payment  of  page  charges.  The  article  must  therefore  be  hereby  
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MATERIAI jS  AND  METHODS  
Male Sprague-Dawley rata (300-400 g) were used for these 
studies. Animals were treated  in  accordance with the  United  
Kingdom  Animals  (Scientific  Procedures)  Act  of  1986.  Rat  
BNP,.**  (hereinafter  referred  to  as  BNP),  glibenclamide,  
sodium  5-hydroxydecanoate  (5-HD),  8-bromo-cGMP  (8-Br-
cGMP),  and  triplienyltetrazolium  chloride  were  from  Sigma  
(Poole,  UK).  HMR-1098  was  a  gift  of  Avenlis  Pharma.  All  
other reagents  were  of analytic  standard.  
Isolated  Heart  Preparation  
Rats  were  anesthetized  with  pentobarbital  sodium  (50  
rug/kg ip). Heparin  (1 IU/g) was administered  concomitantly.  
Excised hearts were perfused retrogradely through  the  aorta  
at  11.3  kPa  with  Krebs-Henseleit.  buffer  [containing  (in  
mmol/1)  118  NaCL  25  NaHCOa ,  11  glucose,  4.7  KC1,  1.2  
MgS0„-7H20,  1..2  KH 2 P0 4 ,  and  1.8  CaCl2-2H20;  aerated  
with  carbogen,  pH  7.3-7.5,  a t  37°C).  Coronary  flow  rate  
(CFR)  was  determined  by  timed  collection  of  the  coronary  
effluent. A saline-filled latex balloon  connected  to  a  pressure  
transducer  was  inserted  into  the  left  ventricle  (LV).  and  
baseline  end-diastolic  pressure  was  set  at  5-10  nmiHg.  
Heart  rate,  LV end-diastolic  pressure,  and  developed  pres-
sures  were recorded  continuously.  
Infarct  Size  Evaluation  
A  4-0  silk  suture  was  positioned  around  the  left  main  
coronary  artery  and  threaded  through  a  plastic  snare  to  
permit  reversible  occlusion  of the  coronary artery.  Coronary  
occlusion was induced  for 35 min by clamping the snare  onto  
the heart.  Reperfusion  was  achieved  by releasing  the  snare.  
At  the  end  of  120-min  reperfusion,  the  coronary  artery  was  
reoccluded,  and  the  risk  zone  was  delineated  with  Evans'  
blue.  Hearts  were  sectioned  (2  mm)  and  incubated  in  1%  
triphenyltetrazolium  chloride  in  phosphate  buffer  (pPI  7.4,  
37°Ci  for 15 min  to define white necrotic tissue when  fixed in  
10% formalin for 24 h.  Images  of the  sections were drawn  by  
an operator blinded  to the experimental treatment. Risk zone 
areas  and  infarct-to-risk  ratios  were determined  by  comput-
erized  planimetiy  (Planimetry-f  version  1.0 for  Windows).  
Infarction  Protocols  
The  experimental  protocols  for the  three  separate  infarc-
tion studies  are  illustrated  in  Pig.  1.  
Study  I:  BNP  concentration-response,  study.  In the  control  
group,  hearts  were  stabilized  for  15-20  min  and  then  sub-
jected  to 35 min  of regional  ischemia,  followed  by  120 min  of  
reperfusion.  BNP  (10 " l 2 - 1 0 - 8  mol/1)  was  added  to  the  
Krebs-Henseleit  buffer,  and  perfusion  was  started  10  min  
before ischemia  and  continued  until  30-min  reperfusion.  
Study  2:  Katp  channel  blockade  study.  BNP  GO " 8  mol/1)  
was  selected  after the  experiments  described  above.  Hearts  
were randomized  to one  of the following experimental  groups  
(Fig.  1):  1)  Control  group,  as  described  above.  Six  control  
hearts  were  perfused  with  0.016%  DMSO  (the  vehicle  for  
glibenclamide).  Because there was  no effect on infarct size  of  
DMSO, these hearts were combined for statistical  evaluation  
with  non-DMSO-treated  control  hearts  to  comprise  group  1.  
2)  BNP (30 - 8  mol/1) treatment,  as  described  above. 3)  5-HD  
(10"4  mol/1), a blocker of mitochondrial  KATP channels (9, 36), 
was  perfused  10  min  before  ischemia  and  continued  until  
30-min reperfusion. 4) 5-HD GO"4  mol/1)  + BNP GO"8  mol/1),  
coperfused as described  above. 5) Glibenclamide G 0 " e  mol/1),  
a  nonselective  blocker  of  sarcolemmal  KATP and  mitochon-
drial  KATP channels  (7,  17,  23,  37),  was  perfused  10  min  
before  ischemia  and  continued  until  30-min  reperfusion.  
Glibenclamide  was  dissolved  in  DMSO  (final  concentration  
not more than  0.016%). 6) Glibenclamide (10"e  mol/1)  +  BNP  
GO"6  mol/1),  coperfused  as  described  above.  7)  HMR-1098  
GO"5  mol/1),  a  selective  blocker  of  sarcolemmal  KATP  chan-
nels  (14,  21),  was  perfused  10  min  before  ischemia  and  
continued until  30-min reperfusion. 8) HMR-1098 GO"5  rool/  
1) +  BNP  GO""8  mol/1), coperfused  as  described  above.  
Study  3: effects  of  8-Br-cGMP.  In  the  third  infarct  study,  
8-Br-cGMP,  a  cell-permeable  analog  of cGMP, was  perfused  
at  10~ s-10"5  mol/1, commencing  10 min. before ischemia  and  
continued  until  30-min  reperfusion.  A  control  group  was  
Time (min) 
i — i — i — , — , — |  ,— \  ,  
Infarct  study  1  -20-10  0  102030  65  155  
Control  1  1  1  
B N P  10" 1 2  - 1 0 " 8  M  1  I  N  
Infarct  study  2  
Control 
BNP  10"8  M 
5-HD  10"4  M, glibenclamide  10"  
6  M  or HMR1098  10"5M  
5-HD  10'4  M, glibenclamide 
10"6 M  or HMR1098  10"5M + 
BNP  10'8  M 
Infarct  study  3  
Control 
8-Br-cGMP  10'8-  10"5M  
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Fig.  1.  Experimental  protocols  for  infarct  studieE.  
Solid lines, t ime course  of B-type natriuretic  peptide  
(BNP) perfusion  or  8-bromo-cGMP  (8-Br-cGMP)  pe-
fusion: dotted lines, ATP-sensitive potassium  (KATP)  
channel  blocker  perfusion;  5-HD,  5-hydroxydecano-
ate. 
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subjected  to coronary  artery  occlusion  and  reperfusion  only,  
as  described  above.  
Myocardial  cGMP  Concentration  
After stabilization,  hearts  were  perfused  for  10  min  with  
BNP  U 0 - 1 2 - 1 0 ' 8  mo 1/1}  as  described  above.  Ventricular  
myocardium was  then  rapidly  freeze-clamped to the  temper-
ature  of liquid  nitrogen. After extraction  with  trichloroacetic  
acid,  the  tissue  cGMP concentration  was  determined  by  ra-
dioimmunoassay  as  described  previously  (5).  
Endogenous  BNP  Release  After  Ischemia  
After  stabilization,  during  which  baseline  samples  were  
collected, hearts  were  rendered  globally  ischemic for 2, 5,  or  
20 min.  Flow was reinstit-uted,  and the coronary effluent was 
sampled  during reflow. Control hearts were perfused without 
ischemia.  The  ventricular  tissue  was  immediately  frozen  in  
liquid  N2.  Coronary  effluent and  ventricular  tissue  samples  
were  analysed  for BNP immunoreactivity  by  radioimmunas-
say  using  a  commercially  available  kit  [RIK  9085  BNP-32  
(rat),  Peninsula  Laboratories;  San  Carlos,  CA].  Tissue  was  
extracted  with  trifluoroacetic acid. The  peptide  was  purified  
on  CIS  columns,  freeze-dried, and  redissolved  in  "RIA buff-
er."  RLA  buffer  concentrate  was  added  to  the  samples  of  
coronary  effluent, and  aliquots  were  used  for the  assay.  On  
the  basis  of  the  competition  of  1261-labeled  BNP  and  unla-
beled  BNP binding to a limited amount  of specific antibodies, 
a  standard  curve  was constructed  from which  the  concentra-
tion  of BNP in the  samples  was  determined.  
Statistical  Analysis  
Data  are  expressed  as means  ±  SE.  Infarct-to-risk  ratios,  
risk  zone volumes,  and  BNP tissue  concentrations  were  an-
alyzed  using  one-way  ANOVA  and  Fisher's  protected  least-
significant-difference post  hoc test.  LV function  parameters,  
CFR,  and  BNP coronary  effluent concentrations  were  evalu-
ated  using  repeated-measures  ANOVA  with  Bonferroni's  
post  hoc  test.  Statistical  significance  between  group  means  
was  defined  as  P  <  0.05.  
RESULTS 
Technical  Exclusions  
A total  of 217 animals  was  used.  For the  concentra-
tion-response  infarct  experiments.  65  hearts  were  
used,  of which  5 hearts  were  excluded:  one  was  dam-
aged  by instrumentation,  one had  failure  of the  tetra-
zolium  stain,  and  three  had  persistent  bradvarrhyth-
mia  in  the  stabilization  phase.  In the  second  series  of  
experiments,  55 hearts  were  used,  of which  5  hearts  
were  excluded:  two  failed  to  reperfuse,  one  had  an  
instrumentation  error that  prevented  precise  LV func-
tion  assessment,  one  had  failure  of  the  tetrazolium  
stain,  and  one  had  persistent  bradyarrhythmia  
throughout  reperfusion. In  the  third  infarct  series,  46  
hearts  were  successfully  perfused  without  exclusion.  
Therefore, we report the data for  156 successfully com-
pleted  infarct  experiments.  An  additional  36  hearts  
were  used  to examine  tissue  cGMP concentration,  and  
15 hearts were used to study the release  of endogenous 
BNP. 
Infarct  Study  1: BNP  Concentration-Response  Study  
The  risk  zone  volumes  were  similar  among  all  the  
groups (Table  1). The control infarct-to-risk  zone ratio 
was  44.8  ±  4.4% without  BNP  treatment,  consistent  
with  previous  results  (20).  Treatment,  with  BNP  lim-
ited  infarct size  in  a concentration-dependent  manner  
(Fig.  2).  Significant  limitation  of  infarction  was  ob-
served  with  BNP  GO"30,  10"9,  and  10" 8  mold).  The  
highest  BNP  concentration  studied  (10  8  mol/l)  re-
sulted  in  the  smallest  infarct  size  (20.1  ±  5.2%,  P  <  
0.01 vs.  control).  
Preischemic  global  coronary flow rate  averaged  12.5  
ml/min  among the  six  experimental  groups.  After  cor-
onary  artery  occlusion,  there  was  a  decrease  in  the  
global  CFR  of  -35%  and  a  recovery  to  preischemic  
values  immediately  after  reperfusion  with  gradual  
"rundown" during the remaining  120-min  of perfusion 
(Fig.  3A).  The  global  CFR  measured  at  intervals  
throughout  the  protocol  did  not  differ  substantially  
among the experimental  groups. There were  no detect-
able differences among the g-oups in any  of the param-
eters  of LV function measured (spontaneous heart rate, 
developed pressure,  or the rate-pressure  product;  data  
not  presented).  Developed  pressure  and  rate-pressure  
product  declined  immediately  after the  onset  of  coro-
nary  occlusion to the  same extent  in  all  experimental  
groups. 
Table  1.  Risk  zone  volume  in  the  BNP  concentration-
response  study  (study  1),  the  KATP  channel  blocker  
study  (study  2),  and  the  8-Br-cGMP  study  (study  3)  
Treatment  Group  n Risk Volume,  mms  
Study  1  
Control 11 353 + 26 
B N P  DO-8  mol/l)  8 311 +  26  
B N P  (KT 8  mol/l)  9 309 + 26 
B N P  (10 - , 0  mold)  8 336 + 33 
B N P  ( 1 0 - "  mol/l)  12 323 ±  IS  
BNP  (10"1 2  mol/l)  12 337 +  15  
Study  2  
Control 10 3 8 4 + 3 2 
B N P  (10  * mol/l) 5 3 4 5 + 1 3 
5-HD  (10 '*  mold)  6 339 + 29 
5-HD  +  BNP  6 312 +  35  
Glibenclamide  (10  6  mold)  4 367 ± 3 6 
Glibenclamide  +  BNP  6 370 + 26 
HMR-10SS  GO  5  mol/l)  5 351 ± 4 0 
HMR-1098  +  BNP  8 348 ± 3 4 
Study  3  
Control 13 320 + 25 
S-Br-cGMP  (10"r '  mol/l)  10 402 ± 1 4 
8-Br-cGMP  GO"6  mol/l)  9 315 ± 2 2 
8-Br-cGMP  GO"7  mol/l)  7 372 ± 3 4 
8-Br-cGMF  (10 '»  mold)  7 329  ± 2 7  
Values  Rre means  ±  SE:  it,  number  of exper iments .  BNP.  B-type  
(brain  or ventricular)  nat r iure t ic  peptide:  KATP channel ,  ATP-sensi-
tive  K  channel;  5-HD,  5-hydrox.vdecanoate:  8-Br-cGMP.  S-bromo-
cGMP.  No statistically  significant  differences between  groups  were  
detected  (one-way  ANOVA).  
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Pig.  2.  Infarct-to-risk  zone  ratios  for  h e a r t s  per fused  with  BNP  
(10  12-10""K  mol/1).  Bars  represent  means  t  SE;  n  =  8 - 1 2  experi-
m e n t s  in  each group.  *P  <  0.05 and  **P  <  0.01 vs.  control  (one-way  
ANOVA). 
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Infarct  Study  2:  KATP  Channel  Blockade  Study  
In the  second series  of infarct experiments, BNP was 
applied  at  a  concentration  of  10"8  mol/1  and  KATP  
channel  blockers  were coperfused with  BNP.  
The risk zone volume did not differ among the groups 
(Table  1). The  control infarct-to-risk  ratio was  47.1  ±  
2.8% (Fig. 4 ). BNPilO"8  mol/1) treatment resulted in  a  
significant  limitation  of infarct size  (21.3  ±  2.8%, P  <  
0.01 vs. control). Coperfusion of BNP with either 5-HD 
or  glibenclamide  resulted  in abolition  of the  protective  
effect  of  BNP  (infarct-to-risk  ratio:  52.3  ±  5.7%  and  
41.0  ±  7.1%., respectively.  P  =  not  significant vs.  con-
trol).  However,  the  infarct  size  limitation  with  BNP  
was  not  abolished  by HMR-1098  (infarct-to-risk  ratio:  
14.7  ±  2.7%, P  <  0.01 vs.  control  and  P  =  not  signifi-
cant  vs.  BNP).  None  of the  KATP  channel  blockers  per  
se  influenced infarct  size.  
As  in  study  1, the  global  CFR  and  LV function were 
not  altered  by B N P  perfusion or any  of the  KATP  chan-
nel  blockers  (Fig.  SB).  
Infarct  Study  3:  8-Br-cGMP  Study  
In  the  third  series  of experiments,  8-Br-cGMP  was  
applied  across a range of concentrations  to examine the 
role  of receptor-independent  elevation  of  intracellular  
cGMP  in  myocardial  responses  to  ischemia-re-
perfusion.  Risk  zone  volume  was  similar  among  the  
experimental  groups,  and  the  control  infarct-to-risk  
ratio  was  38.7  ±  3 . 6 9 1 .  We  observed  a  paradoxical  
inverse concentration response with increasing concen-
Fig.  3.  Global  coronary  flow  ra te  d a t a  for  t he  B N P  conceit t rat i on-
response s tudy  lA 1; Ka tp channel  blockade s tudy  IB);  and  S-Br-cGMP  
s tudy  (CO.  Symbols  indicate  mean  values;  SE  bars  have  been  re-
moved  for  clarity.  
ischemia  reperfusion  
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trations  of 8-Br-cGMP (Fig. 5). Statistically  significant  
limitation  of infarction  was  observed  with  the  lowest  
concentrations  examined (HT7  mol/1: 23.1 ±  6.3%, P  <  
0.05  vs.  control;  10"a  mol/1: 20.8  ±  4.2%, P  <  0.05  vs.  
control).  However,  treatment  with  higher  concentra-
tions  did  not- result in  a significant limitation  of infarc-
tion. 
Perfusion  with  8-Br-cGMP  at  10"5  and  10 " 6  mol/1  
resulted in a nonsignificant increase in the  preischemic  
CFR  (Fig.  3C;  16.0  ±  1.0 ml/min  in the  control  group  
vs.  19.5  ±  1.1 and  20.3  ±  1.1 ml/min in  the  10"s  and  
10"6  mol/1  8-Br-cGMP-treated  groups,  respectively,  
P  =  not  significant).  These  influences  of  8-Br-cGMP  
were not  observed  with the lower, infarct-limiting con-
centrations  of  the  agent.  No  consistent  patterns  of  
50-, 
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Fig.  5.  Iniarct-to-risk  zone  ratios  for  hear t«  perfused  wi th  8-Br-
cGMP.  Bars  represent  means  i: SE:  n  -  7 -13 .  "~P < 0.05 and  ** P  <  
0.01  vs.  contra!  (one-way  ANOVA).  
8-Br-c.GMP  treatment  on  LV  contractility  were  ob-
served  during the  perfusion  protocol.  
Effect  of  BNP  on  Myocardial  cGMP  Concentration  
Perfusion with  BNP for  10 min  caused  a  concentra-
tion-dependent  increase  of the  cGMP concentration  in  
ventricular  myocardium  (Fig.  6).  In  control  tissue,  at  
the time point corresponding to the onset  of myocardial 
ischemia,  the  cGMP  concentration  was  11.6  ±  0.5  
pmol/g  wet  wt  (n  =  9).  Significant  increases  in  the  
tissue  cGMP concentration  were  observed  after perfu-
sion with 10"9 mol/1 BNP (cGMP: 20.3  ±  5.2 pmol/g wet 
wt, n  = 5, P  <  0.05) and  10  8 mol/1 BNP (cGMP: 28.6  ±  
1.5  pmol/g wet wt,  n  =  8. P  <  0.01).  Lower  concentra-
tions  of  BNP  did  not  cause  statistically  significant  
elevation  of the myocardial  cGMP  concentration.  
BNP  Release  and  Ventricular  Myocardial  
BNP  Concentrations  
We  observed  a  low  basal  release  of  BNP  into  the  
coronary  effluent  in  the  range  of  1.1-9.7  pmoi/1  (see  
Fig.  7). In the control group (no ischemia), this efflux of 
BNP remained  stable throughout  35 min  of perfusion. 
Peak postischemic BNP concentrations  in the  coronary  
effluent were  related  to the  duration  of  preceding  is-
chemia:  2-min  ischemia,  11.0  2.4  pmol/1;  5-min  is-
chemia. 20.1  ±  2.2 pmol/1; and 20-min ischemia, 41.5  ±  
3.3  pmol/1  (all  P  <  0.05  vs.  control  values;  Fig.  7).  
Global  ischemia  for  2  and  5  min  was  not  associated  
with  changes in end-diastolic pressure  above  baseline.  
Hearts  subjected  to  20-min  ischemia  displayed  an  in-
crease  in  end-diastolic  pressure  of  ~10  mrnHg  above  
baseline  values.  Myocardial  BNP  concentration  was  
1.58  ±  0.16 pmol/g wet wt in control hearts and  1.77  ±  
0.16,3.69  ±  0.65 (P <  0.05 vs. control), and  1.82  ±  0.14  
pmol/g  wet  wt,  respectively,  in hearts  subjected  to  2-,  
5-,  or  20-min  global  ischemia  with  5-min  reperfusion  
(n  =  3-4  hearts/group).  
DISCUSSION 
The  present  investigation  provides  two  principal  
new  findings.  First,  acute  infusion  of exogenous  BNP  
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Fig.  6.  Ventricular cGMP concentration a f te r  10-inin  perfusion  with  
BNP.  Bars represent  means  +  SE;  n  =  5 - 1 0 .  * P  <  0.01 vs.  control.  
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Fig.  7.  Release  oi BNP into coronary eff luent  dur ing  
control perfusion to;  »  =• 3), a f t e r 2-min  iachemia  (•:  
n - 4 ) ,  5-min ischemia  (•;  n  -  4i, or 20-min  ischemia  
(•;  n  =  4).  * P  <  0.05 vs.  the  corresponding  control  
value  (repeated-measures  ANOVA).  
min 5  min  
5 0  .  
ischemia 2-20 min  reperfusion  
is  markedly  protective  against  myocardial  ischemia-
reperfusion injury, leading to  concentration-dependent  
infarct  size  limitation.  Second,  the  mechanism  of pro-
tection  afforded by BNP is associated  with elevation  of  
cGMP  and  appears  to  involve  KATP  channel  opening.  
The  pharmacological  selectivities  of  the  widely  used  
KATP  channel  blockers,  applied  at  conventional  inhib-
itory  concentrations,  may  indicate  involvement  of the 
mitochondrial  KATP  channel  rather than the  sarcolem-
mal  KATP  channel.  Although  recent  studies  have  re-
ported  that  ANP  (30)  and  the  related  noncardiac  pep-
tide urodilatin  (27) limit infarct size in vivo, this is the 
first  study  to  show  the  cardioprotective  effect  of  BNP 
and  to  provide  evidence  of  a  primary  mechanism  of  
action  of  a  natriuretic  peptide  on  myocardium  medi-
ated  by  K A T P  channel  activation.  
The  cell  surface  receptor  mediating  the  biological  
actions  of  BNP  is  a  particulate  guanylyl  cyclase  A  
receptor,  NPR-A,  abundantly  expressed  in  cardiac  tis-
sue (2, 29). Unlike receptors for adenosine,  bradvkinin,  
ana  opioids, the  NPR-A receptor  is  not  G protein  cou-
pled.  This  receptor  contains  an  intracellular  guanylyl  
c_yclase  catalytic  domain  that  mediates  most  of  the  
biological  action  of the natriuretic peptide  through  the  
conversion  of  GTP  to  cGMP  (4,  13,  20).  We  observed  
significant increases  in  the  ventricular  cGMP  concen-
tration after  10-min  perfusion with  BNP GO'*9 or  10"8  
mol/1).  Although  this  observation  is  consistent  with  
NPR-A activation, we are unable to conclude at present, 
that  the  infarct-limiting  action  of  BNP  in  ischemic  
myocardium  is  a  receptor-mediated  action.  Unfortu-
nately,  reliable  NPR-A  inhibitors  such  as  HS-142-1  
and  A71915  are  not  available  in. sufficient quantity  to  
undertake  perfused  heart  or  in  vivo  studies.  Ap-
proaches  using  cultured  cardiac  myocytes may be fea-
sible but may  not accurately  model endogenous  protec-
tive  mechanisms  in  intact  tissue  where  there  are  in-
teractions  among  several  cell  types  and  humoral  
mediators.  Alternative  approaches  using  mutant  
mouse strains with targeted  deletion of either  pro-BNP  
or NPR-A genes may also be possible in future studies.  
However, interpretation  of findings from such  animals,  
in  the  absence  of  complementary  pharmacological  
data,  may  be  clouded  by  the  uncertainties  of  altered  
expression  of other gene products, high levels of redun-
dancy  in.  signaling  pathways,  and  the  spontaneous  
development of cardiac pathology in these animals.  For  
example, Izumi  et  al.  (12  ) recently reported  that  mice  
with  targeted  deletion  of  the  NPR-A  gene  sustained  
infarcts that  were  20%  smaller  than  wild-type  control  
animals. However, the mutant  animals had  a  substan-
tial  degree  of  LV  hypertrophy.  Moreover,  interpreta-
tion  of this study  is predicated  on the  observation  that  
natriuretic  peptides  upregulated  vascular  adhesion  
molecule  expression  in  vitro,  an  effect  that  has  not  
been  demonstrated  in  humans  or  in  intact  animal  
models. 
Our  observation  that  the  synthetic  cGMP  analog  
8-Br-cGMP  evoked,  at  low  concentrations,  an  infarct-
limiting  effect  similar  to  that  observed  with  BNP  is  
consistent  with  the notion that  elevation  of  intracellu-
lar cGMP may indeed  be a mechanism that is central to 
the  cardioprotective  action  of  BNP.  cGMP  elevation  
has  been proposed  to  be  a mechanism  of injury  limita-
tion  in  ischemic  myocardium  (26),  but  the  distal  mo-
lecular mechanisms  resulting  in enhanced  tolerance  to  
ischemic  injury  associated  with  cGMP  elevation  are  
unclear.  Proposed  mechanisms  include  inhibition  of  
L-type  calcium  channel  opening  (18),  decreased  intra-
cellular  concentrations  of  cAMP  through  a  feedback  
mechanism  and  stimulation  of  cAMP  phosphodiester-
ase (11,18,  22), inhibition  of the mitochondrial  perme-
ability transition  pore  (31). and  opening  of KATP  chan-
nels (16). However, the unexpected finding that  higher  
concentrations  of  8-Br-cGMP  (similar  to  those  fre-
quently  applied  in  isolated  cell  and  tissue  pharmacol-
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ogv) were  not protective is intriguing  and  unexplained  
at  prc-scnt.  Previous  work  has  reported that  high  con-
centrations  of  cGMP  are  associated  with  cell  injury.  
For  example.  Nakamura  et  al.  (25)  reported  that  the  
cytotoxic effects of a NO donor in a  phaeocromocytoma  
line  were  augmented  by  a  cell-permeable  cGMP  ana-
log.  A  role  of  cGMP  and  cGMP-dependent  protein  ki-
nase (cGK) in mediating apoptosis  of pancreatic  p-cells  
has  been reported  (19). Tepperman et al.  (34)  extended  
these  observations  to  rat.  intestinal  epithelial  cells,  
showing that dibutyryl  cCMP at millimolar  concentra-
tions  reduced  cell  viability  in  culture.  This  cytotoxic  
effect of high intracellular concentrations of cGMP may 
be related to the generation  of reactive oxygen  species,  
because  superoxide  dismutase  attenuated  the  injuri-
ous effects of the  cGMP analog in  intestinal  epithelial  
cells.  Thus  our  apparently  paradoxical  observation  
that increasing  concentrations  of 8-Br-cGMP were  not  
associated with infarct limitation, whereas low concen-
trations  were  protective,  may  reflect  an  ambivalent  
effect of cGMP,  both  prosurvival  and proinjury effects 
being mediated by this second messenger depending on 
concentration  and  pathophysiological  context.  
In  myocardium,  sarcolemmal  KATP  channels  were  
originally  postulated  to  participate  in  salvage  from  
irreversible ischemia-reperfusion injury, because  their  
opening  would  produce  an  increase  in  the  outward  
potassium  current  leading  to  shortening  of  action  po-
tential  duration, which would in turn reduce the  Ca2+  
influx through  voltage-dependent  Ca2+  channels  and  
increase  the  time  during  which  the  Na+/Ca2+  ex-
changer  would  operate  to  extrude  Ca2+  from  the  cell.  
Since  1998.  attention  has  focused  on  mitochondrial  
KATP  channels  in  both  ischemic  preconditioning  and  
pharmacological  preconditioning studies  (28). Much  of  
the  evidence  implicating  a role  of mitochondrial  KATP  
channels  is  reliant  on the  reputed  selectivity  of  phar-
macological  agents  such  as  o-HD  (a  blocker  of  mito-
chondrial  KATP  channels)  and HMR-1098  (a  blocker of  
sarcolemmal  KATP  channels).  With  the  caution  that  
pharmacological  specificity and selectivity may be sub-
ject  to  revision,  our  study  provides  pharmacological  
evidence  for  involvement  of  a  K A TP  channel  subtype,  
possibly  a  mitochondrial  KATP  channel,  in the  infarct-
limiting action of BNP.  Further studies in  appropriate  
isolated cell and mitochondrial preparations using bio-
physical  approaches  are  now  being  planned  to  probe  
the specific involvement of mitochondrial  KATP  channel 
opening. 
While  not  constituting  proof  of mechanism,  the  as-
sociation  between  concentration-dependent  elevation  
of  cGMP  by  BNP  and  infarct  limitation  that  we  ob-
served leads us to hypothesize  a role for cGK-I (protein 
kinase  G).  The  cGMP/cGK-I  pathway  could  promote  
K A T P  channel  opening, representing an alternative sig-
nal  cascade  to the  widely  studied  G protein  receptor-
coupled-protein  kinase  C  pathway.  Indeed,  recent  
studies  support the  concept  that  KATP  channel  activa-
tion may be promoted by cGK in a variety of cell  types,  
including  ventricular  myocytes  (10).  The  contribution  
of  cGK signaling  to  mitochondrial  KATP  channel  acti-
vation and infarct limitation  after BNP treatment  will  
be the  subject  of further studies,  using  mice  with  tar-
geted  deletion  of cardiac.  cGK-I.  
BNP is a vasodilator in several  vascular beds includ-
ing coronary epicardial  conductance  arteries  and  coro-
nary  microvessels  (3.  40)  A  surprising  finding  in  our  
studies was the absence  of any gross alterations  in the 
global  CFR secondary to BNP-mediated  coronary vaso-
dilatation.  It likely that a more consistent  and  marked  
effect would be observed at higher concentrations than 
those used in our studies. The highest concentration  of  
BNP  we  used  (10~8  mol/1 J is  at  the  threshold  for  va-
sorelaxation  in  rat  aortic  rings  (13).  At  present,  we  
must  conclude  that  the  protective  effect  of  BNP  on  
ischemic myocardium is apparently independent of cor-
onary  vasodilatation  or  collateral  vessel  recruitment,  
because  the  rat  heart  is  devoid  of  native  coronary  
collateral  vessels.  It  is  of  interest  that  in  a  previous  
study examining the coronary vasodilator  mechanisms  
of ANP  in  a  constant  flow  preparation,  ANP  reduced  
coronary perfusion pressure,  an effect sensitive  to  in-
hibition  by W-nitro-L-arginine  methyl  ester  (40).  The  
possibility  that  BNP-associated  cardioprotection  may  
be  related,  at  least  in  part,  to  NO  generation  and  
activation of soluble guanylyl cyclase is currently being 
investigated in our  laboratory.  
We  observed  that  postischemic.  release  of  endoge-
nous BNP increased in a graded fashion with ischemia 
severity.  Moreover, the increase of tissue BNP after 2-
and  5-min  ischemia  likely  reflects  cleavage  of  the  
stored  propeptide  in  response  to ischemia;  after  a  20-
min  ischemic  stimulus,  tissue  levels  of BNP  were  re-
duced  as  a consequence of massive release  of the  pep-
tide.  The immediate  stimulus to BNP release  could  be  
either ischemia  per se  or local tissue  deformation as  a  
result  of ischemia.  At  present,  we  are  unable  to  com-
ment  on this  except  to  say  that  we  observed  graded  
release  of BNP after ischemia that was not  associated  
with  substantial  changes  in  end-diastolic  pressure.  It  
is  impossible  to  directly  relate  the  concentrations  of  
BNP  in  coronary  effluent  to  the  concentrations  re-
quired  to protect against  infarction. Although the  cor-
onary effluent concentrations  were two to three  orders  
of  magnitude  less  than the  protective  concentrations  
infused,  local  interstitial  concentration  during  ische-
mia, when there is no flow and thus no washout,  would  
be considerably higher than  that  detected in the  coro-
nary effluent during reflow. Thus changes in the  coro-
nary  effluent  concentrations  reflect  changes  in  the  
interstitial concentrations but cannot predict the inter-
stitial  concentrations.  
In conclusion, this study is the first to demonstrate  a  
cardioprotective effect of exogenous BNP against ische-
mia-reperfusion injury.  The  abrogation  of this  protec-
tive  effect  by  glibenclamide  and  5-HD,  but  not  by  
HMR-1098. is  consistent with,  but does not  constitute  
proof of, a mechanism involving opening of the putative 
mitochondrial  KATP  channel.  Although  we  postulate  
that  elevation  of  cGMP with  activation  of  cGK-I  is  a  
plausible  mechanism  of  KATP  channel  opening,  the  
signaling  pathway  underlying  this  newly  defined  ac-
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tion  of BNP  requires  further  elucidation,  as  does  ihe  
involvement  of  NPR-A  activation.  Further  studies  in  
vivo  and  in  other  species  are  indicated  to  elucidate  
fully  the  cytoprotective  potential  of  BNP  and  cGMP  
signaling  in  myocardial  ischemia-reperfusion,  espe-
cially the therapeutic  application  of recombinant  BNP  
and  inhibitors  of  neutral  endopeptidasc.  the  major  
enzymatic  route  for BNP  degradation.  
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Csont,  Tamás,  Csaba  Csonka,  Annamária  Ónody,  
Anikó  Görbe,  László  Dux,  Richard  Schulz,  Gary  F.  
Baxter, and Péter Ferdinandy. Nitrate tolerance does not 
increase  production  of  peroxynitrite  in  the  heart  Am  J  
Physiol Heart Circ Physiol  283: H69-H76,  2002.  First  pub-
lished February 28. 2002;  10.1152/ajpheart.00817.2001.—Clin-
ical studies have suggested that long-term nitrate treatment 
does not improve and may even worsen  cardiovascular mor-
tality,  and  the  possible  role  of  nitrate  tolerance  has  been  
suspected.  Nitrate  tolerance  has  been  recently  shown  to  
increase  vascular  superoxide  and  peroxynitrite  production  
leading to vascular dysfunction. Nevertheless, nitrates exert 
direct  cardiac  effects  independent  from  their  vascular  ac-
tions.  Therefore, we investigated  whether  in vivo  nitroglyc-
erin  treatment  leading  to  vascular  nitrate  tolerance  in-
creases  cardiac  formation  of  nitric  oxide  (NO),  reactive  
oxygen species, and peroxynitrite, thereby leading to cardiac 
dysfunction.  Nitrate  tolerance  increased  bioavailability  of  
NO  in  the  heart  without,  increasing  formation  of  reactive  
oxygen  species.  Despite  elevated  myocardial  NO,  neither  
cardiac markers  of peroxynitrite  formation nor cardiac  me-
chanical  function were  affected  by nitroglycerin,  treatment.  
However,  serum  free  niirotyrosine,  a  marker  for  systemic  
peroxynitrite  formation, was significantly elevated  in nitro-
glycerin-treated  animals.  This  is  the  first  demonstration  
that,  although  the  systemic  effects of nitroglycerin  may be 
deleterious due to enhancement of extracardiac peroxynitrite 
formation, nitroglycerin does not result in oxidative damage 
in the heart. 
nitroglycerin:  nitric  oxide: reactive  oxygen  species:  myocar-
dium 
ISCHEMIC  HEART  DISEASE  is  a  leading  cause  of  death  in  
developed  countries  and the  quality  of life  of  patients  
suffering  from  ischemic  heart  disease  is  significantly  
impaired.  Organic  nitrates  including  nitroglycerin  
have  been  used  successfully in the treatment  and pre-
vention of ischemic heart disease for >100 years.  How-
ever, development of tolerance to tire vascular effects of 
nitrates  due  to  long-term  administration  limits  their  
clinical application (27). Moreover, recent clinical  stud-
ies  (17,  25)  suggest  that  long-term  nitrate  treatment  
does  not improve  and  may  even  worsen  mortality  due  
to cardiovascular reasons. Although the background  of  
nitrate-induced increase in cardiovascular mortality is 
still  not  known,  the  possible  role  of  nitrate  tolerance  
has been  suspected  (17,  25).  
Experimental  evidence on the cellular mechanism of  
some  of the  adverse  effects  of  nitrates  have  been  de-
scribed  only  in  the  past  few  years.  Development  of  
experimental  vascular  nitrate  tolerance  due  to  nitro-
glycerin  treatment  has  been  shown  to  increase  the  
formation  of reactive  oxygen species  (10,  24)  and  per-
oxynitrite  in the  vasculature,  which  leads to  vascular  
dysfunction  (9,  21).  In  light  of  these  observations,  
treatment  of patients  with  organic nitrate  compounds  
may  lead  to  side  effects  possibly  due  to  generation  of  
reactive  oxygen species in the  vasculature.  
Most of the studies describing the possible  oxidative  
effect  of nitrates have looked at their vascular effects. 
There have been  no  attempts  made  so far to  evaluate  
the  effect  of  nitrates  on  the  generation  of  reactive  
oxygen species directly in the heart. However, this  may 
be  the  key  missing  information  relevant  to  the  un-
wanted  effects of nitrates. 
The  reaction  of  nitric  oxide  (NO)  with  superoxide  
radical leads to the formation of peroxynitrite. The rate 
of this reaction is determined by the amount of NO and 
superoxide  and  the  activity  of  superoxide  dismutase  
(SOD)  in  the  cellular  microenvironment.  Endogenous  
formation of peroxynitrite and reactive oxygen  species  
is  known  to  exert  detrimental  effects  on  myocardial  
function  (1,  13,  14,  32).  These  findings  suggest  that  
similar to that in the vascular system, treatment  with  
organic nitrates,  especially  during the  development  of  
nitrate  tolerance,  may  result  in  oxidative  stress  and  
contractile  dysfunction in the  heart.  
On the  other hand,  many studies (2,  6,  7,  15,  16,  26,  
34,  37)  show that  NO  donor  compounds  including  ni-
troglycerin  exert  direct  cardiac  protective  effects.  We  
(7) have  shown that nitroglycerin  exerts  a  direct  myo-
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Mm  sum  neni  of  cardiac  NO  synthase,  xanthine  oxi-
doivdiictasc.  and  SOD  activities.  To  est imate  endogenous  
enzymatic  NO  production,  Ctr  '-de-pendent  and  Oa2 ' -inde-
pendent  NO synthase  activities  in  ventricular  homogenates  
wc-re  measured  by  the  conversion  of  L-|MC]arginine  to  
L-|,4C]citrulJinc  as  previously  described  (13).  Powdered  fro-
zen  ventricular  tissue  was  placcd  in  four volumes  of  ice-cold  
homogenization  buffer  (composition  given  in  Ref.  33)  and  
homogenized  with  an  Ultra-Turrex  disperser  using  three  
strokes  of  20-s  duration  each.  The  homogenate  was  centri-
fuged  (1,000 g  for  10  mini  at.  4"C  and  the  supernatant  was  
kept; on ice for immediate assay  of enzyme activities.  Samples  
were incubated  for 25 min at  37°C in the presence or absence 
of EGTA (1 niMj or EGTA plus JV'-monomethyl-L-arginine  (1  
mM)  to  determine  the  level  of  Ca2 '-dependent  and  Ca2"1-
independent  NO synthase  activities,  respectively.  NO  syn-
thase  activities were  expressed  in  picomoles per  minute  per  
milligram  of protein.  
Activity  of xanthine  oxidoreductase  (xanthine  oxidase  and  
xanthine  dehydrogenase),  the  major  source  of superoxide  in  
ra t  hearts  (11),  was  determined  from  ventricular  homoge-
nates  by a  fluorometric  kinetic assay based on the  conversion 
of pterine to isoxanthopterine  in the presence (total  xanthine  
oxidoreductase activity) and absence (xanthine oxidase activ-
ity)  of the  electron  acceptor  methylene  blue, as  described  by  
Beckman  et  al.  (4). Ventricular  homogenates  were  prepared  
as  for the measurement  of NO synthase  activity.  
Total activity of SOD was measured  by a  spectrophotomet-
r y  assay  using  a  kit  (Randox  Laboratories).  Approximately  
100 mg ventricular tissue was homogenized in  10 volumes of 
ice-cold  phosphate  buffer (0.01  M, pH  7.0).  SOD  activity  in  
homogenates  was  determined  by the  inhibition  of formazan 
dye  formation due  to superoxide  generated  by xanthine  and  
xanthine  oxidase.  
Measurement  of  markers  of  peroxynitrite.  We  measured  
dityrosine  by  spectrofluoromefcry in  the  perfusate  and  free  
ni fro tyrosine  by  enzyme-linked  immunosorbent  assay  
(ELISA)  in  the  perfusate  and  in  the  serum  as  markers  of  
peroxynitrite generation  (41, 42). ELISA (Cayman  Chemical;  
Ann  Arbor,  MI)  was  conducted  as  described  (13).  Briefly,  
serum  or perfusate samples  were  deproteinized  by the  addi-
tion  of 4 volumes  of ice-cold ethanol. After centrifugation, the 
supematants  were evaporated  in nitrogen flow, dissolved  in  
phosphate buffer, and incubated  overnight with  anti-nitroty-
rosine  rabbit  IgG  and  nitrotyrosine  acetylcholinesterase  
tracer  in  precoated  (mouse  anti-rabbit  IgG) microplates,  fol-
lowed  by development  with Ellman's  reagent.  
Proteins  containing  nitrotyrosine  residues  were  used  as  
intracellular  markers  of peroxynitrite  formation in  ventricu-
lar  sections obtained  from control, nitrate  tolerant,  and  pos-
itive  control  hearts.  Positive  controls were  obtained  by infu-
sion  of authentic peroxynitrite  (1 mmol/1 final concentration) 
for  10  min  into  the  perfused  hearts.  The  ventricles  were  
frozen in isopentane cooled in liquid nitrogen and  6-pm-thick  
fresh frozen sections were made  by a cryostate. The  sections  
were  fixed in  acetone  (5 min)  ana,  after being washed,  they  
were blocked for 15 min  in Tris-buffered saline containing  1% 
bovine  serum  albumin,  0.1% Na-azide,  and  0.5% Tween  20.  
Slices  were incubated  with  a  primary  anti-nitrotyrosine  an-
tibody  (rabbit  polyclonal  IgG,  Upstate  Biotechnology;  Lake  
Placid,  NY) for 2 h at  room temperature.  Bovine  anti-rabbit  
IgG was used as a secondary antibody followed by  fluorescein  
isothiocyanate-conjugated  streptavidine  labeling  (DAKO;  
Glostrup,  Denmark)  (19). The  sections were  examined  with  
the use  of confocal laser  scanning  microscopy  (Leica  DMRE;  
Heidelberg,  Germany).  
Statistical  analysis.  Data  were expressed  as  means  z  SE  
and  analyzed  with  unpaired  (-test. P  <  0.05 was accepted  as  
indicating a statistically significant difference compared  with  
the  control  group.  
R E S U L T S 
Vascular  nitrate  tolerance  and.  cardiac  function.  To  
verify the development  of n i t ra te tolerance after in  vivo  
repetit ive  n i t ra te  t rea tment ,  isolated  aortic  rings  ob-
tained  from  control  and  nitroglycerin-treated  (9  x  100  
mg/kg)  animals  were  precontracted  with  an  EC',0  con-
centration  of  norepinephrine.  The  nitroglycerin  con-
centrations  needed  to produce half-maximal  relaxation  
were  0.09  ±  0.01  p.mol/1 in rings  obtained  from  control  
animals  versus  1.79  ±  0.28  p.mol/1  in  nitroglycerin-
t reated  group  (P  <  0.05,  n  =  7  in  both  groups).  This  
20-fold decrease in sensitivity to nitroglycerin  observed  
in the  present  s tudy  is consistent  with  previous  obser-
vations  (6,  17,  35).  
Paramete rs  of cardiac performance in isolated  work-
ing r a t hearts ,  such  as hear t  rate,  aortic  flow, coronary 
flow,  left ventricular  developed  pressure,  left  ventricu-
lar  end-diastolic  pressure,  and  ±dP/d i m a x  were  not  
affected  by  in  vivo  repetitive  nitroglycerin  t rea tment  
compared  with  the  control  group  (Table  1).  
In nontolerant r a t s  (1, 5, or  12 h af ter t reatment  with  
a  single  dose  of nitroglycerin),  nei ther  cardiac function 
(data  not  shown) nor  nitroglycerin  sensitivity  of  aortic  
rings  (12-h  group:  EC5 0  of  nitroglycerin  0.1  ±  0.02  
p.mol/1,  n  =  5,  nonsignificant  vs.  control)  were  signifi-
cantly changed. Nitroglycerin  sensitivity  of aortic r ings 
was  not  fur ther  tested  in the  1-h and  5-h  groups.  
Cardiac  NO  content  and  NO  synthase.  Cardiac  NO  
content  was  significantly elevated  in the  nitroglycerin-
to lerant  group  when  measured  by  ESR  spectroscopy  
a f t e r  ex  vivo  spin  t rapping  of  NO  in  isolated  hear ts  
(Fig.  1A).  
To test whether  elevated NO derives from  exogenous  
nitroglycerin  or  endogenous  enzymatic  sources,  we  
measured  cardiac  activities  of NO  synthases.  Endoge-
nous  enzymatic  sources  of  NO.  Ca2_i '-dependent  and  
Ca 2 + - independent  activities  were  not  changed  in  the  
ventr icular  t issue  due  to  development  of ni trate  toler-
ance  (Fig.  IB).  
Table  1.  Basal  myocardial  functional  parameters  
in  isolated  working  rat  hearts  
Control  Nitrate  
H e a r t  ra te ,  beats/min  278 ±7 285 ± 9 
Coronary  flow,  rnl/min  23.6 Z0 .8 23.8 ±1.2 
Aortic  flow,  ml/ruin  47.8 z  1.8  51.8 ± 2 . 5 
LVDP.  kPa  18.S ±0 .6 19.7 ± 0 . 4 
LVEDP,  kPa  0.54 ±0 .07 0.59 ±  0.05  
+ dP/dtmi,s,  kPa/s  8S2 ± 4 3 898 ± 3 2 
- d P / d W : ,  kPa/s  405 ± 3 0 453 ± 3 9 
Values  are  means  ±  SE:  n  =  7 isolated  hear t s  per  group.  LVDP,  
lef t  ventricular  <LV)  developed  pressure;  LVEDP,  LV  end-diastolic  
pressure;  ±dP/dtim=,  first  derivatives  of  LV  pressure.  Preload  (1.7  
kPa)  and  aftertoad  (9.8  kPa)  were  kept  constant  throughout  the  
perfusion. 
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the  coronary effluent markers  of peroxynitrite  genera-
tion  did  not differ significantly between the  two groups 
(Fig. 3Aj. To further study markers  of peroxynitrite, we 
performed  nitrotyrosine  immunostaining  in  ventricu-
lar  slices.  Nitrotyrosine  immunostaining  detected  by  
confocal  laser  scanning  microscopy  was  negligible  in  
hearts  of  both  control  and  nitrate-tolerant  groups,  
whereas  an  intensive  nitrotyrosine  staining  was  ob-
served  in  positive  control  hearts,  which  were  treated  
with  authentic  peroxynitrite  (images  not  shown).  
In  hearts  of  nontolerant  rats  (1,  5.  and  12  h  after  
treatment  with  a  single  dose  of nitroglycerin),  forma-
tion  of  dityrosine  in  the  coronary  perfusate  was  not  
significantly different compared with controls (data  not-
shown). 
Cardiac  hydroxyl  radical.  We  also  tested  whether  
the formation  of hydroxyl radical,  a  toxic derivative  of  
peroxynitrite  and  superoxide,  is  changed  in. the  heart  
as  a  result,  of  development  of nitroglycerin,  tolerance.  
Isolated  hearts  from control and  nitroglycerin-tolerant  
Cardiac superoxide  production  
Fig.  1.  Cardiac  nitric  oxide  (NO)  content  (A)  and  Ca2 4-dependent  
and  Caa*-rodependent  NO  synthase  (NOS) activities  (B) in  ventric-
ular  tissue  of  control  and  nitroglycerin-treated  rats.  *P  <  0.05  vs.  
control  in.  = 4 - 7  in  each  groups).  
Cardiac,  superoxide.  To  test  whether  nitrate  toler-
ance  increases  cardiac  superoxide  generation,  we  per-
formed  lucigenin-enhanced  chemiluminescence  assay  
in  fresh cardiac tissue. Cardiac  superoxide  generation  
remained  unchanged  due  to  repetitive  nitroglycerin  
treatment  compared  with  the  control  group  (Fig.  2A).  
To  further  verify this  negative  finding,  we  measured  
the  activity  of xanthine  oxidoreductase  enzyme  com-
plex.  a  major  enzymatic  source  of  superoxide  in  rat  
hearts. There was no significant difference in  activities  
of xanthine  oxidase and  xanthine  dehydrogenase  (Fig.  
25).  We  also  tested  the  total  activity  of  SOD  in  the  
heart,  the  major  enzyme  responsible  for  endogenous  
detoxification  of  superoxide.  SOD  activity  was  not  
changed in the nitroglycerin-tolerant  hearts  compared  
with  controls  (Fig.  2C).  
Cardiac  peroxynitrite.  To estimate the peroxyni trite-
generating  capacity  of the  heart,  hearts  were  isolated  
from nitroglycerin-tolerant  and  control  rats  and  were  
perfused with  a buffer supplemented  with  0.3  mmol/1  
L-tyrosine. Formation  of dityrosine and nitrotvrosine in 
B 
Control  Nitrate-tolerant  
Cardiac xanthine  oxidoreductase  
c 
I 
I 
1 
I 
15 
10 
5 -
0 
xo X D H 
Control  Nitrate-
tolerant 
Control  Nitrate-
tolerant 
Total cardiac  SOD  
Control Nitrate-tolerant 
Fig.  2,  Cardiac  superoxide  production  (A),  xanthine  oxidase  (XO).  
and  xanthine  dehydrogenase  (XDH)  activities  (B).  and  superoxide  
dismutase  (SOD)  activity  (C)  in  ventricular  tissue  of  control  and  
nitroglycerin-treated  ra ts  In  = 6 - 8  in  each  group).  
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Markers  of  peroxynitrite  in the  perfusate  
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Fig.  3.  Dityrosine  and  nitrotyrosine,  markers  of  peroxynitri te  (A),  
and  2,6-dihydroxybenzoic  acid  (DHBAj. marke r  of  hydroxyl  radical  
( B \  formation  in  per fusa te  f rom  hea r t s  perfused  with  0.3  mmol/1  
L-tyrosine  or  1 rnxnoLd salicylic  acid  in  control  and  in  vivo  nitroglvc-
erin-treated  groups,  respectively  (»  =  5 - 7  in  each  group).  
D I S C U S S I O N 
This is the first demonstration that repetitive  nitrate  
treatment,  which  leads  to the development  of vascular 
nitrate  tolerance,  results  in  a  sustained  (>12  h)  in-
crease  in serum nitrotyrosine.  This,  however,  does  not  
enhance  production  of reactive  oxygen  species  includ-
ing  peroxynitrite  in  the  heart.  We  have  also  shown  
here  that  nitroglycerin  treatment  increases  the  bio-
availability  of  NO  in  the  heart  even  when  nitrate  
tolerance  develops.  We. further  obsei-ved that  a  single,  
acute  treatment  with  nitroglycerin,  which  does  not  
lead  to nitrate  tolerance, results  in  a. transient  (<5  h)  
increase  in  serum  nitrotyrosine.  
Many previous studies (9,  10, 22, 24) have  suggested  
that nitrate treatment, especially when it results in the 
development  of  nitrate  tolerance,  is  associated  with  
increased  free-radical  generation  in  the  vasculature.  
For  instance,  Munzel  et  al.  (22)  showed  a  twofold  
increase  in  total  superoxide  production  and  a  signifi-
cant  decrease  in vascular  SOD activity in functionally 
damaged  nitrate  tolerant  aortic  rings.  However,  no  
studies  have  examined  the  influence  of nitrate  treat-
ment  and  nitrate  tolerance  on  cardiac  generation  of  
reactive  oxygen, species.  In  contrast,  to  earlier  studies  
on  the  vascular  effects  of  nitrates  and  nitrate  toler-
ance,  here  we have  shown, that  the  generation  of  car-
diac  superoxide,  hydroxyl  radical,  and  peroxynitrite,  
enzymatic  superoxide  synthesis  by  xanthine  oxi-
doreductase  and  its  detoxification  by  SOD,  as  well  as  
the  nonenzymatic  breakdown  of  superoxide  and  per-
oxynitrite .yielding hydroxyl radicals, were not  changed 
in. the  heart  after  in  vivo  nitroglycerin  treatment  re-
sulting  in nitrate  tolerance.  Furthermore,  myocardial  
mechanical  function was not  altered  either  as  a  result  
of vascular nitrate tolerance. This further supports  the 
conclusion  that  superoxide  and  peroxynitrite  genera-
rats  vrere perfused in the presence  of  1. mmol/1 salicylic 
acid.  Formation  of  2,5-dihydroxybenzoic  acid  from  sa-
licylate  in. the  perfusate due to hydroxyl  radical  activ-
ity  was  not  significantly different (Fig.  SB).  
Systemic  peroxynitrite.  Finally,  we  studied,  whether  
in  vivo nitrate  treatment  increased  formation  of  per-
oxynitrite  anion  in  extracardiac  tissues.  Therefore,  
serum  free nitrotyrosine  concentration  was  measured  
in  control  and. nitroglycerin  tolerant  animals,  as  well  
as  in  nontolerant  rats  treated  with  a  single  dose  of  
nitroglycerin  as  a  systemic  marker  for  peroxynitrite.  
Serum  free nitrotyrosine increased approximately  two-
fold in  nitroglycerin  tolerant  rats  compared  with  con-
trols  (Fig.  4).  
To test whether  development  of nitrate  tolerance  or  
nitrate  treatment  itself  affects systemic  peroxynitrite  
formation,  serum  nitrotyrosine was  measured  in  non-
tolerant  rats treated with a single dose of nitroglycerin. 
One hour after a  single nitroglycerin treatment  serum  
nitrotyrosine  increased  approximately  twofold.  How-
ever, there was  no significant increase in  serum  nitro-
tyrosine  level  at  5 and  12 h  after treatment  (Fig.  4).  
Marker  of  peroxynitrite  in the  serum  
* 
40  -
0> c 
%  J  
c  _  •fc  O  
•E  E  20-
E  ^  
3 
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Control  Nitrate-  Nitrate  Nitrate  Nitrate  
tolerant  1 X GTN  1 x GTN  1  x  GTN 
9  x  GTN  1h  5  h  12  h  
12  h  
Fig.  4.  Free  ni trotyrosine  concentration  in  deproteinized  sera  of  
control, nitroglycerin  (GTNVtolerant,  and nontolerant  nitrogiveerin-
t reated  rats.  Serum  samples  were  taken  12  h  a f te r repetitive  nitro-
glycerin t r ea tmen t  in t h e tolerant group and  1,5 .  or  12 h af ter single 
nitroglycerin  t r ea tmen t .  'P  <  0.05  vs.  control,  n  =  5 - 7  in  each  
groups. 
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Lion  in  Lhe myocardium  and  in  the; coronary  vascula-
ture  were  unaffected  by  nitroglycerin  tolerance.  Our  
data  show  that  nitrate  treatment,  does  not  enhance  
oxidative  stress  in  the  heart.  It  has  been  suggested  
thai  NO  donors  induce  delayed  preconditioning  
through  the  stimulation  of  free  radical  generation  in  
the  rabbit heart (26,  371. However,  in those  studies,  a  
pharmacological  approach  (i.e.,  a single  concentration  
of mcrcaptopropionyl  glycine  as  a free radical  scaven-
ger)  was  used  to  investigate  the  involvement  of  free  
radicals  in  the  cardioprotective  effect  of  NO  donors,  
and  this  may be less  rigorous  than  biochemical  mea-
surements of several free radicals and their  enzymatic  
production  and  breakdown  as  seen  in  the  present  
study. 
Although  impairment  of nitroglycerin  bioconversion  
to NO and a decrease  in NO bioavailability  have  been  
shown ex vivo in vessels  from nitrate tolerant  animals  
(23)  and patients  (31),  these  findings were refuted  by  
others  (20).  Here  we  have  demonstrated  that  cardiac  
NO  accumulated  after  repetitive  nitroglycerin  treat-
ment  in  vivo.  This  shows  that  nitrate  treatment,  in-
creases  the bioavailability  of NO in the heart  even  in  
the  state  of  vascular  nitrate  tolerance.  Because  the  
cardiac activities  of NO synthases  did  not change,  the  
enhanced  NO level  must derive from nitroglycerin  ac-
cumulated  in the myocardium due to exogenous  nitro-
glycerin  treatment.  This  is  in  accordance  with  the  
observation  by  Torfg&rd et  al.  (39)  showing  the  accu-
mulation  of nitroglycerin  in  cardiac tissue  after  long-
term nitroglycerin  treatment.  
Increased cardiac NO due to nitrate treatment could 
result  in  enhanced  formation  of  peroxynitrite  in  the  
present  study.  However,  recent  studies  (18)  suggest  
that  peroxynitrite  generation is  mainly  dependent  on  
superoxide  concentrations.  Accordingly,  the  level  of  
superoxide  did  not  change  after  nitrate  treatment  in  
our experiments. Despite the increased level, of cardiac 
NO, markers of peroxynitrite formation in the coronary 
perfusate (dityrosine and free nitrotyrosine) as well  as  
in cardiac tissue (nitration of protein, tyrosine residues) 
were not significantly affected by in vivo  nitroglycerin  
treatment resulting in vascular nitrate tolerance.  This 
shows that the generation of peroxynitrite either in the 
coronary vasculature  or in  the  myocardium  is  not  af-
fected by nitrate treatment. Although enhanced vascu-
lar  peroxynitrite  formation  has  been  reported  in  ni-
trate  tolerance  (9,  21),  this  was  accompanied  by  
increased  superoxide  generation  in  the  vasculature.  
Nevertheless,  in the  heart  (including  coronary  vascu-
lature),  we  have  not  found  any  evidence  of  elevated  
superoxide  or  peroxynitrite  formation.  However,  we  
did  observe a significant increase in  serum  free nitro-
tyrosine  concentration  in  nitrate-tolerant  rats  12  h  
after  the  last  nitroglycerin  injection.  This  shows  a  
sustained,  increased  production  of peroxynitrite  in ex-
tracardiac tissues,  possibly  in the  extracardiac  vascu-
lature. This is in accordance with previous findings (9, 
10.  21,  24)  showing  increased  generation  of  reactive  
oxygen  species  in vascular  tissue  due to  nitrate  toler-
ance.  To  test  whether  increased  generation  of  per-
oxynitrite  is  a  general  phenomenon  of  nitrate  treat-
ment  or whether it  is  specific for nitrate  tolerance,  we  
also measured  serum  nitrotyrosine  after a single  dose  
of  nitroglycerin,  which  does  not  lead  to  tolerance  de-
velopment.  Increase in serum nitrotyrosine was found 
1  h  after administration  of a  single  dose  of  nitroglyc-
erin.  However,  this  increase  was  not  observed  5  and  
12 h after treatment.  This finding suggests that  nitro-
glycerin  treatment  in  the  absence  of nitrate  tolerance  
leads to a transient  increase in extracardiac  peroxyni-
trite  formation.  This is  in  accordance with  findings  of  
Dikalov et  al.  (9),  showing that the  biotransformation  
of  nitroglycerin  is  accompanied  by  superoxide  forma-
tion  in  endothelial  and  smooth  muscle  cells  in  the  
absence  of  nitrate  tolerance.  The  reason  why  nitrate  
tolerance extends the  time frame of peroxynitrite  for-
mation  is  not  clear;  however,  increased  accumulation  
of tissue nitroglycerin  is  a plausible  explanation  (39).  
Unfortunately,  the  endogenous  formation  of  per-
oxynitrite cannot be directly detected in biological  sys-
tems. Therefore, dityrosine and nitrotyrosine,  products  
of the reaction between  peroxynitrite and tyrosine,  are  
the most often used  markers  of peroxynitrite,  despite  
some  criticism.  Some  in  vitro  biochemical  data  sug-
gested that peroxynitrite does not cause tyrosine nitra-
tion at physiological pH (28), but this has been recently 
refuted (18,  30).  Moreover,  peroxynitrite-mediated  ni-
tration  of  tyrosine  residues  was  proposed  to  be  the  
most  likely  mechanism  of  nitrotyrosine  formation  in  
vivo  (30).  Myeloperoxidase  activity  in  the  presence  of  
relatively  high  concentrations  of  nitrite  may  lead  to  
nitrotyrosine formation (12).  However,  both myeloper-
oxidase  activity  and  nitrite  concentration  were  negli-
gible  because  granulocyte-free,  crystalloid-perfused  
hearts  were  used  to  test  cardiac  peroxynitrite  forma-
tion  in  this  study  (13).  In  addition,  concurrent  mea-
surement of nitrotyrosine  and dityrosine decreases the 
possibility  of false  estimation  of peroxynitrite  genera-
tion (29). The possibility  of enhanced  myeloperoxidase  
activity  in  extracardiac  tissues  contributing  to  serum  
nitrotyrosine formation, however,  cannot be  excluded.  
Clinical  trials  (17,  25,  38)  have  suggested  that  ni-
trate therapy may worsen  the prognosis  and  survival  
in ischemic heart disease, although further studies are 
required to  confirm these  findings.  Animal  studies  (9,  
10, 22,  24) showed enhanced generation  of oxygen free 
radicals  and  impaired  vascular  function  associated  
with nitrate treatment.  Moreover, vascular nitrate  tol-
erance  has  been  reported  (36)  to  interfere  with  the  
cardioprotective  action  of  classic  preconditioning  in  
rabbits  in  vivo.  These  observations  may lead  to  a  de-
clining  confidence  in  the  use  of  nitrate  therapy  in  
patients. However, here we have provided several lines 
of  evidence  showing  that  in  vivo  nitroglycerin  treat-
ment  leading  to  vascular  nitrate  tolerance  does  not  
result  in  oxidant  stress  and  subsequent  functional  
damage in cardiac tissue. Furthermore, we (7,16) have 
shown  previously  that  nitroglycerin  exerts  a  direct  
anti-ischemic effect on the myocardium, which does not 
diminish  even  after  the  development  of  vascular  ni-
trate tolerance. These findings may support  toe  safety  
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of nib-ate therapy even in the state of nitrate tolerance. 
However,  nitroglycerin  treatment,  especially  when  
leading  to  vascular  nitrate  tolerance,  induces  an  in-
crease  in  serum  nitrotyrosino.  a  marker  for  systemic  
peroxynitrite  formation. This shows that nitrate treat-
ment.  may  enhance  oxidative  stress  in  extracardiac  
tissues.  The  pathological  significance  of  extracardiac  
oxidative stress due to nitrate treatment  requires fur-
ther investigation. Nevertheless, our results that, nitro-
glycerin  may  induce  oxidative  stress  in  extracardiac  
tissue  but not in  the. heart suggest that  either  cardio-
selecfive  nitrates,  nitrate  compounds  with  additional  
antioxidant  activity,  or  combination  therapy  with  ni-
trates  and  antioxidants  may  increase  the  safety  of  
organic  nitrates  in  the  chronic  treatment  of  ischemic  
heart- disease.  Combined  treatment  with  nitroglycerin  
and  the  antioxidant vitamin C has been used  success-
fully to attenuate the development  of nitrate  tolerance  
in animal studies and humans (3,8).  Our present study 
opens a new perspective for "nitrate-antioxidant" treat-
ment  in ischemic heart  disease.  
In conclusion, in vivo nitroglycerin treatment, which 
results in vascular nitrate tolerance,  may enhance  ox-
idative  stress  in  extracardiac  tissues,  but  does  not  
increase  formation  of  oxygen  free  radicals  and  per-
oxynitrite in the heart.  Moreover, it increases  the  bio-
availability  of cardiac NO. These  findings  support  the  
safety  of nitrate therapy even  in the  state  of vascular 
nitrate tolerance although the importance and possible 
risk  of  nitrate-induced  increase  in  extracardiac  per-
oxynitrite  generation  requires  further  investigation.  
Our results provide a rationale for the development  of  
cardioselective  nitrates  and  promote  further  clinical  
studies  on combination therapy with nitrates  and  an-
tioxidants. 
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